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Tablets are the most common solid dosage forms because of their several 
advantages including the ease of administration, precise dosing, ease of 
manufacturing, good product stability in comparison to liquids, and 
tamper–proofness in comparison to capsules. Direct compression is the 
favoured smart choice for tablet manufacturing. The advantages of direct 
compression: include simplicity, reduced time and the final cost of the 
product due to fewer processing stages, continuous nature, and 
elimination of heat and moisture effects, making direct compression an 
appropriate process for hygroscopic and thermo–sensitive materials. 
However, it is unfortunate that only less than ~20% of pharmaceutical 
powders can be compressed into tablets by direct compression due to 
their inherent poor functional properties required for direct compression. 
The situation is particularly severe when a high dose of a poorly 
compactible drug such as paracetamol must be used. Paracetamol is a 
widely used analgesic drug. The monoclinic form is usually selected in the 
pharmaceutical industry and is the commercially available form because it 
is thermodynamically stable at room temperature and pressure. However, 
the monoclinic form of paracetamol is notorious for exhibiting poor 
tableting properties by direct compression, reduced plastic deformation 
during compression, commonly resulting in fragile tablets with a high 
propensity to cap. 
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 This work commences by providing insights into how, current and 
innovative processing techniques, parameters (milling time, temperature 
and solvents), and the combination of drugs and/or excipient impact the 
mechanical properties of paracetamol. The mechanical properties were 
investigated by applying blending, freeze drying, milling, batch cooling 
crystallisation, solvent evaporation and cocrystals formation, while, 
modifying the physicochemical structure of paracetamol crystals to 
improve tabletability was the rationale.  
The modified particles, with the desired behaviour acquired, were 
characterised using FT−IR, PXRD, laser diffraction, SEM, DSC, TGA, Water 
absorption profile, flowability, stability, content uniformity, dissolution and 
tabletability. 
Tabletabilty data demonstrated an immerse enhancement in the drug’s 
tensile strength upon processing using different blending energy (~8 
folds) and preparation techniques (~11 folds), various freezing 
temperatures (~12 folds) with the polymer polyvinylpyrrolidone using 
various drugs such as Ibuprofen (~5 folds), aspirin and caffeine (~9 
folds), Curcumin (~9 folds) chondroitin sulphate A (~11 folds) and 
cocrystals with the coformer 5–Nitroisophthalic acid (~12 folds). 
Regardless, of the co–processing techniques applied with paracetamol in 
the presence of other drugs and excipient, there was an improvement of 
the tablettabililty of paracetamol in comparison to the drug alone. 
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In conclusion, the co–engineering of poorly compactable model drug 
chosen paracetamol with other drugs and excipient influenced the 
mechanical properties of paracetamol without changes in crystallinity and 
polymorphic structure. 
Keywords: Direct compression; Crystal size; crystal habit; Electrostatic 
interaction; Interactive mixtures; Hydrogen bonding; Mechanical 
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1.1. History of paracetamol 
Cahn and Hepp (1886) applied the name Antifebrin into the medical 
practice of representing the first aniline derivative known as acetanilide 
which was serendipitously found to have analgesic and antipyretic 
characteristics. The quest for less toxic aniline derivatives was impelled 
due to acetanilide’s undesirable toxic effects and the most severe being 
cyanosis due to methemoglobinemia. Although acetanilide and phenacetin 
have fallen into abandonment, paracetamol (PA) has become the most 
widely used analgesic–antipyretic drug in the world, due to the absence of 
some imperilling attributes including its high risk benefit ratio and weak 
potential for harmful drug interactions at standard doses (Bannwarth & 
Pehourcq, 2003). According to Bertolini et al. (2006), paracetamol which 
is part of the class of drug recognised as aniline analgesics is the only 
drug still in use currently.  
Paracetamol, N–acetyl–para–aminophenol (Figure 1) is being used under 
a synonymous name in other countries (United States, Canada, and Hong 
Kong) as acetaminophen.  
 




1.2. Physiochemical properties of paracetamol 
 PA possesses five polymorphic forms (I, II, III, IV and V) (Di Martino et 
al., 1996; Al–Zoubi et al., 2002; Smith et al., 2014). Only forms (I to III) 
are well studied and documented. The form I, II and III of paracetamol 
are well defined with respect to the crystal structures, stability and the 
vibrational spectra (Table 1). 
The thermodynamically stable Form I (monoclinic, P21/a), metastable 
Form II (orthorhombic, Pcab), and Form III (orthorhombic, Pca21) that 
are stable only under strict geometric constraints (Burley et al., 2007; Di 
Martino et al., 1997; Zimmermann and Baranovic, 2011; Bustamante et 
al., 2004; Gaisford et al., 2010). Nevertheless, the polymorphic form I 
(monoclinic PA) which is the marketed form, is of primary interest and it 
is well used in the pharmaceutical companies regardless of its 
shortcomings such as, very poor compressibility, wettability and cohesive 














Paracetamol  Reference (s) 
Molecular formula   C8 H9NO2  
Molecular weight 
(M.W) (g.mol-1) 
     151.16 
 
 
LogKow         0.49 
 
(Machatha and Yalkowsky,2004) 
LogPoct          0.3 (Siissalo et al.,2010) 
solubility(g/dm3) 
(37 °C) in water 
    27.33 ± 2.97 (Mota et al., 2009) 
BCS class I (Wu and Benet,2005) 
pKa 9.5 (Kalantzi et al., 2006) 
Glass transition 
temperature (Tg) 
 21 °C 
 
 23.9 °C 
(Martínez et al., 2014) 
 





 Form I/ Prism, plates; Form II/ Prism, elongated; 
  Form III/needle 
(Nichols and Framptom, 1998; 




 Form I: Onset (170 °C) 
 169 oC 
 171 °C /186 J g−1. 
 
 Form II: (onset): 122 °C/2 J.g−1). 
 (157 °C/ 1 Jg−1; 169 °C/185 J g−1) 
 
 Form III: 155.5 °C 
 
Rossi et al., (2003); Gharaibeh & 
Chick Al-Ard 2011a; Nichols and 
Frampton (1998). 
 
(Nichols and Frampton, 1998) 
 
 




 Form I: 12.1°, 15.5°, 16.7°, and 26.5º; Form II: 10.35°, 
14.7°, 16.7°, 17.2°, 21.5°, 21.85°, 24.03°, 27.4°, 28.4° 
and 29.8°; Form III: (Not observed) 
(Khanmohammadi et al.,2010) 
    (Di Martino et al., 1996; Nichols 





Table 1. Physicochemical properties of paracetamol. 
FT−IR (bands)  Form I (3325 cm–1, N–H stretching vibration), (3163 cm–1, 
hydrogen–bonded O–H stretching, vibration plus other 
combination bands), (1653 cm–1 C=O stretching vibration), 
(1564 cm–1: N–H in–plane bending), (1610, cm–1 1506 cm–1 
and 1441 cm–1: Aromatic ring mode), (1327 cm–1: O–H 
bending vibration), (1259—1227 cm–1: C–O and/or C–N 
stretching), (804 cm−1: –C6H4–); Form II (3338 cm–1, N–H 
stretching), (1651 cm–1, C=O stretching), (1550 cm–1 N–H 
bending) and at 1319 cm–1 assigned to O–H bending shifting 
to 3334, 1660, 1558 and 1323 cm–1);Form III (3334 cm –1: 
N–H stretching), (1660 cm–1, C=O stretching), (1550 cm–1, 
N–H bending), (1319 cm–1, assigned to O–H bending shifting 










Tabletability may be defined as the ability of a powder to be transformed 
into a tablet of specified strength under the effect of compaction pressure 
(Joiris et al., 1998). Poor mechanical properties of the active 
pharmaceutical ingredients (APIs) is one of the numerous issue caused by 
the deficiency in physicochemical properties, which becomes an austere 
hindrance particularly for a high dosed administered drug like PA in the 
successful development of tablet formulation (Tjandrawinata et al., 2016).  
Tableting problems caused by poor mechanical properties of the APIs are 
being traditionally dealt with by, using excipients to correct their 
deficiencies. The marketed PA tablets which consist of the poorly 
compactable monoclinic form I are generally formulated using up to 25 wt 
% of excipients to reduce the occurrence of defective tablets caused by 
capping (the separation of the bottom or top of the tablets), lamination 
(fracture of the tablet in layers parallel to the compact face or chip) (Garr 
and Rubinstein 1991; Santos and Sousa, 2008). However, this approach 
is not always practical when the tablet contains more than 20% APIs that 
are poorly compressible. Additionally, the use of a large number of 
excipients may also lead to unexpected drug instability, larger tablet size, 
and increased manufacturing costs (Shi and Sun 2010).  
1.3.0. Particle engineering to enhance the physicochemical and 
mechanical properties of paracetamol 
Particle engineering has emerged as a promising approach in 
pharmaceutics to modify, physicochemical, micrometrics and 
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biopharmaceutical properties of the poorly compressible drugs. Amid 
different methods for tableting enhancement, physical modifications of 
drug products including, reducing the particle size and modifying crystal 
habits are common approaches to increase drug hardness. These review 
emphases the various particle engineering techniques from bottom–up to 
top–down approaches that can be used to improve PA tableting 
properties. 
1.3.1. Cooling Crystallisation 
The crystallisation process is a critical step in the pharmaceutical industry 
and is essential for separation and purification. It accounts for over 90% 
of all active pharmaceutical ingredients (Acevedo et al., 2016; Seki and 
Su, 2015). The most common crystallisation approach is cooling 
crystallization, in which supersaturation is generated by decreasing the 
temperature and, the rate in which the temperature is decreased further 
influences the level of supersaturation and can be used as a control 
variable to achieve desired solid−state properties (Nagy et al., 2008; 
McNamara et al., 2006). 
Cooling crystallisation possesses benefits such as, the temperature, which 
is a single process variable that is reduced to drive crystallisation. No 
additional raw material is needed, which could create additional problems 
in the product’s purity and increase operating and capital cost (Griffin et 
al., 2017; Nagy et al., 2008). However, it has limitations like, it is known 
to be slow and, a high supersaturation is vital at encouraging crystal 
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growth which attributes to the large width of the metastable zone. Also 
the sudden occurrence of early nucleation of crystals creates many 
crystals which eventually restrict the maximum crystal size that can be 
attained. Furthermore, the crystal product of a batch might not show all 
the wanted properties even, when the temperature is successfully 
controlled (Kaialy et al., 2014; King et al., 2015; Forgione et al., 2015). 
Various researchers over the years have applied the method above to 
improve the poor mechanical performance of paracetamol. Di Martino et 
al. (1996) applied cooling crystallisation to obtain paracetamol form II, 
grown in a nonoxidizing atmosphere as polycrystalline material from the 
fused form I. The resultant orthorhombic form II paracetamol 
demonstrated good compression ability in comparison to the monoclinic 
paracetamol. Also, Nichols and Frampton, (1998) produced orthorhombic 
polymorph (form II) of paracetamol from a laboratory–scale using cooling 
crystallisation technique by nucleation of a supersaturated solution of 
industrial methylated spirit. The obtained orthorhombic form II showed 
improved compaction properties to that of form I. Fachaux et al. (1995) 
used cooling crystallisation technique from a dioxane solution or 
suspension to obtain pure paracetamol. The engineered paracetamol 
crystals exhibited a sintered like crystal structure and dramatically 
improved tabletability, plasticity, disintegration, and dissolution properties 
in comparison to the commercial paracetamol. 
Joiris et al. (1998) applied fast cooling after melting of monoclinic 
paracetamol (Form I) to obtain the orthorhombic paracetamol (Form II). 
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The obtained Form II showed far better tabletability, reduced elastic 
recovery and absence of capping tendency in comparison to the 
monoclinic form I at the compression pressure range between 50 MPa and 
350 MPa. 
Patra et al. (2015) applied cooling crystallisation approach to prepare 
directly compressible paracetamol, with improved compressibility and 
lower elastic recovery was observed with higher compaction pressure 
demonstrated better dissolution rate than conventional granules of 
paracetamol. Garekani et al. (1999) applied cooling crystallisation 
technique to prepare prismatic polyhedral crystals of paracetamol from a 
saturated aqueous solution of paracetamol. The compressibility using the 
Heckel–plot of different crystal forms (polyhedral and thin plate–like 
crystals) of paracetamol was compared. Differences in compressibility 
were found as the polyhedral crystals exhibited the higher slope in the 
Heckel–plot than the plate–like crystals. Garekani et al. (2000) used 
cooling crystallisation procedure and investigated the elastic recovery, 
elastic energy and elastic energy/plastic energy ratio of untreated 
paracetamol powder and crystallised paracetamol in the presence of PVP. 
The investigation demonstrated that particles crystallised in the presence 
of PVP displayed reduced elastic behaviour under pressure and increased 
in tabletability in comparison to untreated paracetamol particles. 
Bucar et al. (2015) made a mixture of nano and micrometre–sized 
crystals of the monoclinic form of paracetamol through sonocrystallisation 
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method in which the powder(nanosized) obtained demonstrated higher 
elastic moduli bulk cohesions (increased cohesion) leading improved 
tabletability behaviour compare to the micrometre–sized crystals of the 
monoclinic paracetamol (Form I). 
1.3.2. Formation of Salt  
Perumalla et al. (2012) prepared paracetamol salt (PA hydrochloride 
monohydrate) from high concentrated hydrochloric acid (Con.HCl) by slow 
cooling crystallisation approach. The formation of PA salt demonstrated 
superior compaction properties than PA form I. The tensile strength (TS) of 
the tablet of PA hydrochloride monohydrate increases with increasing 
pressure and reaches an impressive TS of 2.04 MPa at 200 Mpa. Before 
slightly decreasing at higher pressures whereas, the PA form I could not form 
tablets of appreciable strength at pressures up to 350 Mpa.  
1.3.3. Antisolvent crystallisation  
In this technique, a secondary solvent identified as precipitant or 
antisolvent is included to the solution resulting in the reduction of the 
solubility of the solute in the original solvent and subsequently producing 
a supersaturation driving force (Nowee et al., 2008). 
The advantages of the antisolvent crystallisation include the significant 
changes in the solvent activity; thus, it can have a more deep effect on 
the polymorphic form or the crystal morphology. Additionally, the core 
benefit of antisolvent crystallisation is its use of low operating 
temperature, which is important for thermally sensitive products (Nagy et 
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al., 2008). The disadvantages of this method include high local 
supersaturation at antisolvent induction zones which leads to excess 
primary nucleation subsequently resulting in fine crystal particle formation 
that effortlessly tend to agglomerate and its high-dependence on mixing 
for instance, where poor mixing regimes exist (Takiyama et al., 1998). 
Kaialy et al. (2014a) used various additives such as (PVA), Avicel PH 102 
(microcrystalline cellulose), Brij 58, methylcellulose (MC) and polyethene 
glycol to change the crystal habit of PA by applying antisolvent 
crystallisation technique. The engineered paracetamol crystals showed 
improved tabletability compared to the PA. As the compaction force 
changed from 50 MPa to 100 MPa, the TS of the tablets produced with 
untreated PA could not be measured (zero) at all compression pressures. 
Whereas, that of the tablets produced with the physical mixture with the 
corresponding 0.5% Brij 58 and crystallised PA increased from 0.2 MPa to 
0.9 MPa and 0.3 MPa to 1.5 MPa correspondingly. PAs crystallised in the 
presence of Avicel (or physically mixed with Avicel), Brij 58 and PEG 6000 
demonstrated the best compactibility over a range of compaction 
pressures.  
 FT−IR and DSC analyses indicated that 0.5% Brij 58−crystallised PA did 
not undergo structural conversions compared to untreated monoclinic PA, 
implying that the crystallisation process induced no polymorphic 
transformation. The technological and biopharmaceutical properties of 
paracetamol, the physical stability like the flow and polymorphic 
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transformation crystallinity of paracetamol could be influenced by the 
type, the grade and the concentration of additives used. 
1.3.4. The formation of Eutectic mixture 
The eutectic mixture (EM) is a mixture of two components that are 
immiscible in the solid state but miscible in the liquid state. 
Jain et al. (2014) used the solvent evaporation technique, to formulate a 
eutectic mixture (EM) of aspirin−paracetamol (ASP−PA) (53:47%, w/w). 
The mixture exhibited an increase in compressibility, tabletability and 
plastic deformation compared to the physical mixing, affirmed using 
Heckel analysis which displayed lower (46.9 MPa) with EM as compared to 
PM (222.8 MPa). The greater compressibility and plastic deformation of 
EM in comparison to PM were attributed to its layered microstructure. 
1.4.0. Ultrasound−assisted compaction 
Ultrasound−assisted(US) compaction of pharmaceutical powders extends 
only over the last eight years; it is an innovative technique (Levina, and 
Rubinstein, 2000). Ultrasonic processing offers a net advantage in term of 
productivity, yield, selectivity, better processing time, enhanced quality, 
reduced chemical and physical hazards and environmentally friendly 
(Patist and Bates, 2008; Chemat and Khan, 2011). 
(Levina and Rubinstein, 2000) Used fillers like microcrystalline cellulose 
(MCC) and dicalcium phosphate (DCP) and the binder polyvinylpyrrolidone 
(PVP) to increase the hardness of PA tablets by applying ultrasonic 
assisted compaction method for each formulation (PA/PVP; PA/DCP and 
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PA/MCC) at a compression pressure range of 24−32 MPa. When 
paracetamol was mixed with dicalcium phosphate dihydrate and 
microcrystalline cellulose, stronger compacts were prepared by the US–
assisted compaction compared to the tablets containing no filler. An 
increase in binder PVP concentration and/or US time resulted in a 
significant increase in the hardness of paracetamol tablets produced with 
the US in comparison to the commercial paracetamol. 
1.4. Hot melt extrusion  
Hot melt extrusion (HME) is the process of converting raw material into a 
product of uniform shape and density by forcing it through a die under 
controlled conditions (Breitenbach, 2002). HME offers numerous 
advantages over traditional pharmaceutical processing techniques, 
including, the continuous operation, the possibility of the formation of 
solid dispersions, few processing steps, the absence of solvents/water and 
improved bioavailability (Crowley et al., 2007). Through the short 
duration of the heating process, all components must be thermally stable 
at the processing temperature. Also, this technique necessitates a 
pharmaceutical grade polymer that can be processed at relatively minimal 
temperatures due to the thermal sensitivity of many drugs (Crowley et 
al., 2007). The main disadvantage of extrusion is high shear forces and 
temperatures (Sauceau et al., 2011). 
The direct moulding of isomalt co−extruded with the PA demonstrated to 
be an appropriate method to yield tablets with outstanding physical 
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characteristics. Improved tableting of PA/isomalt tablets was obtained 
using co−extrusion technique before compression and demonstrated 
enhanced tabletabilty in comparison to physical mixture, with the highest 
tensile strength of 2.10 ± 0.16 MPa at 150°C with a compression pressure 
of 25 kN (Ndindayino et al., 2002). 
 1.5. Spray drying  
Spray−drying is a technique based on the transformation of a fluid into a 
dry powder by atomization in a hot drying gas stream that is generally 
air. This method is unique and essential due to the production of dried 
particles from a liquid feed in a single processing step (Rattes and 
Oliveira, 2007). It possesses advantages such as the ease in scaling up, 
less dependence on the properties of drug and polymer. This method is 
fast, convenient and easily performed in mild conditions (Wang and 
Wang, 2002). However, this approach due to the rapid solvent 
evaporation it is recognised to yield amorphous material (Sebhatu et al., 
1994), also with laboratory scale spray−dryers, processing variables must 
be meticulously controlled to avoid difficulties, for example, sticking, high 
moisture content or low yields which are frequently present (Masters, 
1991). Nonetheless, (Vanhoorne et al., 2016) applied spray drying 
technique and used, 25% β−mannitol and 75% PA coating achieved 
∼0.2 MPa at the compaction force of 260 MPa) compared to physical 
mixing over the compaction force range of 50 to 275 MPa. With the 
composition being 5% PVP K30, 20% δ−mannitol and 75% PA coating 
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achieved ∼ two−fold increase in tablet TS compared to physical mixing 
over the compaction force range of 50 to 275 MPa, with the TS increasing 
from 0.8 to 2.1 MPa at 260 MPa. The effect of 5% PVP and 5% 
β−mannitol are comparable, surface coating of PA with 20% δ−mannitol 
is ∼21−fold more effective in enhancing the tabletability of PA than 
physically blending with 20% β mannitol, with the crystal form and 
surface coating contributing 8−fold and 2.6−fold enhancement 
correspondingly (Vanhoorne et al., 2016). 
(Gonnissen and Vervaet, 2007) co−processed paracetamol with water– 
soluble carbohydrates including Erythritol, lactose, maltodextrin, and 
mannitol using spray−drying to enhance the co−processed mixtures with 
an increased in tensile strength from 0.38 ± 0.14 MPa with the spray 
dried paracetamol (absence of carbohydrates) to 2.39 ± 0.52 MPa for the 
mixture of paracetamol/maltodextrin at compression pressure of 74 Mpa. 
Though, the high residual moisture content of 7.10% found in the latter 
mixture could be the reason for the high tensile strength. 
Sadeghi et al. (2013) studied the effect of particle engineering via spray 
drying of the hydro−alcoholic solution in the presence of various 
percentages of PVP K30 (0, 1.25, 2.5 and 5% w/w). Also, the 
co−processed particles exhibited a noticeable improvement in 
tabletability. The tablets produced with physical mixtures containing 2.5% 
PVP were very fragile with no measurable crushing force, and those 
containing 5% PVP showed the maximum crushing force of 6 N (Table 2). 
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Micronised paracetamol (d90 <10 µm, the PA form I was coated with 1%–
10% of hydroxypropyl cellulose (HPC) by applying the spray drying 
technique. The obtained PA tablets demonstrated an increase in tensile 
strength as discussed in (Table 2)(Shi and Sun, 2011).  
Vanhoorne et al. (2014) also applied Crystal coating via spray drying to 
increase the flowability and tabletability of agglomerate individual 
paracetamol particles. The tensile strength of 1.9 MPa obtained from the 
formulation comprises of, 75% paracetamol, 20% amorphous lactose and, 
5% PVP at a compression pressure of 288 MPa, the excellent tabletability 
of this formulation which was ∼5.3 fold higher than that yielded by the 
corresponding physical mixture, with the friability of tablets compacted at 
188 MPa decreased by 36 times to only 0.6% was attributed to the 
coating of paracetamol crystals with amorphous lactose and PVP through 
co−processing. 
1.6. Freeze drying 
Freeze drying (FD) or lyophilisation is an alternative drying technology 
and, it is broadly used in the pharmaceutical industry to provide products 
with enhanced stability and/or desired physicochemical properties, like 
bioavailability or enhanced dissolution rates. Also, this technique involves 
the elimination of frozen water via sublimation (Kaialy et al., 2016). 
Freeze drying is accomplished at relatively low temperatures, and the 
different heat−sensitive biological compounds are not damaged, which 
prolongs stability and circumvent particle aggregation in order to convert 
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the lipid dispersion to a solid state (Krokida and Philippopoulos 2006; 
Varshosaz et al. 2012). However, this approach generates various 
stresses during freezing and drying steps (Abdelwahed et al. 2006). A 
recent investigation demonstrated the formation of a spongy monoclinic 
PA form I prepared on quench−cooling of PA solutions in water–acetone 
mixtures sprayed into a vessel with liquid nitrogen followed by removal of 
solvents by freeze−drying. The obtained microcrystals of PA form I 
demonstrated enhanced compaction properties at a compression pressure 
of 350 MPa which yielded a tensile strength of 1.27 ± 0.27 MPa in 
comparison to the commercial PA with TS value of 0.225 ± 0.03 MPa 
(Ogienko et al., 2011). 
 In the last few decades, the pharmaceutical industry has achieved 
significant progress in its search for new drug compounds by, applying 
combinatorial approaches and high throughput in vivo screening. 
Henceforth, generating highly compactable drug compounds by using 
innovative techniques is now becoming one of the most critical tasks.  
Polymorphs, solvates, salts, amorphous solids are the unique solid forms 
at which a variety of APIs exists. Also, each form shows distinctive 
physicochemical characteristics that can remarkably influence the 
purification, stability, performance properties, bioavailability and 
manufacturability of the drug (Morissette et al., 2004).  
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1.7. The cocrystal route  
Cocrystallisation is renowned as an overall approach of increasing the 
number of solid forms available to an active pharmaceutical ingredient 
(API), and it is a novel technique in pharmaceutical materials science 
(Shan and Zaworotko,2008; Srirambhatla et al., 2014). Also, cocrystals 
are not molecular mixtures of two components or physical mixtures 
(Chieng et al., 2009), as they contain two discrete neutral molecular 
reactants or more components (solids under ambient temperature) 
existing in a definite stoichiometric ratio and are structurally 
homogeneous crystalline materials (Shan and Zaworotko, 2008); by 
definition, these components are organised into three repeated 
dimensional order because they are crystals and each of the components 
has unique positions in the unit cell (Pal et al., 2014). In nature, between 
the components, hydrogen bonding or van der Waals, non–covalent and 
non–ionic interactions are the primary modes of interaction between the 
components. 
The overall drive for investigating pharmaceutical cocrystals as an 
alternative way during drug development is to change the 
physicochemical properties (e.g. Solubility (Zhou et al., 2016), enhance 
the overall stability and efficacy of a dosage form (Blagden et al., 2008), 
mechanical properties (Karki et al., 2009). Nevertheless, for cocrystals to 
occur, it requires some partner molecule that enhances its biological, 
physical, chemical properties and, should be safe to use for human 
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consumption without impeding the pharmaceutical activity of the API, this is 
termed the cocrystal former or coformer (Vishweshwar et al., 2006; Qiao et 
al.,2011; Mohammad et al., 2011). Coformer selection for designing a 
cocrystal is the vital step for designing a cocrystal, and the primary request 
is for a coformer to be pharmaceutically acceptable for example, 
pharmaceutical excipients and compounds categorised as generally as safe 
(GRAS) for use as food additives (Qiao et al.,2011). 
 Solid form screening is being applied to exploit the physicochemical 
property advantage and to achieve regulatory necessities as, it is a 
routine activity in the pharmaceutical industry (Mohammad et al., 2011). 
However, one of the major restrictions of current screening methods is 
that they need large amount of materials, which further often leads to 
crystallisation of individual components; also, it is time-consuming and is 
not transferable to larger scale cocrystal formation (Kuminek et al., 
2016). 
Nonetheless, after the identification of supramolecular synthons for the 
design of new cocrystals (Friščić and jones, 2010), there are two 
sequential phases involved in the screening procedure of choosing 
pharmaceutical cocrystals with preset properties which are, cocrystal 
formation and thermodynamic stability (Manin et al., 2014).  
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1.7.1. The various routes of cocrystals formation 
1.7.1.1. Solution cocrystallisation  
This technique is based on the subsequent two approaches (Childs et al., 
2008): (a) use of non–equivalent reactant concentrations in order to 
achieve the cocrystal stability region in noncongruently saturating 
solvents, which can be exemplified by isothermal ternary phase diagrams 
(TPDs) or (b) the usage of solvents or solvent mixtures where the 
cocrystal consistently saturates and hence the components have 
comparable solubility (Ainouz et al., 2009; Blagden et al., 2008; 
Miroshnyk et al.,2009). However, with solution−based the scale-up of this 
process is also tricky and, this technique habitually needs large quantity 
of solvents and experimental conditions to be tested and can suffer from 
the risk of crystallising the single component phases (Dhumal et al., 
2010). Nonetheless, Hiendrawan et al. (2016) successfully prepared a 
pure cocrystal of PA and 5NIP of 1:1 ratio via the application of rapid 
solvent evaporation technique. The results obtained showed an increased 
tabletability of paracetamol using 29.4 KN compaction pressure, tablets of 
PA−5NIP showed tensile strength value of 2.78 Mpa  
1.7.1.2 Milling 
It is exceedingly hard to relate particles bulk behaviour with its processing 
routes because flow properties of micronised powders in comparison to 
the non–micronised are shown to be poor, which was ascribed to the 
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increase in surface energy (Shah et al., 2017). Also, powders are broadly 
work toughened during the ball milling process (Afshari, and Ghambari, 
2016). Nonetheless, the benefits of this technique include, low 
processing−temperature, low–cost, the potential for easy industrial 
scaling−up (Cai et al., 2010).  
 1.7.1.2.1. Ball Milling  
The material to be ground is partially filled in the ball mill device which is 
customarily, a cylindrical crushing device being utilised for grinding of 
pharmaceutical powders, by rotation around a horizontal axis and the 
grinding medium regularly contains stainless steel balls or flint pebbles or 
ceramic balls (Khadka et al., 2014) (Figure 7). 
 There are two different methods for cocrystal formation via grinding or 
milling. Neat grinding, also known as dry grinding, this approach entails 
one or both reactants displaying significant vapour pressures in the solid 
state. Neat grinding operates mechanically, using a ball mill or a vibratory 
mill or manually using a mortar and pestle to mix the stoichiometric 
cocrystal components (Friščić and Jones, 2009). To date, neat grinding 
has been used to meritoriously prepare many varieties of pharmaceutical 
cocrystals (Jayasankar et al., 2006; Lu and Rohani, 2009; Myz et al., 
2009). Maeno et al. (2009) prepared cocrystals with PA using coformers 
like oxalic acid (OXA) and trimethylglycine (TMG) in 1:1 molar ratio) 
although, the compression and dissolution properties of APAP–TMG were 
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like that of the APAP–OXA cocrystal. Both cocrystals demonstrated 
enhanced tabletabilty compared to PA. 
Grinding (liquid−assisted) or wet co–grinding (also referred to as 
kneading, solvent drop) works by adding small amounts of an appropriate 
solvent during grinding, significant enhancements in the kinetics of 
cocrystal formation can be attained, moreover, the nature of solvents 
used in grinding may have a profound impact on the process of the 
mechano–chemical reaction. The choice of solvent used in grinding is 
significant, and a straightforward prerequisite is that the solvent chosen 
should be capable of dissolving at least part of the original components 
(Shan et al., 2002). According to the Q3C guideline, solvents are 
distributed into four classes (Class 1 possesses environmental hazards, 
and human carcinogens. Class 2 represents possible causative agents of 
irreversible toxicity like neurotoxicity or teratogenicity or non–genotoxic 
animal carcinogens solvents. Class 3 have an acceptable daily exposure of 
up to 50 mg and are commonly used in the chemical and pharmaceutical 
industry. Thus, for toxicological reasons manufacturers are increasingly 
required to reduce the number of solvents used in drug production 
(Grogowska and Parzcewski, 2010). 
Karki et al.(2009) applied liquid−assisted technique in the formation of PA 
cocrystal using theophylline (THP) and naphthalene (NAP) 
phenazine(Phe2) and oxalic acid (OXA) as coformers, which showed 
improved tabletability (Figure 2) also, the enhanced mechanical 
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properties were attributed to differences in crystal packing, the obtained 
cocrystals exhibited a layered structure in comparison to monoclinic PA 
(corrugated structure)(Figure 3). 
 
Figure   2. Tableting results of paracetamol form I. (a) Cocrystal with 
theophylline; (b) cocrystal with naphthalene; (c) cocrystal with oxalic 
acid; (d) cocrystal with phenazine. Adapted from (Karki et al., 2009). 
 
                                  
 
        
Figure 3. Paracetamol and its cocrystals (a) Molecular diagram of 
paracetamol; single hydrogen-bonded sheet in the cocrystal of 
paracetamol(yellow) with (b) oxalic acid, (c) theophylline, (d) 
naphthalene and (e) a single hydrogen-bonded and p-stacked chain in the 
cocrystal of paracetamol and phenazine. Adapted from(Karki et al., 
2009). Cocrystal formers are shown in black.               






1.7.1.3. Supercritical fluid technology 
 
Over the last years, the interest in the use of supercritical fluids mainly 
supercritical CO2 for particle engineering has received consideration from 
the pharmaceutical industry. The method can be carried out at near-
ambient temperatures consequently avoiding the thermal degradation of 
the substance in addition, carbon dioxide has comparatively, low toxicity, 
low critical temperature (31.1 °C) and low cost thus, makes it by far the 
most vital processing medium (Martín and Cocero, 2008; Shekunov et al., 
2001). However, the drawback of this technique is the obvious routes to 
commercial scale–up because of the high cost of large pressure vessels 
and, many of the supercritical researches have been carried out on batch 
reactions in sealed autoclaves (Han and Poliakoff, 2012).  
Hiendrawan et al. (2016) successfully employed the above technique to 
obtain pure PA−DPA cocrystal with enhanced tableting and dissolution 
properties than commercial paracetamol at a compression pressure range 
of 4.9 kN−29.4KN. 
Zhao et al. (2018) produced a cocrystal PA–TMG using the Supercritical 
CO2 anti-Solvent (SAS) and ball milling (BM) techniques. For the cocrystal 
obtained with SAS, various operating parameters such as volume ratio 
(Vr), solution flow (Fl), the precipitation pressure (P) and temperature of 
precipitation (To) be employed. The optimal PA–TMG cocrystals presented 
a much larger tensile strength (with DC = 61.17 ± 1.82 %) and TS = 
11.13 ± 0.46 MPa) over a compression pressure of 20kN to 80kN. Higher 
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drug content of PA and smaller particle size, which provides a larger total 
area for bonding and higher bonding strength than larger particles (Sun 
and Grant, 2001). In contrast to the BM sample, which recorded a TS of 
20 kN (1.9 MPa) and 80kN at 5MPa (Zhao et al., 2018). Regardless of the 
techniques employed in the study, the tensile strengths were far better 
than that of the commercial Paracetamol. 
1.8.0 The use of functional excipients 
Excipient characterisation efforts have become more established because 
excipients in pharmaceutical dosage forms are immensely seen as vital 
contributors to the general characteristics of the dosage (Wasylaschuk et 
al., 2006). Notwithstanding, the physicomechanical properties of 
excipients which encompass good flowability, compressibility, low or no 
moisture sensitivity, low lubricant sensitivity, and good machineability 
even in high–speed tableting machinery with reduced dwell times 
(Chowdary et al., 2012). Also, excipients provide an enhanced tablet 
binding, disintegration and better active pharmaceutical ingredients 
bioavailability, also processability of different active pharmaceutical 
ingredients into dosage forms due to their wide variety of functionalities 
(Eraga et al.,2015). 
Formulation development offers a route to prepare a robust dosage form 
to resist post–compaction handling and transportation that includes 
choosing the suitable excipients to disguise or compensate lacks that are 
intrinsic to an API (Sun, 2009; Okoye et al., 2010).  
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A cellulose powder coated with 2% colloidal silica, known as Vitacel M80K 
is a newly developed direct compressible vehicle (DCV) and other known 
DCVs such as Elcema (P050+2% Aerosil 200) and AVICEL PH 101 were 
blended with paracetamol separately, further compressed using two 
compression forces at 10kN and 20kN. Paracetamol, M80K, Elcema 
P050+2% Aerosil 200 and AVICEL PH 101 resulted in the production of 
tablets with enhanced hardness, reduced disintegrating time and friability. 
The effect of increasing the applied compression force from 5 to 35 kN on 
the hardness and friability of paracetamol tablets formulated with the 
various DCVs, it was apparent that the increase in tablet hardness as a 
function of compression force was higher for M80K and ELC+ tablets than 
for Avicel tablets. Nonetheless, M80K−paracetamol tablets showed 
minimum friability values and the highest hardness sensitivity towards the 
increase of the applied compression force between 5 and 35 kN than the 
commercial paracetamol alone (Nada and Graf, 1998).  
Obeidat et al. (2015) applied physical mixing of paracetamol with two 
polymers, Carbopol®971P NF and Eudragit®E100 of different sieved sizes 
to improve the crushing strength of PA tablets using different compression 
pressure (245 MPa, 490 MPa and 735 MPa) and, the obtained 
formulations  sustained the release of PA. However, the compression 
pressures applied for each formulation were deemed extremely high. 
Nonetheless, the crushing strengths of the formulations were better than 








Additives Coformers Compaction 
pressure 
Outcomes Reference(s) 
Spray drying PVPk30 (0, 1.25%, 
2.5% and 5%) 
-  
15kN 
(25, 50, 75 and 
110) N 
 
Sadeghi et al. 
(2013) 
PM PVPK30 (2.5% and 5%) - (0 and 6N) 





(1.51, 1.95, 2.84 





(Sun and Shi, 2011) 









(11.6 ± 1.5) kg  
 
(Maeno et al., 2014) Oxalic acid  13.0 ± 1.4(kg) 
52 
 
1.9.0. Factors influencing compaction properties 
Mechanisms for inter–particle interaction can be categorised as two broad 
classes, chemical and physical interactions. Physical interaction is due to 
intermolecular forces, for example, hydrogen bonding and van der–Waals. 
While, chemical interaction entails mostly metallic or electrostatic bonds, 
ionic and covalent. Inter–particle interaction is argued to be controlled by 
the material surface properties (Kendall, 1994). Also, the physical 
properties of pharmaceuticals are linked to one other, due to the 
modification of one of the properties, it can immensely affect the 
performance and processing of the solid dosage forms as well as, their 
compressibility (Sun, 2011). 
1.9.1. Surface properties 
The rise of the free surface energy of solid plays a pivotal role in 
interparticulate interaction, because ions or atoms located at a surface 
have a different distribution of intramolecular and intermolecular bonding 
forces than those existing within a particle, which is due to the unsatisfied 
attractive molecular forces that spread out to some small distance beyond 
the solid surface. So, surface properties of a powder material have a 
crucial impact on their flow and intermolecular attraction (Booth and 
Newton, 1987). Particulate attractive forces comprise of those called 
adhesion, which is between un−like particles and, conversely between like 
particles called cohesion (Otsuka, 1998). The attractive forces’ resistance 
to relative movement of particles consists of, the adsorbed moisture, 
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residual solvent and electrostatic forces on the surface of solid particles, 
whereas, the other type resists the differential movement of constituent 
particles when exposed to an external force (Marshall, 1986). 
1.9.2. Compression 
The powder bed undergoes severe densification and the powder particles 
move collectively to form aggregates with significant, cohesive strength 
due to, mechanical interlocking, formation of solid bridges and Van der 
Waals forces; following the movement of the upper punch towards the 
bottom punch (Alderborn and Nystrom, 1996; Shah et al., 2017)(Figure 
4,5 & 6). 
1.9.3. Decompression  
The compaction pressure falls rapidly as the distance between the two 
punches rises, and some of the elastic strain induced during compression 
will recuperate, this takes place once the upper punch starts to move 
away from the lower punch, a subsequent decrease in the relative density 
during this process afterwards follows an increase in the volume of the 
powder bed. Defects, like fracture of powder compacts and cracks, are 
more likely to be induced by a quicker elastic recovery, or spring–back, 
during decompression. So, controlling the elastic recovery rate is vital in 
the processing of powder compacts (Wu et al., 2005). There is a rise in 
the amount of particle surface area capable of forming interparticulate 
bonds as fine particles enter the voids between the larger ones and give a 
closer packing arrangement in this process also the energy is evolved 
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because of interparticulate friction (Marshall, 1986). Furthermore, the 
extent of volume reduction will be contingent upon the type of volume 
reduction mechanisms involved that pharmaceutical powder beds will 
undergo, and the mechanical characteristics of the powder, for example, 
plastic substances which undergo an irreversible process during 
deformation and leads to a lasting change in particles shape. Whereas for 
the elastic substance, the process is reversible, and its particles shape 
returns to its initial after undergoing deformation (Sun and Grant, 2001). 
Brittle materials that suffer extensive fragmentation produces tablets with 
a comparatively high porosity which halt further volume reduction, 
because of many bonding points that are being formed. On the other 
hand, for a ductile material because of the high degree of plastic 
deformation that occurs, it enables the particles to move to proximity to 
one another which frequently leads in tablets with reduced porosity. Also, 
different crystal habits possess different tendencies to pack in a closed 
structure, for example, spherical, cubical, and acicular (Booth and 
Newton, 1987; Joiris et al., 1998). 
1.9.4. Other factors influencing compaction properties. 
Particle size, size distribution (Vanhoorne et al., 2016 ;Sun and Grant, 
2001; Sun and Himmelspach, 2005); crystal habit (Garekani et al., 
2000;Kaialy et al., 2014), temperature (Olusanm et al.,2010), 
crystallinity (Kaialy et al., 2016), polymorphism (Al–zoubi et al., 2000; Di 
Martino et al., 2000), amorphism (Sadeghi et al., 2000), inter–planar d–
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spacing (Shariare et al., 2012), Moisture Content (Alderborn and 
Ahlneck,1991; Joiris et al., 1998; Gupta et al., 2005; Sun,2008), surface 
energy (Heng et al., 2006), molecular packing in crystal lattices, plasticity 
(Chattoraj et al.,2010; Karki et al., 2009; Jain et al.,2014), energy of 
mixing (Agbor Rose and Kaialy, 2019) are among the most common 
elements that can change the compression properties, because they play 
a crucial role in enhancing the tensile strength of the powder bed and 
decreasing the density variation within the tablet during interparticulate 
bond formation (Doelker and Massuelle, 2004).  
 The development of oral formulations that can explicitly release the 
medicament for optimal therapeutic benefits was facilitated due to its 
variable and versatile physiological conditions (Jindal et al., 2016). 
Materials and methods that lead to the production of compressed tablets 
at a comparatively reduced cost, high speed, and containing a precise 
quantity of an active pharmaceutical ingredient (API) have been 
developed over the past decades by tablet manufacturers (Gohel and 
Jogani, 2005). In order to, circumvent the production of weak tablets with 
surface damage by chipping, which cannot only alter content uniformity 
but is unappealing and disagreeable. These tablets can result in waste 
that no longer meets required product specifications since they are 
frequently susceptible to breakage via production transportation and end 
use (Hare et al., 2018; Sun, 2011). Tablet product design guiding; (i) 
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rational excipient selection (ii) appropriate selection of the manufacturing 










Figure 4. Phases observed during powder compaction. (a) particles 
packed in the die before compaction; (b) particles are deformed under 
maximum compaction pressure at the end of compression phase; (c) a 
porous tablet formed with an extensive recovery of elastic particles during 
decompression phase;(d) a dense tablet of plastic particles is formed after 





Figure 5. The relationship between crystal structure and powder 
tabletability. Modified from (Sun, 2009). 
 
Figure 6. Different interparticle interaction mechanisms. Adapted 







































1.10. AIMS AND OBJECTIVES 
  
Tablets remain the best form of oral drug delivery. However, due to the 
poor pharmaceutical properties such as, poor tableting properties, 
amorphorcity, polymorphism and inadequate stability which many drugs 
possess nowadays, leads to the decrease of their bioavailability. Although 
many pharmaceutical industries and research scientists are yet to 
formulate and acquire paracetamol crystals with improved 
physicomechanical properties while maintaining the thermodynamically 
stable form. So, the aim of this research is to apply various co–processing 
techniques which can influence paracetamol crystals in the presence of 
functional excipient/drugs like; excipient polyvinylpyrrolidone (plastically 
deforming), ibuprofen (plastically deforming upon milling), Chondroitin 
sulphate, aspirin, caffeine (plastically deforming) and curcumin that own 
favourable mechanical properties due to the functional groups that they 
possess and could be the potential resolution to enhance the poor 
pharmaceutical properties of paracetamol crystals. 
The objectives of the thesis comprise of: 
1. Effect of preparation methods, mixing conditions and freezing 
temperatures on paracetamol and polyvinylpyrrolidone mixtures in order 
to evaluate their impact on the mechanical properties of paracetamol in 
comparison to the commercial paracetamol 
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2. Engineering of binary mixtures of paracetamol/ibuprofen, 
paracetamol/curcumin and paracetamol/chondroitin sulphate A and 
ternary mixtures of paracetamol/aspirin/caffeine on the tabletability of 
paracetamol  
3. A successful preparation of paracetamol–5-Nitroisophthalic acid 
cocrystals via the applicability of engineering methods to increase the 
tensile strength of paracetamol crystals. 
This research is explicitly based on the tabletability/compaction process. 
We focus on an approach where; the powder is compressed by the upper 


































2.1. Materials  
Paracetamol (PA,4-hydroxyacetanilide; acetaminophen; 4-
acetamidophenol, >98.0%), polyvinylpyrrolidone K30 (PVP K30, average 
molecular weight: 40,000), ibuprofen (IBU, 2−(4−isobutyl 
phenyl)propionic acid, >98.0%), caffeine (CAF, C8H10N402, >98%), aspirin 
(ASP, Acetylsalicylic acid, >98%), 5-nitroisophthalic acid (5NIP, 
C8H5NO6), curcumin (CUR, E,E –1,7–Bis (4−hydroxy-3-methoxyphenyl) –
1,6–heptadiene–3,5-dione (Natural) and chondroitin sulphate c sodium 
salt from bovine trachea (CHONS, C13H21NO15S > 98%, MW: 58,000 
g/mol) were purchased from Tokyo chemical industry (Tokyo, Japan); 
95% butanol, acetone, methanol,  100% absolute ethanol used in the 
content uniformity test, APC pure n–hexane (Cheshire, UK) and sodium 
chloride used for water absorption analysis were all purchased from Fisher 
Scientific (Gillingham, UK); BOC liquid nitrogen (Dudley, UK) and distilled 
water respectively.  
2.2. Methods 
2.2.1. General techniques employed for the preparation 
of formulations  
2.2.1.1 Physical mixing (PM) or low shear mixing 
A calculated quantity of various powders under investigation was mixed 
using a V–shaped powder mixer (GHP72, Zhejiang Wisely Machinery, 
Jiangsu, China; 50cm × 22cm × 22cm, L×W×H). Mixing was performed 
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at a rotation speed of 50 rpm (ten rotations clockwise followed by ten 
rotations anticlockwise repetitively) for 30 min under laboratory 
conditions (22 °C, 50% relative humidity (RH). 
2.2.1.2. High shear mixing 
A calculated amount of various powders under study was blended using a 
powerful motorised high shear mixer (Tefal, Berkshire, UK). It operated 
by rotation of two double–edged blades (6.5 cm×1.5 cm) at ~500 rpm in 
a 186–cm3 bowl at different time intervals.  
2.2.1.3. High–speed homogenization mixing 
A calculated amount of various powders under study was mixed in a high–
speed homogeniser (HSH, Silverson L5M, Massachusetts, USA) at 4000 
rpm for 10 min. The resultant suspension was filtered (< 0.45 μm, 
cellulose filter paper, Fisher Scientific, UK) and then left to dry in an oven 
(Memmer, Durham, UK) at 50 °C for 12 h. 
2.2.1.4. Batch cooling crystallisation (BCC) technique 
 
 Supersaturated aqueous solutions containing PA mixtures under study 
were prepared by dissolving in different amounts in each solvent under 
constant stirring of 200 rpm at a specific temperature. After being wholly 
dissolved all solutions were removed from heating and allowed to settle 
and cool (uncovered) at ambient conditions (22ºC, 50% RH) for some 
specific days until no apparent water could be observed in crystallisation 
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media of any samples. Then, each powder under study was harvested 
then left to dry in an oven (Memmer, Durham, UK) at 40 ºC. 
2.2.1.5. Solvent evaporation (SE) preparation 
 
A calculated amount of different powders under analysis was dissolved in 
different quantities of each respective solvent. The resultant solution of 
each mixture was stirred at 200 rpm using Stuart heat–stirrer at a 
constant temperature of 70 ºC until all the solvents present evaporated. 
The precipitated crystals in beakers were left to dry in an oven (Memmer, 
Durham, UK) at 40 ºC until no apparent water could be observed in 
crystallisation media of the sample. 
2.2.1.6. Freeze drying (FD) technique 
 
 Freeze dried of various components under investigation were prepared 
accordingly, each solution was obtained by introducing into a 500 mL 
round–bottomed flasks (Shotts DURAN) and subsequently freeze–dried by 
applying a protocol as entails. The flasks encompassing the frozen 
formulations of PA solutions were rapidly placed on the shelves of a Christ 
Beta 1–8 LD Freeze Dryer (Martin Christ Gefriertrocknungsanlagen GmbH, 
Osterode am Harz, Germany) using manifolds. The primary drying was 
performed at a shelf temperature of −40 oC vacuum pressure of 0.500 
Mbar and a safety pressure of 0.770 Mbar while the final drying was 
performed at a shelf temperature of –25 ºC, the vacuum pressure of 
0.370 and a safety pressure of 0.633 Mbar). The freeze-dried 
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formulations were collected after 72h after which, they were transferred 
into sealed glass vials over silica gel until used. 
2.2.1.7. Milling (ML) technique  
 
Various formulations under investigation were milled into a hardened 
stainless steel jar vial (80 mL) using a Fritsch Pulverisette 6 (Fritsch 
GmbH Pulverisette 5, Idar−Oberstein, Germany), a planetary ball mill 
equipped with 18 balls (diameter ≈10 mm) at a constant speed of 400 
rpm using different time intervals with no repetitions and the powder and 
further stored in a sealed glass vials at room temperature until required. 
All mixtures prepared were stored in sealed glass vials for at least seven 
days at the laboratory conditions (22 ºC, RH = 50%). Preparations were 
performed at least in triplicate using an identical protocol to ensure 
reproducibility. 
2.3. Sieving  
Each mixture of PA formulation was poured onto the top of 500 μm 
sieve (Retsch® Gmbh Test Sieve, Germany) which was placed above 
another 1000 μm sieve. The sieve shaker (Retsch® Gmbh Test Sieve, 
Germany) was operated for 15 min. After sieving, the required size 
fraction (<500 μm) was collected. All engineered samples were stored in 
sealed glass vials for at least seven days under laboratory conditions 
(22°C, 50% RH) before further investigation to allow any possible charge 
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relaxation to occur (Kaialy, 2016a). The mixtures were prepared in 
triplicate (or better) using an identical protocol to ensure reproducibility. 
2.4. Content uniformity 
Five samples were selected randomly from different spots of each PA‒
PVP mixture to determine the quantity of PA in the mixture. Each sample 
weighed 526.3 mg ± 0.5 mg (corresponding to 500 mg unit dose of PA) 
and was dissolved in a fixed amount of solvent (hydro−alcoholic solution, 
25% ethanol/water v/v). Each solution was analyzed for PA content using 
an ultraviolet spectrophotometer (Biochrom WPA Biowave II UV/visible, 
Cambridge, UK) at a wavelength of 250 nm. A calibration curve for the 
concentration of PA was constructed with a coefficient of determination of 
0.9996. The samples were diluted for the drug concentrations to fall 
within the range covered by the calibration curve. For each mixture, the 
PA content uniformity was calculated as the percent amount of 
paracetamol in the nominal dose (500 mg). The degree of paracetamol 
content homogeneity was evaluated using the percent coefficient of 
variation (%CV: ratio of the standard deviation of drug content to the 
average drug content in the sample expressed as a percentage). A higher 
%CV value indicates a decrease in drug content homogeneity. A mixture 
is considered homogeneous when the content uniformity of the drug 
content is between 90% and 110%, and the CV is below 6%, according to 
the FDA guidelines (Williams, Adams, Poochikian, & Hauck, 2002). 
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2.5. Laser diffraction analysis 
Volume-weighted particle size analyses of various powders under 
investigation were conducted using a Malvern Mastersizer 2000 (Malvern 
Instruments, Germany) laser diffraction particle size analyzer equipped 
with a dry sampling system (Aero S, Malvern Instruments, UK). The 
particle size range covered by the laser diffractometer was 0.1–3500 μm. 
Before measurement, a background reading was taken. The dispersion air 
pressure was adjusted to 2.0 bars, and the feed rate was adjusted to 
30%. The measurement time was 5 s. The particle sizes at 10% (d10%), 
50% (d50%, median diameter), and 90% (d90%) of the volume distribution, 
and the volume mean diameter (VMD, the average diameter based on the 
unit volume of a particle) were calculated automatically using the Malvern 
software (version 2.20). The span (calculated using Eq. (1)) of the 
volume distribution was used as a measure of the width of the distribution 
of size relative to the median diameter. Three samples were measured for 




.          (1) 
2.6. Scanning electron microscopy 
A representative specimen of each sample was gently mounted on an 
aluminium stub (G301, Agar Scientific, Essex, UK) with double-sided 
adhesive carbon tabs (G3347N, Agar Scientific). To increase the electrical 
conductivity on the surface of the samples, a sputter coater (Emscope 
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SC500, Quorum Technologies, Laughton, UK) was used to coat the 
samples with gold (15 nm layer thickness) in an argon atmosphere before 
observation. The morphological properties of the various powders under 
study were examined using a field-emission scanning electron microscope 
(SEM, Zeiss EVO050, Germany) with an acceleration voltage of 10 kV and 
a beam current of 10 µA. The powders were handled with care during 
preparation. 
2.7. Bulk properties 
An accurately weighed amount of each powder was gently poured into 
a 10-mL glass measuring cylinder using a glass funnel. The bulk volume 
was recorded, and then the cylinder was tapped (Tapped Density Tester, 
Copley Scientific, UK) under laboratory conditions (22 °C, 50% RH) for 
500 taps. The volume was recorded after every 50 taps. The experiments 
showed that 500 taps were adequate to reach the maximum reduction in 
volume of the powder beds. The bulk density (or apparent density, Db), 
tap density (or drop density, Dt), and Carr index (CI, Eq. (2)) of each 




) × 100.         (2) 
Based on the calculated CI values, powder flowability was described as 
excellent (CI < 10%), fair (CI 16%–23%), or extremely poor (CI > 38%). 
The packability was determined from the tapped density, according to 















,           (4) 
Where n is the tap number, C denotes the volume reduction (Eq. (4)), 
and V0 and Vn are the powder bed volumes at the initial and n
th tapped 
state, respectively. The plot of n/C versus n is linear. The cohesivity is a 
constant related to cohesion, represented by 1/b, and is obtained from 
the intercept of the plot through the modified Kawakita and Lüdde's 
equation. Three different samples were analyzed for each product. 
2.8. Powder X–ray diffraction 
To monitor the phase purity of PA co–processed under different 
conditions, powder X–ray diffraction (PXRD) structural patterns of all the 
various powders under investigation were recorded using a Panalytical 
Empyrean diffractometer (PANanalyical, Almelo, The Netherlands) with Cu 
Kα radiation (1.54056 Å) operated under laboratory conditions (22 °C, 
50% RH). Each sample was placed in a sample holder, surface-smoothed 
with a glass slide, and scanned between 2θ values of 5° and 40° with a 
step-by-step increase of 0.01°/s. The sample stage was spun at 30 rpm. 
The instrument was calibrated using a silicon standard. The reproducibility 
of the PXRD patterns was verified by collecting multiple patterns of three 
different specimens of each sample. 
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2.8.1. Determination of the percentage of crystallinity 
(Alternative technique) 
Following the technique employed in (Section 2.8.0) the background of 
the diffractogram of some specific samples were determined, followed by 
a scan list. Also, the scan statistic of the diffractogram of each sample 
was expanded. Also, the constant background which was initially set at 
minus one was changed to minus 241 in order to correct the crystallinity 
value as shown in (Table 21). 
2.9. Fourier transforms infrared spectroscopy 
The molecular structure of the starting materials and all the mixtures 
were analysed using an Alpha Platinum–ATR Fourier transform infrared 
(FT–IR) spectrometer (Bruker, USA) to investigate whether PA was 
chemically altered or whether any interaction with PA at the molecular 
level occurred during the preparation of different mixtures. A few 
milligrams of each powder was placed in the middle of the sample stage 
and were compressed by clicking the top of the arm of the sample stage. 
The samples were scanned under laboratory conditions (22 °C, 50% RH) 
over a wavenumber range of 400–4000 cm−1 with a 1 cm−1 resolution. 
Before each measurement, a background spectrum of air was acquired 
under the same instrumental conditions. The spectrum produced for each 
sample was the average of 15 scans. The acquired spectra were 
processed using Opus software (version 7.5.18, Massachusetts, USA)
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2.10. Thermogravimetric analysis (TGA) 
An accurately weighed sample of the starting materials and all the 
mixtures was placed in an open pan and analysed using a 
thermogravimetric analyser (Perkin–Elmer Thermal Analysis Series 7, 
Norwalk, USA). Mass calibration was performed with a 100–mg calibration 
weight. Each sample was heated from room temperature to 600 °C at a 
heating rate of 10 °C/min. The internal atmosphere was maintained by 
purging nitrogen as a purge gas at a flow rate of 20 mL/min. The 
reduction in the mass of the samples was measured. 
2.11. Differential scanning calorimetry (DSC) 
Differential scanning calorimeter (DSC Q2000 DSC (TA Instruments, 
Hertfordshire, UK) was used to examine the various samples. The 
commercial PA, commercial 5NIP, and the cocrystals powders (2.0 mg ± 
0.5 mg) were heated individually, from 50 to 300 ºC at a scanning rate of 
10 ºC/min, in hermetically sealed T zero aluminium pans. A purge gas of 
nitrogen was passed over the pans with a flow rate of 50 mL/min. The 
instrument was calibrated using indium (> 99.999%, DE, USA). Indium 
standard was used to calibrating the cell constant (enthalpy) and 
temperature, conducted at a heating rate of 10°C/min. A calibration check 
was made, before experimentation, using the indium standard 
(Onset=156.6 °C ± 0.2 °C, Peak Area=28.45 J/g ± 0.5 J/g). All the peak 
and onset temperatures and their enthalpies were calculated using TA 
TRIOS Software V4.3.1. 
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2.12. Karl Fischer titration  
The (residual) moisture content of both the commercial materials and the 
engineered powders were determined by the Karl–Fisher method (Metter 
Toledo, C20 Coulometric KF Titrator, Switzerland). The Fischer reagent 
solution was Hydranal1 Coulomat AF (Sigma-Aldrich, USA). Following the 
calibration of the instrument, samples were rapidly added into the titrator 
vessel at the laboratory temperature (22 ºC), and the titration of each 
sample was repeated three times. 
2.13. Water absorption 
An accurately weighed sample of some of the powders under study 
was stored in a desiccator containing a saturated solution of pure sodium 
chloride, which gives a relative humidity of 75% at 25 °C (Richardson & 
Malthus, 1955). The mass of each stored sample was recorded at a time 
interval of 1, 3, 6, 12 months. The final mass (Wf) was noted when there 
was no further change in the sample mass. The percent moisture content 




 ×100     (5) 
2.14. Preparation of tablets 
Compression of the various powders under processing was carried out 
using a manual single punch Specac press (KBR 25.011; Gemini BV, The 
Netherlands) fitted with 13-mm-diameter flat-faced punches to produce 
round tablets with a target mass corresponding to a 500–mg unit dose of 
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PA. Before compression, the compaction surfaces were lubricated with 1% 
(w/v) magnesium stearate (Acrõs Organics, New Jersey, USA) in acetone 
(Fisher Scientific, UK) to reduce the friction between the die and the 
tablet, and to prevent the tablets from sticking to the die walls and punch 
faces. Tablets were compressed at increasing compression pressures of 
37, 74, 111, 148, 185, and 222 MPa under load for 10 ± 1 s dwell time. 
Tablet diameter and thickness were measured using a digital micrometer 
(Fisher Scientific, UK) immediately after ejection and 24 h after ejection 
to allow for elastic recovery and possible hardening of tablets. Tablets 
were stored in screw-capped glass vials (22 °C, 50% RH). The results 
were generated as the mean and standard deviation (SD) of three 
determinations. 
2.15. Crushing strength and capping tendency 
The crushing strength was determined from the force required to 
fracture the tablet by diametral compression on a motorised Vankel Tablet 
Hardness Tester (Benchsaver VK 200, USA). The tensile strength (TS) of 




          (6) 
Where D and t are the diameter and thickness (mm) of the compact, 
respectively, and F is the force exerted to fracture the compact. Tests 
were carried out 24 h after ejection. Five tablets were selected for 
crushing strength measurements. 
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2.16. Friability test 
 Ten tablets compressed at a specific compression pressure of some of 
the samples were selected randomly, and the tablets were accurately 
weighed (initial weight). The tablets were placed in a friability tester and 
rotated at a constant speed of 25 rpm for 4 min in Erweka friabilator. The 
tablets were cleaned from loose dust and reweighed (final weight) and the 





× 100                                                               (7) 
 
Where: W1 = collective weight of tablets before testing. W2 = collective 
weight of tablets after testing. 
2.17. UV calibration curve of PA in aqueous media 
 A stock solution of PA reference standard was prepared by transferring 
10 mg of the drug into a 100 ml of volumetric flask and diluting with 
distilled water. From this stock solution, seven various concentrations 
(0.001, 0.002, 0.003, 0.004, 0.005, 0.1 and 0.2 mg/ml) of each solution 
were transferred to 100 ml volumetric flasks and diluted with distilled 
water. The UV absorbance reading of this solution was measured at 250 
nm for PA using UV/Visible spectrophotometer (UV–160, Shimadzu, 
Japan). Distilled water was used as a reference. Then, the absorbance 
versus concentration of solutions was plotted to obtain the calibration 




Figure 8. UV absorption calibration curve of PA reference standard in 
aqueous media at 250 nm. 
2.18. In–vitro dissolution studies 
This dissolution test was carried out to obtain the release profiles PA, the 
engineered mixtures to evaluate the inherent dissolution properties of 
different crystals. The dissolution profiles of paracetamol powders were 
evaluated using USP dissolution apparatus 2 (paddle method). Three 
tablets were tested for each formulation. The dissolution medium (900 mL 
of distilled water) was equilibrated to 37 ± 0.5 ºC at 50 rpm using the 
rotating paddle. Samples were withdrawn at pre-determined time 
intervals (5, 10, 15, 20, 25, 30, 40, 50 60, 75, 90, 105, 120, 140, 160 
and 180 min). The amount of the paracetamol dissolved in the dissolution 
media was properly diluted and assayed spectrophotometrically at 250 
nm max using a spectrophotometer (UV-160; Shimadzu, Kyoto, Japan). 
All determinations were carried out in triplicate. 
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2.18.1. Dissolution parameters 
The percentage of paracetamol dissolved was calculated, and a minimum 
of three determinations was carried out for each sample (mean ± SD, n = 
3). The dissolution efficiency (DE, Equation 7) (Khan, 1975) and the mean 
dissolution time (MDT, Equation 8), such mathematical analyses enable 
statistical comparisons between the various formulations. The DE is the 
area under the dissolution curve produced up to a certain time, t, 
expressed as a percentage of the area of the rectangle. 
Where t is the total time of drug release, y is the percentage of drug 
release at time t and Y100 is a 100% drug release. The MDT is a model-
independent method that is suitable for dosage forms having different 
mechanisms of drug release. 
 The MDT is the time at which 50% of the drug is dissolved from its solid 
state under dissolution conditions (Equation 8). 
Where j is the sample number, n is the number of dissolution samples, ∆t 
or tj is the time at the mid – point between t and t – 1 (which can be 
calculated using (t + (t –1))/2) and ∆Mj is the additional amount of drug 















2.18.2. Comparison of release profiles 
The dissolution behavior of PA and the formulations tablets in deionised 
water were analysed. The drug release characteristics for the two 
formulations (PM (FDPA–FDCHONS)) and FD (PA–CHONS) and variables 
(PA and FDPA) under investigation were compared, by calculating the 
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𝑋 100} ……..                                                       (10)   
Where, Rj and Tj are the cumulative percentage dissolved at each of the 
selected n time points of the commercial particles (reference) and freeze–
dried mixtures (test product), respectively. In general, the dissolution 
profiles were taken as similar with f1 value lower than 15 and f2 value 
higher than 50.  
2.19. Statistical analysis 
One-way analysis of variance (ANOVA) test was employed to statistically 
compare mean results in this study, considering statistical probability (P) 
values less than 0.05 as indicative of significant difference. When ANOVA 
indicated a significant difference, Tukey’s Honestly Significant Difference 
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3.1.0. Effect of mixing conditions  
3.1.1. Introduction 
Tablets are the most popular solid dosage forms because of their 
several advantages, including ease of administration, precise dosing, ease 
of manufacture, good product stability in comparison with liquids, and 
lower vulnerability to tampering than capsules, and most desired in 
comparison to capsules followed by powders and fines granules (Sunada 
and Bi, 2002; Brniak et al., 2015; Morissette et al. 2004; Gohel & Jogani, 
2005). Direct compression (DC) is the favoured modern choice for tablet 
manufacturing. The advantages of DC include simplicity, reduced time 
and final cost of the product because of fewer processing stages, 
continuous nature, and elimination of heat and moisture effects. These 
latter attributes make DC suitable for processing hygroscopic and 
thermo–sensitive materials (Jivraj, Martini, & Thomson, 2000). However, 
it is unfortunate that less than ~20% of pharmaceutical powders can be 
compressed into tablets by DC because of their inherent poor functional 
properties required for DC (Armstrong, 2007). The situation is particularly 
severe when the formulation requires a high dose of a poorly compactible 
drug such as paracetamol (PA). PA is a widely used analgesic drug. The 
monoclinic form is usually selected in the pharmaceutical industry and is 
commercially available because it is the most thermodynamically stable 
form at room temperature and pressure. However, the monoclinic form of 
PA is notorious for exhibiting poor tableting properties by DC, reduced 
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plastic deformation during compression, and poor flowability. These flaws 
commonly result in fragile tablets with a high propensity to cap. Such 
poor mechanical properties have been explained in terms of the 
monoclinic crystal structure of PA (Beyer, Day, & Price, 2001). 
Crystallization has been extensively investigated as a particle engineering 
technique to improve the functional properties of poorly compactible 
drugs via the formation of an amorphous state (Berggren, Frenning, & 
Alderborn, 2004), a modified polymorphic form (Di Martino Guyot-
Hermann, Conflant, Drache, & Guyot, 1996), and/or particle shape 
(Kaialy, Larhrib, Chikwanha, Shojaee, & Nokhodchi, 2014). However, 
studies on the effects of secondary manufacturing processes, such as 
mixing, on the tableting performance of poorly compactible drugs have 
been limited (Sallam & Orr, 1985). Mixing has evolved from being an 
empirical process to be a meticulously controlled process, therefore, 
optimum mixing is crucial for the manufacture of nearly all solid dosage 
forms (Kaialy, 2016b). 
This work is aimed to study the influence of mixing conditions on the 
tableting properties of PA processed in the presence of 
polyvinylpyrrolidone (PVP), which is a plastically deforming binder under 
compaction. Because PVP contains carbonyl groups, it has the potential to 
interact via hydrogen bonding with drugs that contain amine groups, such 
as PA (Garekani, Ford, Rubinstein, & Rajabi-Siahboomi, 2000). A PVP 
concentration of only 5% (w/w) was used in this investigation because PA 
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requires high doses (300–1000 mg) for its analgesic and antipyretic 
actions. This means that a minimal amount of excipient(s) should be 
added to the formulation to minimise the mass of the final dosage form. 
The effects of various dry and wet mixing conditions on the 
physicochemical and mechanical properties of PA–PVP mixtures were 
studied. 
3.2. Engineering of PA–PVP formulations 
3.2.1. Low energy dry mixing 
Tumble mixing is known to produce low shear forces, whereas hand 
mixing produces medium shear forces (Kaialy, 2016b). 
3.2.1.1. Low shear (LS) or physical mixing (PM)  
PA and PVP (95:5 w/w) powders were mixed using the technique in 
(Section 2.2.1.1).  
3.2.1.2. Medium shear (MS) mixing 
PA and PVP (95:5 w/w) powders were hand mixed by vigorous 
shaking in a plastic bag sample container for 10 min under laboratory 
conditions (22 °C, 50% RH). 
3.2.2. High energy mixing 
3.2.2.1. Dry high shear (DHS) mixing 
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PA (15g, w/w), PA and PVP (95:5 w/w) powders were blended using the 
high shear mixing technique as described in (Section 2.2.1.2).  
3.2.2.2. Wet high shear (WHS) mixing 
PA and PVP (95:5, w/w) powders were suspended in n-hexane (50 mL), 
using the technique in (Section 2.2.1.2) mixed above for 3 min. After 
mixing, the resultant suspension was filtered (< 0.45 μm, cellulose filter 
paper, Fisher Scientific, UK) and then left to dry in an oven (Memmer, 
Durham, UK) at 50 °C for 12 h. 
3.2.2.3. High–speed homogenization mixing 
PA and PVP powders (95:5, w/w) powders were suspended in 200 mL 
of n-hexane and then mixed in a high-speed homogeniser by applying the 
technique in (Section 2.2.1.3).  
3.2.2.4. Tablet preparation 
Each tablet weighs 526.3 ± 0.5 mg for the various formulations and 500 
mg ± 0.5 mg for PA compressed using the method described in (Section 
2.14).   
3.3. Results and discussion 
3.3.1. Content uniformity 
The percent drug content uniformity obtained from all PA‒PVP mixtures 
was acceptable (LS, 100.6% ± 5.9%; MS 100.7% ± 2.8%; DHS, 100.7% 
± 1.2%; WHS, 108.5 % ± 2.9% and HSH, 101.9% ± 5.4%). The %CV of 
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PA content varied with (LS, 5.8%; MS, 3.5%; DHS, 5.8%; WHS, 2.9% 
and HSH, 5.4%) satisfying the acceptance level and indicating adequately 
homogeneous PA content in all mixtures, as well as accurate and 
reproducible processes of mixing, sampling, and analysis. 
3.3.2. Particle size and shape distributions 
PA–PVP mixtures prepared using low energy (LS and MS) mixing 
conditions showed slightly reduced VMDs and slightly increased span 
values compared with commercial PA (Table 3). This was caused by the 
VMD value of the PVP particles, which was lower than that of commercial 
PA (Table 3), as confirmed by SEM micrographs. The PA–PVP mixtures 
prepared using low energy (LS and MS) conditions showed statistically 
similar particle size distributions (PSDs). This agreed with SEM 
observations, which showed no striking differences in the structures of 
mixtures prepared at low energy conditions (Figure 9). A trend of lower 
VMD could nevertheless be observed with the increase in shear introduced 
during physical mixing (i.e., LS > MS > DHS) (Table 3). For example, the 
VMDs of PA–PVP mixtures prepared using LS, MS, and DHS conditions 
were 521 ± 24 μm, 504 ± 13 μm, and 80 ± 4 μm, respectively (Table 3). 
The mixtures prepared using high energy conditions (DHS, WHS, and 
HSH) showed smaller and broader VMDs (VMDs ranging from 52.3 ± 4 
μm to 80 ± 4 μm, span values ranging 3.5 ± 0.2 to 6 ± 0.2) compared 
with the mixtures prepared using low energy (LS and MS) conditions 
(VMDs ranging from 504 ± 13 μm to 521 ± 24 μm, span values ranging 
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from 1.5 ± 0 to 1.7 ± 0) (Table 3). The shift towards lower VMDs for the 
mixtures prepared using high energy conditions was caused by the in-situ 
generation of intrinsic fine particulates (as evidenced by the lower d10% 
values, Table 3) from particle collisions and attrition/fracturing during dry 
high energy mixing. This was confirmed when PA samples processed 
using high shear mixing in the absence of PVP showed considerably 
smaller VMD than commercial PA (Table 3). The generation of such fine 
particulates will have a significant influence on powder bulk properties 
(i.e., compactibility, cohesivity, bulk density, flowability, and tensile 
strength) as discussed later (Sections 5.2.4 and 5.2.6). The difference in 
morphologies between various mixtures was clearly observed in the SEM 
micrographs (Figure 9). However, the VMDs (recorded by laser diffraction, 
Table 3) of the particles prepared by high energy (DHS, WHS, and HSH) 
conditions were larger than shown in the SEM micrographs (Figure 9), 






Figure 9. Scanning electron microscopy micrographs of commercial 
paracetamol (PA), commercial polyvinylpyrrolidone (PVP), and PA–PVP 
mixtures (5% PVP, w/w) prepared using low shear (LS), medium shear 
(MS), dry high shear(DHS), wet high shear (WHS) and high-speed 
homogenization (HSH) mixing conditions. Size bars denote magnification. 
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 Table 3. Particle size distribution for commercial paracetamol (PA), 
commercial polyvinylpyrrolidone (PVP), and PA–PVP mixtures (5% PVP, 
w/w) prepared using, low shear (LS), medium shear (MS), dry high shear 
(DHS), wet high shear (WHS) and high-speed homogenization (HSH) 
mixing conditions. Data given for particle size at 10% (d10%), 50% (d50%, 
median diameter), and 90% (d90%) of the volume distribution, the volume 
mean diameter (VMD), and the span of the volume distribution (see 
Eq.(1)). Data expressed as mean ± SD, n = 3. 
 
3.3.3. Powder density and cohesivity 
All PA–PVP mixtures showed lower bulk and tap densities, higher 
cohesivities (1/b), and higher CI values than commercial PA (Table 4). 
The reductions in bulk and tap densities as well as the increases in 
cohesivity of PA–PVP mixtures when compared with PA showed increasing 
Product d10% (µm) d50% (µm) d90% (µm) VMD (µm) Span 
PA 254 ± 22 506 ± 30 911 ± 39.3 548 ± 30.2 1.3 ± 0 
PVP 42.1 ± 0.5 100.4 ± 1.1 209 ± 2 119.3 ± 4 1.7 ± 0 
DHS(PA) 4 ± 0.1 25.2 ± 1 152 ± 8.3 53.3 ± 2.2 6 ± 0.3 
LS(PA–PVP) 181± 13 487 ± 24.5 899 ± 42 521 ± 24 1.5 ± 0 
MS(PA–PVP) 176 ± 6 468 ± 14 880 ± 21.4 504 ± 13 1.5 ± 0 
DHS(PA–PVP) 4.5 ± 0.1 36 ± 0.3 211 ± 8 80 ± 4 6 ± 0.2 
WHS(PA–PVP) 4 ± 0.1 25 ± 0.5 134.3 ± 7 52.3 ± 4 5.3 ± 0.3 
HSH(PA–PVP) 9.6 ± 3 34.1 ± 5.3 128.4 ± 26 57 ± 13.5 3.5 ± 0.2 
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trends with increasing mixing energy during dry mixing (LS < MS < DHS), 
although the bulk density, tap density, and cohesivity of the mixtures 
prepared using LS and MS conditions were not statistically different (p > 
0.05) (Table 4). The mixtures prepared using wet mixing conditions (WHS 
and HSH) showed further reductions in bulk density (63.0% and 58.6% 
for WHS and HSH, respectively) as well as increases in cohesivity 
(197.1% and 487.1% for WHS and HSH, respectively) when compared 
with the original commercial PA powder (Table 4). The reduction in bulk 
density was previously shown to result in an increase in the tensile 
strength of tablets (Nokhodchi, Maghsoodi, Hassan-Zadeh, & Barzegar-
Jalali, 2007; Zuurman, Riepma, Bolhuis, Vromans, & Lerk, 1994). The 
reductions in the bulk and tap densities for the mixtures prepared using 
low energy mixing conditions compared with commercial PA were caused 
by the presence of 5% (w/w) PVP powder, whose bulk and tap density 
values are less than those of commercial PA. The reductions in bulk and 
tap densities for the powders prepared using high energy conditions 
compared with mixtures prepared using low energy conditions were 
caused by their considerably smaller particle sizes (Table 3). This led to 
substantial increases in the strength of the interparticle forces as reflected 
by higher cohesivity values (Table 4). 
Commercial PA powder showed free-flowing noncohesive behaviour 
(CI: 3.2% ± 0.3%) (Table 4). Such powders are not very compressible 
during the consolidation process because they will consolidate before 
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tapping because of weak interparticle forces. Consistent with the patterns 
in the bulk and tap density changes, all PA–PVP mixtures showed higher 
CI values than commercial PA (Table 4), indicating their poor flow 
properties. The mixtures prepared using high energy conditions 
demonstrated notably poor flowabilities than those prepared using low 
energy conditions as indicated by their considerably higher CI values 
(42.3% ± 2.1% to 46.3% ± 1% versus 8.3% ± 1% to 9% ± 0%) (Table 
4). This provides further evidence for their stronger interparticle forces, 
which are attributable to their lower VMDs (Table 3) (Kaialy, Alhalaweh, 
Velaga, & Nokhodchi, 2012). These powders were highly compressible 
because of strong interparticle cohesive forces that produced inefficient 
packing and high voidage. The structures of such cohesive powders 
collapse considerably during consolidation, which is revealed as a large 











Table 4. Bulk density (Db), tap density (Dt), cohesivity (1/b), and Carr 
index (CI) for commercial paracetamol (PA), commercial 
polyvinylpyrrolidone (PVP), and PA–PVP mixtures (5% PVP, w/w) 
prepared using, low shear (LS), medium shear (MS), dry high shear 
(DHS), wet high shear (WHS) and high-speed homogenization (HSH) 
mixing conditions and PA processed using high shear mixing in the 
absence of PVP (DHS(PA)).Data expressed as mean ± SD, n = 3. 
Product Db (g/cm
3) Dt (g/cm
3) 1/b CI (%) Flow character 
PA 0.8 ± 0 0.8 ± 0 4 ± 0 3.2 ± 0.3 Excellent 
(CI <10%) 
PVP 0.4 ± 0 0.5 ± 0 8 ± 3.3 22 ± 2.5 Fair 
16<CI<23% 
DHS(PA) 0.3 ± 0 0.6 ± 0 27 ± 2.3 45 ± 0.1 Extremely poor 
(CI >38%) 
LS(PA–PVP) 0.7 ± 0 0.8 ± 0 9 ± 2.5 9 ± 0 Excellent 
(CI <10%) 
MS(PA–PVP) 0.7 ± 0 0.8 ± 0 11 ± 1.2 8.3 ± 1 Excellent 
(CI <10%) 
DHS(PA–PVP) 0.3 ± 0 0.5 ± 0 28 ± 8.3 42.3 ± 2.1 Extremely poor 
(CI >38%) 
WHS(PA–PVP) 0.3 ± 0 0.5 ± 0 12 ± 0 43 ± 0 Extremely poor 
(CI >38%) 




3.3.4. Solid-state properties 
Commercial PA and all PA–PVP mixtures exhibited comparable, sharp, 
characteristic diffraction angles of 12.10°, 13.83°, 15.5°, 16.7°, 18.29°, 
20.4°, and 24.40° 2θ corresponding to the monoclinic form of PA (Figure 
10) (Khanmohammadi, Garmarudi, Moazzen, & Ghasemi, 2010; Di 
Martino et al., 1996). The absence of high reflections at 10.35°, 21.85°, 
and 24.03° 2θ (Khanmohammadi et al., 2010; Di Martino et al., 1996) 
from the PXRD patterns of all PA–PVP mixtures ruled out the 
transformation of the monoclinic form to the orthorhombic form, which is 
less stable than the monoclinic form and thus unsuitable for scaling up 
(Beyer et al., 2001). This indicated that the initial crystalline state of 
commercial PA is retained for all PA‒PVP mixtures regardless of the 
mixing method. This is advantageous because it warrants the long-term 
physical stability of all mixtures during storage and allows direct 
comparative evaluation of the PA products. The high crystallinity of PA 
could be attributed to its relatively low glass transition temperature (23–




Figure 10. Powder X–ray diffraction (PXRD) patterns of  commercial 
paracetamol (PA), commercial polyvinylpyrrolidone (PVP), and PA–PVP 
mixtures (5% PVP, w/w) prepared using, low shear (LS), medium shear 
(MS), dry high shear (DHS), wet high shear (WHS) and high-speed 
homogenization (HSH) mixing and PA processed using high shear mixing 
in the absence of PVP (DHS(PA)). 
The FT–IR characteristic bands of the monoclinic form of PA (Table 5) 
were present in the spectra of commercial PA and all PA‒PVP mixtures 
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(Figure 11). The diagnostic bands of the PA orthorhombic form (C–C 
aromatic stretching peaks at 1614, 1507, 1626, 1513, and 1453 cm−1) 
(Al-Zoubi, Koundourellis, & Malamataris, 2002) were absent from the 
spectra of commercial PA and all PA‒PVP mixtures, confirming the purity 
of the PA monoclinic form for all products under investigation. Analysis of 
the molecular structures of PA and PVP (Figure 1; Table 5) suggests that 
H-bonding may exist between the N–H or O‒H moieties (H donors) of PA 
and the carbonyl group (C=O, H acceptor) of PVP. Such intermolecular 
interactions should be reflected by shifts in the N–H, O‒H, and C=O 
stretches. The mixtures prepared using low energy conditions showed 
insignificant changes in absorption intensities in comparison to neat 
commercial PA (Figure 11), indicating a low level of interparticle 
interaction. The mixtures prepared using dry high shear (DHS) conditions 
showed minor reductions in absorption intensities (i.e., increased band 
broadening) between 3300 and 3350 cm−1 as well as between 3100 and 
3200 cm−1 compared with the peaks observed for commercial PA (Figure 
11). The band broadening became more pronounced for the mixtures 
prepared using wet high energy conditions (WHS and HSH) (Figure 11). 
This indicated a higher level of intermolecular hydrogen bonding between 
PA and PVP in the mixtures prepared using high energy conditions than 
those prepared using low energy conditions. In addition, the mixtures 
prepared using wet high energy (WHS and HSH) conditions showed 
decreases in the absorption intensities between 1640 and 1660 cm−1 
(amide I, carbonyl stretch), between 1600 and 1620 cm−1 (skeletal aryl 
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C–C stretch) between 1560 and 1570 cm−1 (amide II, N‒H in plane 
deformation), and between 1500 and 1520 cm−1 (aryl C=H, C=H 
symmetric bending). Such reductions in the absorption intensities indicate 
the presence of weak hydrophobic interactions between PA and PVP. 
Therefore, the FT–IR spectra indicated that hydrogen bonding and other 
types of weak hydrophobic interactions are more likely to occur in PA‒PVP 
mixtures prepared using wet high energy mixing conditions (WHS and 
HSH), followed by minimal interactions observed in the mixture prepared 
using dry high energy (DHS) condition, and no interactions in the 
mixtures prepared using low energy conditions. Therefore, it is likely that 
the level of interparticle interactions between PA and PVP in a mixture 
depends on the energy (i.e., magnitude of shear/inertial forces) 
introduced during mixing. Higher shear forces introduced during mixing 
results in higher levels of PA–PVP interaction. This is probably because the 
increase in shear forces during mixing presses the PVP particles into the 







Table 5. Chemical structure and characteristic FT-IR absorption bands of 









3326 (associated N–H 
stretch), 3162 (H-bonded 
O‒H stretch), 1654 (amide 
I, carbonyl stretch), 1610 
(skeletal aryl C–C stretch), 
1565 (amide II, N‒H in 
plane deformation), 1507 








3469 (O‒H stretching), 
1698 (pyrrolidone group 
C=O stretching), 2987 (C‒H 
asymmetric stretching-
CH2), 1427 (C‒H bending), 







Figure 11. Fourier transform infrared (FT−IR) absorption spectra of 
commercial paracetamol (PA), commercial polyvinylpyrrolidone (PVP), and 
PA–PVP mixtures (5% PVP, w/w) prepared using, low shear (LS), medium 
shear (MS), dry high shear (DHS), wet high shear (WHS) and high-speed 




The TGA curves of commercial PA and PA–PVP mixtures showed 
weight loss in the temperature range between 170 and 255 °C, 
corresponding to melting of the stable monoclinic form (de Oliveira et al., 
2017) then there was a significant rapid weight loss due to degradation 
(Hughey, Keen, Brough, Saeger, & McGinity, 2011) (Figure 12). PVP 
showed weight loss that started at about 340 °C, implying that weight 
loss was caused by thermal degradation (i.e., thermal decomposition of 
PVP molecular chains). No weight loss occurred below 100 °C (Figure 12), 
indicating the absence of a significant amount of free (surface) water in 
all mixtures. A slight shift towards lower melting onsets was observed for 
the mixtures prepared using high energy conditions when compared with 
the mixtures prepared using low energy conditions (Figure 12). This 
difference may be attributable to their starkly different physical properties 
such as their considerably lower VMDs (Table 5) and/or because of the 
interaction between PA and PVP. Smaller particles could have slightly 
lower melting points than larger particles of the same material because of 
lower resistance to heat transfer (Kaialy et al., 2012). 
The moisture content was measured in all mixtures under 
investigation. This is because the moisture content of a powder affects 
powder flowability through interparticle forces including capillary forces 
and liquid bridging (Leuenberger & Imanidis, 1986). The presence of 
water could also affect the particle surface microstructure by a 
dissolution–precipitation process (Finot, Lesniewska, Mutin, Hosain, & 
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Goudonnet, 1996), potentially affecting the mechanical properties of the 
particles exposed to high relative humidity. The results of the present 
study showed that commercial PA and all PA–PVP mixtures gained 
negligible amounts of moisture (< 0.7%, w/w) when stored at 75% RH 
(22°C) for six months, confirming their low hygroscopicity and potential 




Figure 12. Thermogravimetric analysis curves of commercial paracetamol 
(PA), commercial polyvinylpyrrolidone (PVP), and PA–PVP mixtures (5% 
PVP, w/w) prepared using, low shear (LS), medium shear (MS), dry high 
shear (DHS), wet high shear (WHS) and high-speed homogenization 
(HSH) mixing conditions. 
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3.3.5. Tableting properties 
Commercial PA showed poor mechanical properties, with the highest 
TS of only 0.18 ± 0.02 MPa at a compression pressure of 148 MPa. 
However, the mechanical properties of the commercial PA (TCI Chemicals, 
UK) investigated in this study were better than those for a previously 
reported commercial PA (Sigma–Aldrich, Gillingham, UK) (Kaialy et al., 
2014), which achieved no TS at all compression pressures. Such improved 
character could be attributed to morphological differences between these 
two commercial grades. While Sigma–Aldrich PA particles showed an 
elongated (needle) habit (Kaialy et al., 2014), the TCI Chemicals product 
had particles with subangular, polyhedral shapes with relatively flat 
surfaces (Figure 9). These could have increased interparticle contact 
points and thus increased the degree of densification during compression. 
The presence of 5% (w/w) PVP as an additive improved the mechanical 
properties of paracetamol in all PA–PVP mixtures (Figure 13). For 
example, the TS of PA–PVP mixture compressed at 222 MPa was 0.5 ± 
0.0 MPa, 1.4 ± 0.1 MPa, 1.9 ± 0.2 MPa, and 3.2 ± 0.2 MPa for the 
mixtures prepared using LS/MS, DHS, WHS, and HSH conditions (Figure 
13). PA–PVP mixtures prepared using low energy conditions exhibited 
statistically similar (p > 0.05) tabletability profiles, whereas the mixture 
prepared using DHS conditions exhibited a remarkable improvement in 
tabletability compared with the mixtures prepared using LS and MS 
conditions. For example, with the compression pressure increasing from 
37 to 222 MPa, the TS of tablets increased from 0.1 to 0.4 MPa and from 
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0.2 to 1.4 MPa for the mixtures prepared using LS/MS and DHS 
conditions, respectively (Figure 13). This indicated that the DHS 
conditions resulted in an increase in the TS of tablets from 1.8 to 3.5 
times compare with the LS/MS conditions over the compression pressure 
range of 37 to 222 MPa. The mixtures prepared using wet high energy 
conditions (WHS and HSH) clearly exhibited further improvements of 
tabletability in comparison to the mixtures prepared using dry high shear 
(DHS) conditions. For example, when the compression pressure increased 
from 37 to 222 MPa, the TS of tablets prepared using WHS increased from 
0.4 ± 0.1 MPa to 1.8 ± 0.3 MPa, while that prepared using HSH increased 
from 1.3 ± 0.1 MPa to 3.0 ± 0.2 MPa (Figure 13). It is therefore clear that 
the PA–PVP mixture prepared using HSH conditions showed the best 
compression properties among the mixtures under investigation, scoring a 
TS of 2.9 ± 0.1 MPa at a compression pressure of 148 MPa. Compared 
with the mixtures prepared using low energy conditions, the mixtures 
prepared using HSH gave tablets that were ~8–14 times stronger under 
the compression pressure range of 37 to 222 MPa. The improved 
tabletability for PA‒PVP mixtures compared with commercial PA was 
caused by the combination of a brittle (PA) and plastic (PVP) material 
(Larhrib & Wells, 1998). The increased tensile strengths of the tablets 
containing mixtures prepared using high energy conditions compared with 
those mixed using low energy conditions are indicative of stronger 
interparticle bonding for the former products. Such superior tabletability is 
attributed to the higher level of PA‒PVP interaction via hydrogen bonding 
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in the case of the mixtures prepared using high energy conditions (Figure 
11). In addition, in contrast to the mixtures prepared using low energy 
mixing conditions, in which the morphologies of both commercial PA 
(subangular/polyhedral) and commercial PVP (hollow spherical) particles 
could be observed (Figure 9), no distinct individual commercial PVP 
particles were visualized in mixtures prepared using high energy 
conditions (Figure 9). This indicated that the low energy mixing conditions 
were unable to provide sufficient energy to extensively delaminate and 
spread PVP onto PA surfaces. In contrast, high energy mixing conditions 
caused attrition, corrosion, and compressive coating of PVP onto PA 
surfaces, or a combination of the foregoing effects. It is assumed that one 
contributor to the superior tableting performance of monoclinic PAs mixed 
with PVP using high energy conditions (compared with use of low energy 
conditions) must be the increased surface coating of plastic PVP wrapping 
the fragmenting PA. Vanhoorne, Peeters, Van Snick, Remon, and Vervaet 
(2014) indicated that the presence of amorphous lactose is crucial for the 
production of co–processed powders with improved mechanical 
properties. Although the PA–PVP mixture prepared in this study using 
HSH contained no amorphous lactose (Figure 13), its tabletability 
behavior outperformed that of the spray-dried formulation (75% 
paracetamol, 5% PVP, and 20% amorphous lactose) reported by 
Vanhoorne et al. (2014) (maximum TS of 1.9 MPa at a compression 
pressure of 288 MPa). The absence of amorphous products in the 
mixtures prepared in this study make them potentially more stable in the 
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long term than the formulations prepared by Vanhoorne et al. (2014). The 
tableting behaviour of PA processed using high shear mixing in the 
absence of PVP was as poor as commercial PA. Such results confirm that 
improvement in the PA mechanical properties was because of a higher 
level of PA–PVP interaction induced by high energy mixing, and not 
caused by a particle size reduction effect. 
 
 
Figure 13. Tensile strength (mean ± SD, n = 5) versus compression pressure of 
commercial paracetamol (PA), commercial polyvinylpyrrolidone (PVP), and PA–
PVP mixtures (5% PVP, w/w) prepared using, low shear (LS), medium shear 
(MS), dry high shear (DHS), wet high shear (WHS) and high-speed 
homogenization (HSH) mixing conditions and PA processed using high shear 




The effects of mixing conditions on the micrometric and mechanical 
properties of PA‒PVP mixture should not be ignored. In contrast to low 
energy mixing conditions, high energy mixing conditions promoted 
hydrogen bonding between PA and PVP with following improvements in 
the mechanical properties of the resultant mixtures. High energy mixing 
conditions were therefore successfully applied to produce PA with 
improved tensile strength in the presence of 5% (w/w) PVP additive. This 
method should have general applicability to many poorly compactible 
drug entities. 
Cooperative research and development between mixing equipment 
providers and pharmaceutical manufacturers is required in the future to 
optimize the quality of interactive mixtures for tableting. Future studies 
should also concentrate on the application of various mixing methods to 
improve the functional properties of a wide range of drugs including 
chemical drugs and Chinese drugs and herbal extracts that are prepared 
















4 CHAPTER 4: EFFECT OF VARIOUS PREPARATION 
















Crystallisation has been referred to as an art rather than a science. The 
primary objective of crystallisation systems engineering is to develop an 
advanced understanding of its phenomena, enabling the efficient bulk 
processing of high–quality crystalline products. Crystallization in many 
industries is the most common way of production of high–value 
chemicals, with high purity and desired size and shape (Nowee et al., 
2007), and it has been used over the past years as a particle engineering 
method to enhance the physicochemical properties of poorly compactible 
drugs (Garekani et al., 2000 a & b; Abioye et al., 2016). Crystallization 
process can be carried out using many methods including; cooling 
crystallisation (Joiris et al., 1998), antisolvent crystallisation (Kaialy et al. 
2014), spray drying (Vanhoorne et al., 2014; Sagechi et al., 2004), co–
spray drying (Vanhoorne et al. 2016; Gonnissen et al. 2008), modified 
polymorphic forms (Martino et al., 1996) and particle shape modification 
(Rasenack & Müller 2002; Kaialy et al. 2014) which were discussed in 
(Section 1.3.0). However, none of the authors has compared the 
tabletability properties of PA to PA–PVP mixtures using all at once the 
engineering techniques which includes: Physical mixing, cooling 
crystallisation, solvent evaporation, Freeze drying and milling. 
Since many APIs possess poor tableting properties, co–processing 
methods will be very prevalent and invaluable in the presence of 
5%(w/w) binder/polymer polyvinylpyrrolidone (PVP) incorporated in the 
formulation to improve the manufactured tablets’ properties.  
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In this investigation, the tabletability properties of commercial PA will be 
compared to the mixtures of PA−PVP engineered using different 
preparation methods.  
4.1. Engineering of PA–PVP formulations 
4.1.1. Physical mixing 
PA and PVP (95:5 w/w) powders were mixed using low shear mixing 
method as described in (Section 2.2.1.1). 
4.1.2. Batch cooling crystallisation 
25% w/v solution was prepared by dissolving 25 g of PA–PVP mixture in a 
hydro–alcoholic solution of (125 mL of ethanol and 375 mL) of deionised 
water) for a final volume of 500 mL under stirring (200 rpm) at 70 ºC. 
The resultant clear solution was left uncovered in laboratory conditions for 
seven days using batch cooling crystallisation method as described in 
(Section 2.2.1.4). The crystals obtained were sieved using the technique 
described in (Section 2.3). 
4.1.3. Solvent evaporation (SE) 
25% w/v solution was prepared by dissolving 25 g of PA–PVP mixture in a 
hydro–alcoholic solution of (125 mL of ethanol and 375 mL of deionised 
water) for a final volume of 500 mL under stirring (200 rpm) at 70 ºC. 
The solvents present were evaporated using Stuart heat–stirrer for 1h at 
a constant temperature of 70 ºC. The precipitated crystals obtained were 
left to dry using solvent evaporation method as described in (Section 
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2.2.1.5). The engineered powders were sieved as described in (Section 
2.3). 
4.1.4. Freeze drying 
25% w/v solution was prepared by dissolving 25 g of PA–PVP mixture in a 
hydro–alcoholic solution of (125 mL of ethanol and 375 mL of deionised 
water) for a final volume of 500 mL under stirring (200 rpm) at 70 ºC. 
The resultant clear solution containing PA−PVP mixtures obtained was 
allowed to cool down and was frozen at –20 ºC, for two days then was 
freeze dried using the technique described in (Section 2.2.1.6). The FD 
(PA–PVP) formulations were sieved using the technique described in 
(Section 2.3).  
4.1.5. Milling (PA−PVP) 
 PA–PVP powders (25 g w/w) were milled for five mins using the milling 
method as described in (Section 2.2.1.7). 
4.1.6. Tablet preparation 
Each tablet weighs 526.3 mg ± 0.5 mg for the various formulations 
and 500 mg ± 0.5 mg for PA compressed using the method described in 
(Section 2.14).   
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4.2. Results and discussions 
4.2. 1. Content uniformity 
The percentage drug content uniformity obtained from all PA–PVP 
mixtures was acceptable (LS, 100.6% ± 5.9%; BCC 94.8.% ± 3.8%; SE, 
106.5% ± 5.9%; FD, 95.6% ± 5.1% and ML, 105.2% ± 5.8%). The %CV 
of PA content varied with (LS, 5.8%; BCC, 4.1%; SE, 5.3%; FD, 5.8% 
and ML, 5.3%) which falls in the adequate range which implies 
satisfactorily uniform PA content in all the mixtures using various 
preparation techniques.  
4.2.2. Particle size distributions 
Commercial PVP showed considerably smaller PSDs than 
commercial PA. PA–PVP mixture prepared using physical mixing showed 
statistically similar (P>0.05) VMD to commercial PA, whereas PA–PVP 
mixtures prepared using batch cooling, solvent evaporation, freeze-drying 
and milling showed considerably smaller PSDs compare to commercial PA 
(Table 6), as affirmed by SEM micrographs (Figure 14). The PSDs of PA–
PVP mixtures showed the following descending rank order according to 
the preparing techniques: physical mixing > batch cooling > solvent 





Figure 14. Scanning electron microscopy (SEM) and particles size 
distributions micrographs of commercial paracetamol (PA), commercial 
polyvinylpyrrolidone (PVP), and PA−PVP mixtures (95:5, w:w) co-
processed by physical mixing (PM), batch cooling crystallisation (BCC), 
solvent evaporation (SE), freeze drying (FD), and milling (ML). 
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     Across the mixtures investigated, the mixtures prepared using 
freeze−drying, and milling techniques showed a considerable reduction in 
their VMDs along with a significant increase in their span values indicating 
they are smaller and more heterogeneous in size distributions (Table 6). 
The significant reduction in PSDs in the case of freeze−dried PA−PVP 
mixture could be due to, the in−situ generation of intrinsic fine particles 
during the freezing drying process, whereas, in the case of milled PA–PVP 
mixture which is due to interparticle and particle−surface collisions and 
fracturing/attrition during milling, as evident by the reduction in d10% 
values (Table 6). The generation of such fine particulates will have a 
significant influence on powder bulk properties (i.e. compactibilty, 













Table 6. Particle size distribution (i.e. particle size at 10% (d10%), 50% ( d50%, median diameter and 90% (d90%) 
volume distribution and span) (mean ± SD, n = 3) for commercial paracetamol (PA), commercial 
polyvinylpyrrolidone (PVP), and PA−PVP mixtures (95:5, w:w) co–processed by physical mixing (PM), batch 
cooling crystallisation (BCC), solvent evaporation (SE), freeze drying (FD), and milling (ML). 
Product  d10% (µm) d50% (µm) d90% (µm) VMD (µm) Span 
PA 254 ± 22 506 ± 30 911 ± 39.3 548 ± 30.2 1.3 ± 0 
PVP 42.1 ± 0.5 100.4 ± 1.1 209 ± 2 119.3 ± 4 1.7 ± 0 
PM(PA−PVP) 181 ± 13 487 ± 14 899 ± 42 521 ± 24 1.5 ± 0 
BCC(PA−PVP) 103 ± 0 348 ± 3 710 ± 12 383.3 ± 4 1.7 ± 0 
SE(PA−PVP) 94.3 ± 6 212 ± 10.1 411 ± 36 219 ± 12 1.8 ± 0.2 
FD(PA−PVP) 8.1 ± 0 38 ± 0.3 56 ± 1.3 81.3 ± 28.4 3.2 ± 0.1 
ML(PA–PVP) 2.3 ± 0.1 17.3 ± 0.2 91 ± 2 35.3 ± 1.3 5.1 ± 0.1 
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4.2. 3. Powder density and cohesivity 
All PA−PVP mixtures displayed significantly lower bulk and tap 
densities, higher cohesivities and higher CI values than commercial PA 
(Table 7). The slight reductions in the bulk and tap densities for the 
mixture prepared using physical mixing technique compared to 
commercial PA are due to the presence of 5% (w/w) PVP powder whose 
bulk and tap density values are smaller than those of commercial PA 
(Table 7). The reductions in bulk and tap density, as well as the increase 
in cohesivity of PA−PVP mixtures compared to commercial PA (Table 7), 
are due to their smaller PSDs (Table 6). Interestingly, a direct relationship 
was established when plotting the bulk density of PA−PVP mixtures 
against their VMDs (Table 6), indicating that the bulk density (i.e. the 
porosity) of PA−PVP mixture powders decreased with decreasing their 
particle size. Commercial PA powder showed free–flowing no cohesive 
behaviour (CI: 3.2% ± 0.3%), (Table 7). Such powders are not very 
compressible during compaction because they will compact before tapping 
due to weak inter-particle forces. All PA− PVP mixtures showed higher CI 
values than commercial PA, which is consistent with the patterns 
observed for bulk and tap density changes (Table 7), indicating their 
relatively poorer flow properties. The mixtures prepared using freeze 
drying, and milling samples displayed exceptionally poor flowability as 
evident by their considerably high CI values (47.3% ± 1.1% and 40.0% ± 
0.6% respectively (Table 7).  
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Table 7. Bulk density (Db), tap density (Dt), cohesivity (1/b) and Carr’s 
index (CI) (mean ± SD, n = 3) for commercial paracetamol (PA), 
commercial polyvinylpyrrolidone (PVP), and PA−PVP mixtures (95:5, w:w) 
processed by physical mixing (PM), batch cooling crystallisation (BCC), 
solvent evaporation (SE), freeze drying (FD), and milling (ML). 




) 1/b CI (%) Flow 
character 
PA 0.8 ± 0 0.8 ± 0 4 ± 0 3.2 ± 0.3 Excellent 
CI <10% 
PVP 0.4 ± 0 0.5 ± 0 8 ± 3.3 22 ± 2.5 Fair 
16 < CI <23 
PM (PA−PVP) 0.7 ± 0 0.8 ± 0 9 ± 2.5 9 ± 0 Excellent 
CI <10% 
BCC(PA−PVP) 0.7 ± 0 0.8 ± 0 15 ± 2.5 15 ± 0.6 Good 
CI <16% 
 
SE(PA−PVP) 0.5 ± 0 0.6 ± 0 11.3 ± 2 22 ± 1.1 Fair 
16 < CI <23% 
FD(PA−PVP) 0.1 ± 0 0.3 ± 0 14 ± 1.5 47.3 ± 1.1 Extremely 
poor 
CI > 38% 





4.2.4. Solid state properties 
Commercial PA and all of the PA−PVP mixtures displayed PXRD 
characteristic angles at 2θ values of 12.10º, 13.83º, 15.5º, 16.7º, 18.29º, 
20.4º and 24.40º, and FT–IR diagnostic bands at 3325 cm−1 (N–H 
stretching vibration), 3161 cm−1 (hydrogen−bonded, O−H stretching 
vibration), 1653 cm−1 (C=O stretching vibration), 1564 cm−1 (N–H in-
plane bending), 1610 cm−1, 1506 cm−1 and 1440 cm−1 (aromatic ring 
mode), and 1327 cm−1 (O–H, bending vibration), corresponding to the 
monoclinic form of paracetamol (form I) (Figure 15) (Nichols and 
Frampton, 1998; Di Martino et al.,1996; Wang et al., 2002). The absence 
of PXRD characteristic angles at 10.35º, 21.85º and 24.03º 2θ and FT–IR 
bands at 1658 cm-1, 1558 cm-1, 1440 cm-1, 1240 cm-1, and 837cm-1 from 
the PXRD patterns and FT−IR spectra in mixtures prepared using physical 
mixing, solvent evaporation, freeze−drying and milling ruled out the 
presence of the orthorhombic form (form II) (Di Martino et al., 1996; 
Moynihan and O’Hare, 2002) in the foregoing mixtures. However, the 
PA−PVP product prepared using batch cooling crystallisation showed 
mixtures of the monoclinic and the orthorhombic form, also, the 
orthorhombic form known to be relatively less stable than the monoclinic 
form. This indicated that the initial crystalline state of commercial PA is 
retained in all PA−PVP mixtures regardless of the processing method 
employed (Figure 16). Although, there was some difference in the relative 
intensity of the peaks which could be due to either the differences of the 
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size of the crystals or the alteration of the crystal habit because the 
relative abundance of the planes exposed to X–ray source is transformed 
(Garekani et al., 2001). PVP showed no detection of any prominent peak 
of the polymer, a characteristic of the amorphous state (Figure 16). The 
analysis of the molecular structures of PA and PVP shows that major 
H−bonding interactions may exist between the O‒H stretch or the N–H 
stretch (strong H donors) of PA and the carbonyl group (C=O, strong H 
acceptor) of PVP. Such intermolecular interaction would be fed back by 
the change of shifts in the N–H stretch, O‒H stretch and C=O stretch. 
PA−PVP mixtures prepared using batch cooling crystallisation did 
not display remarkable changes in absorption intensities compared to the 
commercial PA (Figure 15), indicating insufficient miscibility to allow 
interaction. The PA−PVP mixture prepared using physical mixing showed 
minor reductions in absorption intensities (i.e. increased band 
broadening) between 3300 cm-1 and 3350 cm-1 as well as between 3100 
cm-1 and 3200 cm-1 compared to the peaks observed with the commercial 
PA (Figure 15). The band broadening became more pronounced for the 
mixtures prepared using SE, FD and ML, indicating a higher level of 
intermolecular hydrogen bond interaction between PA and PVP in the 
preceding mixtures compared to the mixtures prepared using physical 
mixing and batch cooling crystallisation. 
Additionally, PA–PVP co-processed using milling showed significant 
reductions in the absorption intensities between 1640 cm-1 and 1660 cm-1 
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(due to amide I, i.e. carbonyl stretch), between 1600 cm-1 and 1620 cm-1 
( skeletal aryl C–C stretch) between 1560 cm-1 and 1570 cm-1 (amide II, 
N‒H in–plane deformation), and between 1500 cm-1 and 1520 cm-1 (due 
to aryl C=H, C=H symmetric bends). Such reductions in the absorption 
intensities indicate the presence of weak hydrophobic interactions 
between PA and PVP.  
Therefore, the FT–IR spectra indicated that hydrogen bonding and other 
types of weak hydrophobic interactions are more likely to occur according 
to the following rank order based on the technique by which PA and PVP 
were co−processed: Batch cooling crystallisation < Physical mixing < 
Solvent evaporation < Freeze−drying <Milling. This could be because 
milling affords a higher level of interparticle interactions between PA and 
PVP than the other techniques under investigation due to higher 
magnitude of shear/inertial forces introduced during mixing caused by 
particle–particle and particle−surface collisions which can press PVP 






Figure 15. Fourier transform infrared spectroscopy (FT–IR) spectra of commercial paracetamol (PA), commercial 
polyvinylpyrrolidone (PVP), and PA−PVP mixtures (95:5, w: w) co–processed by physical mixing (PM), batch 




Figure 16. Powder X–ray diffraction (PXRD) patterns of commercial 
paracetamol (PA), commercial polyvinylpyrrolidone (PVP), and PA−PVP 
mixtures (95:5, w: w) co-processed by physical mixing (PM), batch 
cooling crystallisation (BCC), solvent evaporation (SE), freeze drying 
(FD), and milling (ML). 


























      TGA analysis showed commercial PA and PA–PVP mixtures processed 
via physical mixing, batch cooling crystallisation, solvent evaporation, 
freeze drying, and milling were thermally stable until 254 ºC ± 2 ºC, 
which agrees with degradation temperatures results reported previously 
for PA (Tomassetti et al., 2005). 
A slight shift towards lower melting onsets was observed for the PA–PVP 
mixture processed via freeze–drying, which could be attributed to the 
highly porous nature and the smaller PSDs of the freeze−dried PA−PVP 
formulation that can  potentially lead to relatively lower resistance to heat 
transfer in comparison to PA−PVP mixture formulations prepared by other 
methods. Commercial PVP began to decompose at temperatures above 
126 °C.  
 No significant weight loss was observed at temperatures below 100 °C 
for all samples (Figure 17) ruling out the presence of surface (free) water 
in all products under investigation as confirmed by their Karl fisher results 














Figure 17. Thermogravimetric analysis (TGA) profiles of commercial 
paracetamol (PA), commercial polyvinylpyrrolidone (PVP), and PA−PVP 
mixtures (95:5, w:w) co–processed by physical mixing (PM), batch 
cooling crystallisation (BCC), solvent evaporation (SE), freeze drying 




Table 8. Water content of commercial paracetamol (PA), commercial 
polyvinylpyrrolidone (PVP), and PA−PVP mixtures (95:5, w: w) co-
processed by physical mixing (PM), batch cooling crystallisation (BCC), 
solvent evaporation (SE), freeze drying (FD), and milling (ML). 
 
 
4.2.5. Tableting properties  
 Commercial PA displayed poor mechanical properties, with the highest TS 
of only 0.18 ± 0.02 MPa at a compression pressure of 148 Mpa (Figure 
18) like that obtained by (Agbor Rose and Kaialy, 2019). In comparison to 
commercial PA, the addition of PVP regardless of the method utilised 
showed an increase in tabletabilty of the PA−PVP mixtures (Figure 18). 
The TS of the mix of PA−PVP processed using different techniques 
compressed at 222 MPa was 0.4 ± 0.0 MPa, 0.4 ± 0.0 MPa, 1.2 ± 0.1 
MPa, 3.4 ± 0.0 MPa and 4.1 ± 0.1 MPa for mixtures prepared using PM, 
Product  Moisture content (%)  
PA 0.17 ± 0.0 
PVP 6.62 ± 0.0 
PM(PA−PVP) 0.73 ± 0.3 
BCC(PA−PVP) 0.17 ± 0.1 
SE(PA−PVP) 0.50 ± 0.0 
FD(PA−PVP) 0.57 ± 0.0 
ML(PA−PVP) 0.7 ± 0.1 
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BCC, SE, FD and ML method (Figure 18). PA−PVP mixtures using PM and 
BCC method were not statically different (P>0.05) tabletability profiles, 
whereas, the mixture prepared using SE methods exhibited a notable 
improvement in tabletability compare to the mixtures prepared using PM 
and BCC (Figure 18). 
For example, as the compression pressure increased from 37 MPa to 222 
MPa, the TS tablets increased from 0.1 to 0.4 MPa, 0.2 to 0.4 MPa and 
from 0.3 to 1.2 MPa for the mixtures prepared using PM, BCC and SE 
methods correspondingly (Figure 18), indicating that the SE method 
resulted in an increase in the tensile strength of tablets in comparison to 
PM and BCC over the compression range of 37 MPa to 222 MPa .The 
mixtures prepared using FD and ML exhibited a further increase of 
tabletability compared to the mixtures prepared using the SE technique. 
When the compression pressure increased from 37 MPa to 222 MPa, the 
TS of tablets prepared using FD increased from 0.9 ± 0.0 MPa to 3.4 ± 
0.0 MPa. Meanwhile, the PA–PVP mixture obtained using milling method 
increased from 0.4 ± 0.1 MPa to 4.1 ± 0.1 MPa (Figure 18). PA−PVP 
mixtures prepared using ML displayed the best compression properties 
among the combinations in this study, with a TS of 4.1 ± 0.1 MPa at a 
compression pressure of 222 MPa. In contrast to the other techniques 
applied, the mixtures prepared using ML achieved stronger tablets under 
compression pressure range of 37 MPa to 222 MPa.  
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The increased tensile strengths of the tablet mixtures prepared using FD 
and ML techniques compared to those prepared using (PM, BCC and SE) 
could be due to their differences in crystal habits (Figure 14), because 
crystal shape, through its effects on the relative alignment of crystallites 
throughout compression can impact compaction profiles (Higuchi et al., 
1963; Celik, 2011). Moreover, Sun and Hou, (2008); Chow et al., 2014 
showed that the formation of flat hydrogen–bonded layers or stacking 
hydrogen–bonded columns in the crystal structure could improve the 
tableting performance of poorly compressible powders. 
The high content of fine particulates of the mixtures prepared using ML 
compared to (BCC and SE) could also contribute to the increased cohesive 
inter−particulate forces between PA and PVP (Table 6 & 7) (Kaialy et 
al.,2016) leading to the increased degree of particle deformation, 
densification and magnitude and extent of bond formation during 
compaction (Kaialy, 2016). The tabletability profile (Figure 18) of the 
co−processed PA−PVP mixture prepared using ML technique 
demonstrated a far better tensile strength (TS) than that of Vanhoorne et 
al. (2016) who applied spray drying method with a formulation which 
comprises of (75% paracetamol, 5% PVP and 20% δ-mannitol) with a 




Figure 18. Tabletability profiles (mean ± SD, n = 5), of commercial 
paracetamol (PA), commercial polyvinylpyrrolidone (PVP), and PA−PVP 
mixtures (95:5, w:w) co-processed by physical mixing (PM), batch cooling 








It is remarkable how the methods of preparation have an immense impact 
on the micrometric and mechanical characteristics of paracetamol–
Polyvinylpyrrolidone mixtures (PA: PVP; 95:5; w:w) which is of great 
importance. Regardless of the engineered method employed, there was 
an improvement in tabletability for the mixtures of PA–PVP obtained using 
physical mixing, batch cooling crystallisation, solvent evaporation, freeze 
drying and milling techniques in comparison to the commercial 
paracetamol. Freeze drying and milling methods demonstrated excellent 
tabletability characteristics in comparison to the other techniques, which 
could be due to the increased hydrogen bonding interaction between 
paracetamol and polyvinylpyrrolidone leading to, subsequent reductions in 
bulk density and enhancement in mechanical properties. Freeze and 
milling methods should be considered in the future to improve the 
tabletability of poorly compactable drugs. Even though the flowability was 
not good, the content of uniformity of PA in all the different mixtures fell 




















5 CHAPTER 5: EFFECT OF FREEZING 
















Freeze drying is a technical process which includes the desiccation of a 
substance, followed by sublimation of water from the solid state at 
reduced pressure (Craig et al., 1999). This process provides products with 
desired physicochemical properties, such as, improved mechanical 
properties and enhanced dissolution rates (Kaialy et al., 2016) and allows 
the stabilisation and preservation of thermal sensitive APIs and biologicals 
that have reduced shelf life in solution (Liu, 2006). Additionally, freeze 
drying made it possible to achieve a 1:1 paracetamol/2–hydroxypropyl–
β–cyclodextrin host–guest complex, with solubility nearly six times higher 
than that of commercial paracetamol in comparison to kneading and 
physical mixing in water–ethanol mixture (Talegaonkar et al., 2007). 
Freeze drying technique was employed by Ogienko et al. (2011) to 
increase the tabletability of paracetamol, as discussed in (Section 1.7). 
However, the tablets obtained from the study were compressed using 
extremely high pressure. In this study for the first time, different freezing 
temperatures will be employed to obtain drug-polymer system to increase 
the tabletability of PA–PVP mixtures. 
5.1. Engineering of PA and PA–PVP formulations 
 
5.1.1 Freeze drying  
25% w/v solutions were prepared by dissolving 25 g of PA and 25 g of 
PVP independently in hydro–alcoholic solutions of (125 mL of ethanol and 
375 mL of deionised water) for a final volume of 500 mL under stirring 
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(200 rpm) at 70 ºC. The resultant clear solutions containing PA only and 
PVP only obtained were allowed to cool down and frozen using liquid 
nitrogen, while the vessel was stirred to allow maximum surface area for 
ten minutes and freeze dried using the method as discussed in (Section 
2.2.1.6). The FD Pas powders were sieved using the technique described 
in (Section 2.3).  
   25% w/v solution was prepared by dissolving 25 g of PA–PVP mixture in 
a hydro–alcoholic solution of (125 mL of ethanol and 375 mL of deionised 
water) for a final volume of 500 mL under stirring (200 rpm) at 70 ºC. The 
resultant clear solution containing PA−PVP mixture obtained was allowed 
to cool down and was frozen at –20 ºC, –80 ºC and –196 ºC and was 
freeze dried using the technique described in (Section 2.2.1.6). The FD 
(PA–PVP) formulations were sieved using the technique described in 
(Section 2.3).  
5.1.2. Physical mixing (PM)  
 Freeze–dried paracetamol (FD PA) and freeze−dried polyvinylpyrrolidone 
(FD PVP) (19:1 w:w) powders were mixed using low shear mixing 
technique as described in (Section 2.2.1.1).  
5.1.3. Preparation of tablets 
Each tablet has a weight of 526.3 ± 0.5 mg for the various formulations 
and 500 ± 0.5 mg for PA and FDPA, all compressed using the method 
described in (Section 2.14).   
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5.2. Results and discussions 
5.2.1. Laser diffraction  
As shown in (Table 9), the extent of agglomeration which is being 
expressed by the increase in mean median diameter (d50%). It is quite 
evident that the degree of agglomeration increases as the temperatures 
decrease from –20 ºC to –196 ºC for example, the d50% values range 
from 38 ± 0.3 µm to 64 ± 2.5 µm. Since PVP acted as a binder favouring 
agglomeration during the FD process which is affirmed by the SEM 
micrographs (Figure 19) which further demonstrate agglomerate 
comprises of, spherical and larger coalesced particles in which single 
particles are tough to differentiate (Figure 19). The mean diameter (VMD) 
of the FD samples increased with the decreased in temperatures (–20 ºC 
> –80 ºC > –196 ºC). For example, the VMD of the freeze–dried samples 
increased from 81.3 ± 28.4µm to 121 ± 11.2 μm when the temperature 
of freezing decreased from –20 ºC to –196 ºC as shown in (Table 9). The 
increased mean diameter of the freeze–dried samples is probably due to 
the increase in the size of the crystal ice formed during the freezing 
process at various temperatures. Also, it could be due to the presence of 
PVP which increases agglomeration and adhesion of particles–particles 
interaction (Vanhoorne et al., 2016). FD (PA−PVP) mixture frozen in liquid 
nitrogen exhibited narrow and broader PSDs (Table 9) in comparison to 
FPA, FD (PA−PVP) −20 ºC and FD (PA−PVP) −80 ºC. 
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Table 9. Particle size distribution (i.e. particle size at 10%(d10%),50%( 
d50%, median diameter and 90%(d90%) volume distribution and span) 
(mean ± SD, n=3) for commercial paracetamol (PA) and freeze–dried 
paracetamol(FDPA), freeze–dried polyvinylpyrrolidone(FDPVP), and 
PA−PVP mixtures (95:5, w:w) co-processed by physical mixing (PM) and 
freeze drying(FD) with different freezing temperatures (–20 ºC, –80 ºC 







Product  d10% (µm) d50% (µm) d90% (µm) VMD (µm) Span 
PA 254 ± 22 506 ± 30 911 ± 39.3 548 ± 30.2 1.3 ± 0 
FDPA 4.2 ± 0 16 ± 0.1 86 ± 1.3 32 ± 1 5 ± 1 
FDPVP 61 ± 3.2 279 ± 15. 550 ± 38.1 231 ± 29.1 2 ± 0.2 
PM(FDPA−FDPVP) 4 ± 0 12.4 ± 0.1 56 ± 3.5 23 ± 1 4.1 ± 0.3 
FD(PA−PVP)–20 ºC 8.1 ± 0 38 ± 0.3 56 ± 1.3 81.3 ± 28.4 3.2 ± 0.1 
FD(PA−PVP)–80 ºC 10.4 ± 0.1 42.4 ± 1 56 ± 3.5 80.4 ±15 3.4 ± 0.3 
FD(PAP−PVP)–196 
ºC 
14 ± 0.2 64 ± 2.5 255.3 ± 17.2 121 ± 11.2 
 
4 ± 0.2 
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Table 10. Bulk density (Db), tap density (Dt), cohesivity (1/b) and Carr's 
index (CI) (mean ± SD, n=3) for commercial paracetamol (PA) and 
freeze–dried paracetamol(FDPA), freeze–dried 
polyvinylpyrrolidone(FDPVP), and PA−PVP mixtures (95:5, w:w) co-
processed by physical mixing (PM) and freeze drying(FD) with different 
freezing temperatures (–20 ºC, –80 ºC and –196 ºC). 
 
The SEM micrographs as displayed in (Figure 19) shows that commercial 
PA portrays a polyhedral shape (Kaialy et al., 2014) whereas, in the case 
of FD PA, there was an alteration in shape from polyhedral to the plate–
like habit with holes at the edges (Figure 19). The freeze−dried (PA−PVP) 
samples frozen from −20 ºC and −80 ºC also produced a flat surface with 
finger−like shaped edges which could increase the interlocking of the 
particles. The freeze−dried PA−PVP sample frozen from −196 ºC 





) 1/b CI (%) 
PA 0.8 ± 0 0.8 ± 0 4 ± 0 3.2 ± 0.3 
FDPA 0.1 ± 0 0.3 ± 0 15.3 ± 0.2 52.3 ± 1 
FDPVP 0.2 ± 0 0.2 ± 0 17.2 ± 1 23 ± 0 
PM(FDPA−FDPVP) 0.1 ± 0 0.2 ± 0  13 ± 5 58 ± 4.3 
FD(PA−PVP)–20 ºC 0.1 ± 0 0.3 ± 0 12.1 ± 1.5 47.3 ± 1.1 
FD(PA−PVP)–80 ºC 0.1 ± 0 0.2 ± 0 9.3 ± 1.1 44 ± 2 
FD(PAP−PVP) −196 ºC 0.1 ± 0 0.2 ± 0 9.5 ± 2.4 43 ± 0 
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reported a change in crystal habit of PA using the same amount of PVP 






Figure 19. Scanning electron microscopy for commercial paracetamol 
(PA) and freeze–dried paracetamol (FDPA), freeze–dried 
polyvinylpyrrolidone(FDPVP), and PA−PVP mixtures (95:5, w:w) co-
processed by physical mixing (PM) and freeze drying(FD) with different 
freezing temperatures (–20 ºC, –80 ºC and –196 ºC). 
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5.2.2. Solid state 
Percentage of relative crystallinity of samples was calculated by the 
following equation (De Villiers et al., 1998)  
% Relative crystallinity = (IS / IR) Χ 100                  (Equation 9) 
Here, IS is the area under a distinct peak exactly at 24.41° 2θ in the 
freeze–dried samples and IR is the area under a peak at the same position 
in commercial crystalline paracetamol. The peak at 24.41° 2θ is the 
largest and most distinguished peak in X–ray diffraction spectra of 
paracetamol (Figure 20). 
Table 11. The relative peak intensity for paracetamol samples obtained 









FD(PA–PVP) −20 oC 82 
FD(PA–PVP) −80 oC 43 
FD(PA–PVP) −196 ºC 39 
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The PXRD spectra of commercial PA and freeze–dried samples are 
displayed in (Figure 20). The PXRD spectra portrayed similar diffraction 
patterns at 2θ values for all the samples suggesting that all the FD 
particles did not undergo any structural changes (Figure 20). A significant 
reduction in relative to, the degree of crystallinity of the freeze–dried 
samples using various freezing temperatures (−20 ºC, −80 ºC, –196 ºC) 
were encountered as shown in (Table 11). For example, the freeze–dried 
PA sample obtained in the absence of PVP exhibited about 6% reduction 
in crystallinity, whereas as the temperatures decreased from −20 ºC to –
196 ºC for the processed PA–PVP mixtures, there was a significant 
decrease in the percentage of crystallinity. The freeze–dried PA-PVP 
samples obtained from freezing using liquid nitrogen in the presence of 
5% PVP displayed only 39% crystallinity compared to FD (PA−PVP) −20 
ºC and FD (PA−PVP) −80 ºC that recorded 82% and 43% relative degree 
of crystallinity. According to (Sethia and Sequiilante, 2005; de Villiers, 
1998; Frank, 1990), the production of partially amorphous paracetamol 
particles could be due to the rapid evaporation rate of the hydroalcoholic 
solvent and the use of reduced temperature which facilitates rapid 
solidification of the crystals leading to the production of the amorphous 
phase. Also, Kaialy et al., (2016) stated that freeze drying process could 
induce the formation of amorphous products. The PXRD and DSC 
techniques were used to demonstrate how lyophilised mannitol displayed 




In this study, all the formulations showed a water content below (<1%) 
(Table 12), which is essential, especially when it comes to the stability of 
the freeze–dried samples. Also, all the freeze–dried samples were stable 
when exposed to higher temperatures as discussed in (Section 5.2.4). 
Table 12. The water content (n=3) for commercial paracetamol (PA) and 
freeze–dried paracetamol (FDPA), freeze–dried polyvinylpyrrolidone 
(FDPVP), and PA−PVP mixtures (95:5, w:w) co-processed by physical 
mixing (PM) and freeze drying(FD) with different freezing temperatures (–
20 ºC, –80 ºC and –196 ºC). 
Product  Water content (%) 
PA 0.2 ± 0 
PVP 6.6 ± 0 
FDPA 0.5 ± 0 
FD PVP 8.4 ± 0 
PM (FDPA– FD PVP) 0.9 ± 0 
FD(PA–PVP)–20 ºC 0.6 ± 0 
FD(PA–PVP)–80 ºC 0.5 ± 0 






Figure  20. Powder X–ray diffraction (PXRD) patterns for commercial 
paracetamol (PA) and freeze–dried paracetamol (FDPA), freeze–dried 
polyvinylpyrrolidone (FDPVP), and PA−PVP mixtures (95:5, w:w) co-
processed by physical mixing (PM) and freeze drying(FD) with different 




5.2.3. Fourier transform infrared  
 FT–IR studies were conducted to further investigate the nature and 
extent of interactions between the drug and polymeric carrier in the solid 
state. In polymer blends, mixing of two components at the molecular 
level will cause changes in the oscillating dipole of the molecules; this will 
manifest itself as changes in the frequency and bandwidth of interacting 
groups in the spectrum. Therefore, if interaction existed between the drug 
and polymer, the functional groups in the FT–IR spectra will show band 
shifts and broaden as compared to the spectra of the pure drug and 
polymer (Kovanda et al., 2011). 
(Figure 21) Shows that PA infrared spectra were the monoclinic form I as 
reported in the literature (Al–zoubi et al., 2002). The FT–IR spectrum of 
PA was well discussed in (Section 3.3.4). As for FDPVP, the intense 
bandwidth at 1640.28 cm−1 corresponded to the non–hydrogen bonded 
amide C=O (Figure 21). The FD samples such as FD PA, FD (PA–PVP)–20 
ºC, PM (FDPA–FDPVP) demonstrated slight reduction in absorbance 
intensity followed by FD (PA–PVP) –80 ºC and FD (PA–PVP) –196 ºC which 
demonstrated further reduction in absorbance intensity at 1644.37cm−1 
which established as the freezing temperature decreases. The peak at 
3300–3100 cm−1 is assigned to the non–hydrogen bonded N–H stretch of 
an amide of a PA molecule which is hydrogen bonded (3158.16 cm–1) 
through the carbonyl group to a PVP molecule. The N–H band shifts to 
lower wavenumbers from 1558.68 cm–1 to 1556.64 cm–1 with broadening 
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indicating the formation of hydrogen bonding between the N–H groups of 
the drug and the carbonyl groups of the polymer. PA and PVP molecules 
are associated with intermolecular hydrogen bonding between the amide 
(PA) and carbonyl (PVP) functional and increased its bond strength. 
Therefore, in this investigation the presence of PVP in the amorphous 
phase of co–freeze dried PA–PVP mixtures could be stabilised by the 
intermolecular hydrogen bond between PA and PVP and improve its 
physical stability against recrystallisation. FT−IR spectra co–freeze dried 
PA–PVP mixtures demonstrated the presence of intermolecular 




Figure 21. Fourier transform infrared (FT–IR) absorption spectra for 
commercial paracetamol (PA) and freeze–dried paracetamol (FDPA), 
freeze–dried polyvinylpyrrolidone(FDPVP), and PA−PVP mixtures (95:5, 
w:w) co-processed by physical mixing (PM) and freeze drying(FD) with 




5.2.4. Thermogravimetric analysis 
Figure 22 shows the thermograms of PA, PVP, FD PVP and their respective 
mixtures of PM(FDPA–FDPVP) and FD(PA–PVP) powders using various 
temperatures. All the formulations demonstrated a similar pattern and a 
reduction in water weight loss towards reduced temperature in 
comparison to PA, which could be due to the presence of PVP and the 
freeze drying technique applied. However, no water weight loss before 
100°C implying the absence of surface water in all the formulations. The 
thermogram also shows the FD samples began to decompose at 
approximately 218°C. FDPVP started to lose weight below 100°C due to 




Figure 22. Thermogravimetric analysis (TGA) profiles for commercial 
paracetamol (PA) and freeze–dried paracetamol (FDPA), freeze–dried 
polyvinylpyrrolidone(FDPVP), and PA−PVP mixtures (95:5, w:w) co-
processed by physical mixing (PM) and freeze drying(FD) with different 





5.2.5. Tableting properties 
The influence of compression force on crushing strengths of tablets 
prepared from freeze drying PA in the absence or presence of PVP are 
shown in (Figure 23). Effect of compression force on the crushing 
strengths of tablets prepared from the physical mixing of PA with PVP 
using various freezing temperatures are displayed in (Figure 23). The 
tabletability profile shows that PA at all compression forces produced 
weak tablets with a measurable crushing strength and likewise with FDPA 
in the absence of PVP which produced weaker tablets at various 
compression pressure with high capping tendency in comparison to FD 
(PA–PVP) mixtures (Figure 23). The FD (PA–PVP) particles demonstrated 
an immense increase in their compaction properties compared to PA, and 
formed tablets with excellent crushing strength and the absence of 
tendency to cap for example, FD (PA–PVP)–20 ºC, FD (PA–PVP)–80 ºC 
and FD (PA–PVP)–196 ºC recorded TS values of, 3.4 ± 0.0 MPa, 3.8 ± 0.2 
MPa and 4.2 ± 0.1MPa at 222 MPa. It was quite evident that the reduction 
in freezing temperatures employed on the various freeze–dried samples 
resulted in a profound increase in the crushing strength of the tablets and 
according to, Olusanmi et al. (2010) processing temperatures are known 
to impact mechanical properties especially, the hardness of the materials. 
In this investigation, the strong interparticulate bonding between PA and 
PVP particles which is indicated by, the higher crushing strength of the 
tablets could be due to the formation of the partially amorphous state 
that occurred during the co–freezing process at various freezing 
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temperatures, and the presence of the amorphous binder PVP is known to 
form strong hydrogen bonding with PA (Garekani et al.,2000b). 
The tensile strength of the physical mixture of FDPA–FDPVP compressed 
at different compression pressure (Figure 23), clearly demonstrated that 
the tablets strength even at 5% w/w PVP content was 2.8 ± 0.1MPa, but 
that of FD(PA–PVP) –196 ºC in the presence of 5% PVP produced tablets 
with crushing strengths of 4.2 ± 0.1MPa (Figure 23). This was because 
the PA–PVP mixture freeze–dried with liquid nitrogen produced larger 
particles in comparison to the other samples under dissimilar freezing 
temperatures (–20 ºC and –80 ºC) and the physical mix, which was 
clearly shown by their differences in VMDs values (Table 10) and 
according to Osborne et al. (2011) bigger granules can be expected to 
possess more binder–rich domains which further produced tablets with 
considerable tensile strength and reduced friability. Also, these results 
show that the enhancement in tabletability of FD (PA−PVP) –196 ºC was 
not only due to the binding nature of PVP but also the solid properties and 
the semi–crystalline state of the crystals. The presence of the amorphous 
state in pharmaceutical powder plays a vital role in their compactibility 
(Vanhoorne et al., 2014; Takeuchi et al., 1998; Bauer-Brandl, 1996; 
York, 1992). The results obtained from this study showed superior 
compactibility properties using freeze drying technique compared to spray 
drying in the presence of plastically deforming particles like Lactose or δ-
mannitol applied by (Vanhoorne et al., 2014; 2016). 
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 Tablet with a minimum tensile strength of 2.0 MPa is required to 
safeguard the integrity of the pharmaceutical tablet, which indicates 
adequate strength for handling and transportation. Based on the 
observations in this study, all the values were >2.0 MPa suggesting an 
excellent tablet tensile strength from all the formulations regardless of the 
freezing temperatures.  
The friability is a measure of the mechanical strength of the tablets. The 
friability data of the PM (FDPA–FD PVP); FD (PA–PVP) –20 ºC, FD (PA–
PVP)-80 ºC tablets (mass loss of 21.31%; 1.25% and 1.30%) was higher 
compared to the FD(PA–PVP) –196 ºC tablets (mass loss of 0.91%). The 
differences in particle sizes, as shown by their VMD values (Table 11) can 
explain the differences in friability between the various freezing 
temperatures applied to the PA–PVP mixtures. Moreover, it appears from 
that FD (PA–PVP) –196 ºC had more intragranular pores and amorphous 
sites (Table 11; Figure 19) compared to their counterparts. Intragranular 
pores increased tablet strength, while the amorphous domains discourage 
tablets fragmentation/breakage under stress (oscillations in friability test) 
leading to reduced tablet friability. 
The friability of the tablets consisting of the engineered powders of FD 




Figure 23. Tabletability profiles (mean ± SD, n = 5), for commercial 
paracetamol (PA) and freeze–dried paracetamol (FDPA), freeze–dried 
polyvinylpyrrolidone(FDPVP), and PA−PVP mixtures (95:5, w:w) co-
processed by physical mixing (PM) and freeze drying(FD) with different 
freezing temperatures (–20 ºC, –80 ºC and –196 ºC). 
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 5.3. Conclusions 
This investigation clearly showed how the effect of freezing temperatures 
impacted the particle size, crystallinity and mechanical characteristics of 
paracetamol–Polyvinylpyrrolidone mixtures freeze–dried in the presence 
of 5% PVP w/w from a hydroalcoholic solution. It was quite evident that 
irrespective of the temperature of freezing employed, there was an 
enhancement in tabletability for the freeze–dried mixtures of PA–PVP in 
comparison to the commercial paracetamol. The best tabletability results 
were obtained with the PA–PVP mixture was frozen at –196 ºC compared 
to the other mixtures frozen at –20 ºC and –80 ºC. The PA–PVP mixtures 
frozen using liquid nitrogen had the best tabletability result which could 
be due to, the drastic reduction in the percentage of relative crystallinity 





























6 CHAPTER 6: EFFECT OF VARIOUS PREPARATION 















Ibuprofen [C13H18O2 – (RS)–2– (4– (2–methyl propyl) phenyl) propanoic 
acid] (IBU) is a non–steroidal anti−inflammatory drug used mainly as 
antipyretic and analgesic (Soares and Carneiro, 2014) also, the third most 
used anti–inflammatory agent in the world (Andini et al., 2012). At lower 
doses (0.6–1.2 g per day), IBU is well suited for the treatment of fever, 
pain, migraine, and dysmenorrhoea (De Brabander et al., 2004) and in 
the therapy of rheumatoid arthritis and osteoarthritis, it is used in high 
doses; 1800–3200 mg daily or 200–800 mg every 4–6 h as a single dose 
(Kachrimanis and Malamataris, 1998). 
IBU is a colourless needle−like crystalline powder with a molecular weight 
of 206 g/mol with melting temperature ranges from 75–77 ºC and boiling 
points of 157 ºC (Paradkar et al.,2003; Krupta et al., 2007). IBU has two 
possible enantiomers, (R)–ibuprofen and (S)–ibuprofen (Qiao et al., 
2011). However, it has poor water solubility at room temperature (Drug 
bank, Ibuprofen, 2012). The frequently used needle− shaped crystals of 
IBU demonstrates poor flowability due to high cohesivity and adhesivity, 
and it exhibits poor compaction behaviour; thus, must be granulated in 
most cases before tableting. Another problem in manufacturing is the 
high tendency of sticking to the punches (Rasenack and Müller, 2002; 
Mallick et al., 2013; Manish et al., 2005). Nonetheless, combining 
analgesics into a single product may ease compliance by reducing the 
total number of medications in which the patient is obliged to take to 
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manage pain, therefore, the use of a mixture of oral analgesics vs an 
individual agent offers numerous potential benefits (Raffa,2001; Tanner 
et al., 2010). 
A combination of paracetamol‒ibuprofen therapy is currently available in 
the market (NuromolTM) as a tablet. In this work is aimed to prepare 
direct compression grades of PA in the presence of IBU particles which are 
less brittle under compaction. 
IBU contains one carboxylic acid group that can act as a hydrogen−bond 
donor, so it has the potential to interact via hydrogen bonding with drugs 
continuing amine groups like PA. The ratio of (5:2, w/w) of PA to IBU was 
used in this study. The effect of the different processing methods on the 
physicochemical and mechanical properties of PA–IBU mixtures was 
investigated.   
6.1.0. Engineering of PA–IBU formulations 
 
6.1.1 Physical mixing    
 PA and IBU (5:2 w:w) powders were mixed using low shear mixing 
technique as described in (Section 2.2.1.1). 
6.1.2. Batch cooling crystallisation 
 PA and IBU powders (5:2, w:w ratio) were dissolved in a mixture of 
ethanol/distilled water (50/50, v:v). After being wholly dissolved, the 
resultant solution was left uncovered under laboratory conditions for 
seven days using batch cooling crystallisation method as described in 
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(Section 2.2.1.4). The crystals obtained were sieved using the technique 
described in (Section 2.3). 
6.1.3. Freeze drying  
 PA and IBU powders (5:2, w: w ratio) were dissolved in the mixture of 
ethanol/distilled water (50/50). The resultant clear solution containing 
paracetamol−ibuprofen mixture obtained was allowed to cool down and 
was frozen using liquid nitrogen, while the vessel was stirred to allow 
maximum surface area for ten min then was freeze dried using the 
technique described in (Section 2.2.1.6). The FD (PA–IBU) powders were 
sieved using the technique described in (Section 2.3).  
6.1.4. Compact milling (CPM) (PA−IBU)  
 PA and IBU powders (14 g in total at 5:2, w: w ratio) were compacted 
into a tablet using 3000 kp and were further milled for one min by 
applying the milling technique as described in (Section 2.2.1.7). 
6.1.5 Milling (PA−IBU) 
 PA and IBU powders (14 g in total at 5:2, w: w ratio) were milled for five 
min by using the milling method as described in (Section 2.2.1.7). 
6.1.6. Tablet preparation 
Each tablet weighs 700 mg ± 0.5 mg for the various formulations of 
which 200 mg is of IBU and 500 mg of PA. Both the formulations and the 
commercial paracetamol and commercial Ibuprofen (500 mg ± 0.5 mg) 
were all compressed using the method described in (Section 2.14).   
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6.2. Results and Discussions 
6.2.1. Particle size distributions 
PA–IBU mixture prepared using PM mixing method displayed an increase 
in both VMD and span values compared to the marketed PA (Table 13) 
this could be due to the ratio of IBU to that of PA particles whose VMD 
values are lesser (Table 13) as affirmed by SEM micrographs (Figure 24). 
However, the mixtures obtained using both CPM and BCC processing 
methods demonstrated a drastic reduction in VMDs and an increased in 
span values compare to the commercial PA (Table 13), and their PSDs 
showed statistically different results. This is affirmed by the SEM 
observations, which showed a difference in the structure of mixtures 
prepared using (CPM and BCC) (Figure 24). On the other hand, the 
mixtures prepared using DHS, FD and ML processing techniques revealed 
smaller and varied PSDs (VMD of 30.3 ± 0.5 µm, 47 ± 4.3 µm and 43 ± 
5.2 µm) in comparison to the mixtures using PM, CPM and BCC methods 
which displayed broader PSDs (VMDs ranging from span values ranging 
from 125 ± 4.5 µm to 821 ± 37.4 µm (Table 13). The change towards 
lower PSDs for the freeze–dried sample could be due to the in−situ 
generation of intrinsic fine particles during the FD preparation (as shown 
by its d10% values) (Table 13). On the other hand, the fines particles 
during ML are due to the collisions of the metallic balls and the PA–IBU 
particles. The difference in morphologies between the various mixtures is 
envisaged from their SEM micrographs (Figure 24) as the engineered 
samples showed irregular–shaped structures compared to their 
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commercial components. This could lead to differences in tabletabilty 
properties. 
 Table 13. Particle size distribution (i.e. particle size at 10%(d10%),50%( 
d50%, median diameter and 90% (d90%) volume distribution and span) 
(mean ± SD, n=3) of commercial paracetamol(PA), commercial 
ibuprofen(IBU) and the mixtures (PA:IBU, 5:2 w/w) prepared using 
physical mixing (PM), compact milling(CPM), batch cooling 
crystallisation(BCC), dry high shear (DHS), freeze drying (FD) and 
milling(ML)  
Samples d10% (µm) d50% (µm) d90%(µm) VMD (µm) Span 
PA 254 ± 22 506 ± 30 911 ± 39.3 548. ± 30.2 1.3 ± 0 
IBU 26.1 ± 0.5 88 ± 3.3 389.3 ± 8.5 144 ± 14 4 ± 0.5 
PM(PA−IBU) 80 ± 5.2 634.3 ± 17 1780.3 ± 9 821 ± 37.4 3 ± 0.1 
CPM(PA−IBU) 11 ± 0.4 76 ± 3.5 313 ± 11.5 125 ± 4.5 4 ± 0.1 
BCC(PA−IBU) 16.4 ± 0.1 97.3 ± 1 595 ± 13 277 ± 29.3 6 ± 0.5 
DHS(PA−IBU) 3.3 ± 0.1 15.3 ± 0.4 82.1 ± 1.1 30.3 ± 0.5 5.1 ± 0.1 
FD(PA−IBU) 5 ± 0 19.4 ± 0.2 112 ± 9.4 47 ± 4.3 5.5 ± 0.4 




Figure 24. Scanning electron microscopy micrographs of commercial 
paracetamol(PA), commercial ibuprofen(IBU) and the mixtures (PA:IBU, 
5:2 w/w) prepared using physical mixing (PM), compact milling(CPM), 
batch cooling crystallisation(BCC), dry high shear (DHS), freeze drying 
(FD) and milling (ML). 
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6.2.2. Powder density and Cohesivity  
The various mixtures of PA−IBU exhibited lower bulk, high cohesivity and 
high CI values than the marketed PA (Table 14). The mixtures prepared 
using DHS, FD and milling methods showed a further reduction in bulk 
densities, increased in cohesivities compared to commercial PA, PM, CPM 
and BCC powders (Table 14). Additionally, as displayed in (Figure 24), the 
DHS (PA–IBU), FD (PA–IBU) and ML (PA–IBU) demonstrated irregular 
crystal shapes in comparison to PA PM (PA–IBU), CPM (PA–IBU) and BCC 
(PA–IBU) powders which influences the packing density (ter Horst et al., 
1999). 
The reduction in bulk and tap densities were shown to increase the tensile 
strength of tablets (Chen et al., 2018; Di Martino et al., 2002). Most 
powdered pharmaceuticals, compaction of smaller particles leads to the 
formation of stronger tablets as, the smaller particles offer a larger total 
area for bonding than larger particles (Grant and Sun, 2001). The slight 
reductions in the bulk for the mixture prepared using PM method 
compared to PA is due to the presence of (14%, w/w) IBU powders whose 
bulk and tap density values are slightly smaller than those of PA (Table 
14). 
The marketed paracetamol demonstrated the least CI value as shown in 
(Table 14) indicating a better flow property compared to the other 
powders under investigation. Such powders, present uniformed−sized 
shapes so it must be difficult to orient in different direction and fracture 
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during compaction resulting in poor compaction. All PA− IBU mixtures 
showed higher CI values which is consistent with the patterns in bulk and 
tap density changes compared to commercial PA (Table 14) indicating 
their relatively poorer flow properties. The mixtures prepared using FD 
and ML samples displayed poorer flowability than (PM, CPM and BCC) as 
shown by their considerably higher CI values (42% ± 0% and 51% ± 2% 
versus 12% ± 0 %, 40% ± 1% and 32 % ± 1% (Table 14). Which 
further, attribute to the lower PSDs to stronger interparticle forces (Li et 
al., 2004; Kaialy et al., 2012) likewise, the difference in bulk densities is 
also linked to their dissimilar crystal habits, leading to different contact 
points and cohesive and frictional forces between crystals. Those factors 
impact sliding of the particles against each other, which leads to different 














Table 14. Bulk density (Db), tap density (Dt), cohesivity (1/b) and carr’s 
index (CI) (mean ± SD, n=3) for commercial paracetamol(PA), 
commercial ibuprofen(IBU) and the mixtures (PA:IBU, 5:2 w/w) prepared 
using physical mixing (PM), compact milling(CPM), batch cooling 




6.3. Solid state properties 
6.3.1. Powder X−ray diffraction   
The PXRD analysis was carried out for Commercial PA, commercial IBU 
and all PA–IBU mixtures prepared using PM, BCC CPM, FD and ML 





) 1/b CI (%) 
PA 0.8 ± 0 0.8 ± 0 4 ± 0 3.2 ± 0.3 
IBU 0.6 ± 0 0.71 ± 0 14 ± 0 22 ± 1 
PM(PA−IBU) 0.74 ± 0 0.84 ± 0 7.5 ± 1 12 ± 0 
CPM(PA−IBU) 0.5 ± 0 0.8 ± 0 7.2 ± 4.0 40 ± 1 
BCC (PA−IBU) 0.43 ± 0 0.63 ± 0 41 ± 0 32 ± 1 
DHS(PA−IBU) 0.24 ± 0 0.43 ± 0 29 ± 2 44 ± 1 
FD(PA−IBU) 0.13 ± 0 0.3 ± 0 24.4 ± 2 51 ± 2 
ML(PA−IBU) 0.31 ± 0 0.53 ± 0 52 ± 0 42 ± 0 
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IBU displayed characteristic peaks at 2θ values of ∼6O, 12O, 13.5O, 16O, 
17O, 18O, 19O, 20O, 20.5O, 22O, and 22.5O (Ali et al., 2010) and PA PXRD 
pattern as displayed in (Figure 25) and possessed characteristic peaks as 
discussed in (Section 3.3.3). Both commercial samples’ PXRD patterns 
revealed their crystalline nature due to the numerous sharp and intense 
peaks present. All PXRPD values for PA−IBU mixtures showed that all 
diagnostic peaks for PA and IBU were present in PM (PA–IBU), CPM (PA–
IBU), DHS (PA–IBU), FD (PA–IBU) and ML (PA–IBU) mixtures (Figure 25). 
The absence of high reflections at 10.35 o, 21.85o and 24.03o 2θ (Di 
Martino et al., 1996) in PM (PA–IBU), CPM (PA–IBU), DHS (PA–IBU), FD 
(PA–IBU) and ML (PA–IBU) mixtures ruled out the transformation of the 
monoclinic form to the orthorhombic form, which is less stable than the 
monoclinic form. However, the BCC method employed showed a different 
pattern (peak position) at 2θ values of 12.16°, 13.83°, 15.5° and 24.03° 
(Martino et al., 1996) an indication of the mixture of monoclinic PA and 
orthorhombic forms of PA. Also, IBU was less prevalent than PA in BCC 
(PA–IBU) mixture could be due to its lost during filtration using the batch 
cooling crystallisation process described in (Section 2.2.1.4) which will 
reduce the appearance of IBU in BCC (PA–IBU) mixture in the comparison 
the mixtures prepared using PM, CPM, DHS, FD and ML techniques. In 
some cases, the intensity of the peaks was higher than those of neat IBU 
and PA, which could be due to their high crystalline nature. 
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 The residual moisture measured for the PA–IBU was insignificant 
(<0.16% w/w), which is ideal for storage stability (Barresi et al., 2009) 
(Table 15). 
 
Figure 25. Powder X–ray diffraction (PXRD) patterns of (a) commercial 
paracetamol(PA), (b) commercial ibuprofen(IBU) and the mixtures (PA: 
IBU, 5: 2 w/w) prepared using (c) physical mixing (PM), (d) compact 
milling(CPM), (e) batch cooling crystallisation (BCC), (f) dry high shear 
(DHS), (g) freeze drying (FD)and (h) milling (ML). 
6.3.2. Infrared spectroscopy 
The FT–IR analysis of PA, IBU and PA–IBU mixtures (Figure 26) displays 
the spectra of PA and IBU confirming that the presence of both drugs in 
the various mixtures irrespective of the method applied which is vital 
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regarding any chemical changes/interactions at the molecular level during 
the engineering process. 
The diagnostic bands for PA orthorhombic form (Section 3.3.4) were 
absent from the spectra of commercial PA and all PA‒IBU mixtures, 
confirming the purity of PA monoclinic form phase for all products under 
investigation. From the molecular structures of PA and IBU (Table 5 & 15) 
indicate that H–bonding effect may exist between the N–H stretch or the 
O‒H stretch (H donors) of PA and the carbonyl group (C=O, H acceptor) 
of IBU which could probably induce hydrogen bonding interactions in all 
the PA–IBU mixtures prepared using the various techniques. The 
marketed IBU spectra  showed characteristic broad absorption peaks at 
3078.60 cm–1 and 3066.36 cm−1 corresponding to OH group usually from 
carboxylic acid which has strong tendency to form hydrogen–bonded 
dimers, O–H group from carboxylic acid which is attributed by the 
presence of the broad absorption bands at 3500–2500 cm−1 (Coates, 
2000). 
IBU shows characteristic peaks at 2960 cm−1 for the aryl C−H stretching 
and three aliphatic alkyl groups. The carbonyl group can be found at 
approximately, 1700 cm−1 on IBU spectrum (Ma et al.,2013), 1513 cm−1, 
1463 cm−1, 1378 cm−1 which are used by C=C vibration of the phenyl ring 
and the C− H bond vibration (Zhao et al., 2014; Ambrogi et al., 2001; 
Qiu et al., 2005; DeLeon et al.,2012). C–0 stretching at 1228.20 cm–1, 
the C=O stretching of the carboxylic acid of IBU at 1703.05 cm–1 which 
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demonstrated high intensity which could be due to the immerse dipole 
moment of the carbonyl bond. 
The FT–IR spectrum of (5:2; PA: IBU) of PM(PA–IBU), CPM(PA–IBU), 
BCC(PA–IBU), DHS(PA–IBU) and FD(PA–IBU) mixtures displayed in 
(Figure 26) showed specific bands corresponding to the bands in the 
individual components of the mixture remained the same indicating an 
insufficient intermolecular interaction between both drugs. However, the 
band corresponding to the stretching vibration of the carbonyl group of 
IBU shifted from 1709.75 cm–1 to 1731.83 cm−1 indicating a slightly 
stronger hydrogen bonding interaction in solid state between PA and IBU 
for the mixture prepared using milling (ML (PA–IBU) technique as shown 




Figure  26. Fourier transform infrared spectroscopy (FT–IR) spectra of 
(a) commercial paracetamol(PA), (b) commercial ibuprofen(IBU) and the 
mixtures (PA:IBU, 5:2 w/w) prepared using (c)physical mixing (PM), 
(d)compact milling(CPM), (e) batch cooling crystallisation(BCC), (f) dry 













Table 15. Chemical structure and characteristic FT–IR absorption bands 
of Ibuprofen (IBU) (Namur, 2009). 
 
 
6.3.3. Thermogravimetric analysis 
The TGA profiles of commercial PA, commercial IBU and PA–IBU mixtures 
are displayed in (Figure 27). Single step mass loss and decomposition 
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were observed in both PA and IBU, and the various (PA–IBU) mixtures in 
the TGA derivative curves. The melting point of IBU has been reported to 
be at 71.7± 0.1 ºC (Passerini et al., 2002). A weight loss in PA particles 
as the temperature increases as discussed in (Section 3.3.4) whereas, 
IBU showed 100% mass loss at 292 ºC, due to the complete melting of 
the sample which is closer to the result obtained by (Krupa et al., 2010). 
No apparent water loss is found near the temperature of 100 ºC for PA, 
IBU and PA–IBU mixtures. The TGA curves of the IBU and PA binary 
mixtures (Figure 27) showed slightly significant weight loss in the 
temperature from 200 ºC to a final decomposition at 500 ºC. BCC and 
DHS samples displayed a shift from 200 ºC towards lower melting points, 
which could be attributed to the decomposition of the organic fraction of 
IBU at a higher temperature. Meanwhile, in FD sample, the weight loss at 





Figure 27. TGA thermal profiles of  commercial paracetamol(PA), 
commercial ibuprofen(IBU) and the mixtures (PA:IBU, 5:2 w/w) prepared 
using physical mixing (PM), compact milling(CPM), batch cooling 


























6.4.4. Stability studies 
The results of the current investigation, showed that the PA and all PA–
IBU mixtures gained negligible amounts of moisture (<0.08%, w/w) when 
stored at 75% RH conditions (22 ºC) for three months, confirming their 
low hygroscopicity and thereby, potentially excellent stability (SM 1). 
6.5. Tableting properties 
PA showed poor mechanical properties, as discussed in (Section 3.3.5) 
(Figure 28). Similarly, the compression of IBU crystals at all compaction 
pressures produced weak compacts with low tensile strength, with its 
highest tensile strength recorded at 148 MPa was (0.98 ± 0.07 MPa). The 
engineered samples of PA–IBU (5:2, w/w PA: IBU) showed an improved 
tabletability (Figure 28). For example, the TS of PA–IBU mixture 
compressed at 222 MPa was 0.3 ± 0.0 MPa, 0.8 ± 0.2 MPa, 1.2 ± 0.0 
MPa, 1.4 ± 0.0 MPa, 1.7 ± 0.2 MPa and 1.9 ± 0.1 MPa for the mixtures 
prepared using PM, CPM, BCC, DHS, FD, and ML methods (Figure 28). The 
mixture prepared using DHS method exhibited a remarkable improvement 
in tabletability compared to the mixtures prepared using PM, CPM and 
BCC methods. For example, the compression pressure increasing from 37 
MPa to 222 MPa, the TS of tablets increased, from 0.2 MPa to 0.3 MPa 
and from 0.4 MPa to 1.4 MPa, for the mixture prepared using PM and DHS 
methods respectively (Figure 28) which implies that the DHS method 
resulted in an increase in the TS of tablets compared to PM method as 
fines from this product must have filled cavities between comparatively 
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larger particles and DHS showed smaller particles sizes compared to PM 
crystals (Table 14) (Aher et al., 2003; Di Martino et al., 2001). The 
mixtures prepared using, FD and ML techniques demonstrated additional 
enhancement of tabletability compared to DHS method. As the 
compression pressure increased from 37 MPa to 222 MPa, the TS of 
tablets prepared using FD increased from 0.8 ± 0.1 MPa to 1.7 ± 0.2 
MPa. Meanwhile, the ML mixture increased from 0.7 ± 0.1 MPa to 1.9 ± 
0.1 MPa (Figure 28). It is evident, that the PA–IBU mixture prepared 
using ML method showed the best compression properties among the 
mixtures under investigation, recording a TS of 1.9 ± 0.1 MPa at a 
compression pressure of 222 MPa. In comparison to the mixtures 
prepared using PM, CPM and BCC. Such superior tabletability is attributed 
to the decrease in particle size which is known to enhance tensile strength 
by an increase in the overall bonding area (Liu et al., 2013; Alderborn, 
2002). Additionally, the ductile fracture caused by shear stresses in the 
mill could be assumed as, one of the contributing factors to the superior 
tableting performance of monoclinic PA mixed with IBU in comparison to 
PA and IBU mixed using the other methods as, IBU plastically deform 
during milling (Larsson and Kristensen, 2000; More et al., 2013) by 
covering the brittle PA. Furthermore, during compression crystal habit can 
also influence compaction profiles through its effect on the relative 
orientation of crystallites (Lin et al., 2017; Celik, 2011; Nokhodchi et 
al.,2008; Bandyopadhyay, 1998; Sun and Grant,1999; Wong and Pilpel, 
1990; Garekani et al., 2000a and Garekani et al., 2000b). The ML 
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samples (Figure 24) depicts an irregular shape in comparison the other 
methods applied, and the better compaction is being observed in case of 
particles of more irregular size and shape (Aher et al., 2013).  
Figure 28. Tabletability profiles (mean ± SD, n = 5) for commercial 
paracetamol(PA), commercial ibuprofen(IBU) and the mixtures (PA:IBU, 
5:2 w/w) prepared using physical mixing (PM), compact milling(CPM), 
batch cooling crystallisation(BCC), dry high shear (DHS), freeze drying 





































In this study, the engineered crystals of PA‒IBU mixtures displayed 
improved tableting properties in comparison to the commercial grades of 
PA, IBU, and their conventional physical mixture in the presence of (2% 
IBU w/w). The tablets obtained using the milling technique demonstrated 
far better tabletability results in comparison to the compact milling, batch 
cooling, dry high shear and freeze drying methods, which was due to their 
enhanced micrometric properties and strong hydrogen bonding 
interactions leading to improved mechanical properties between the PA 
and IBU particles. Thus, paracetamol and ibuprofen can be simultaneously 








































Particle size reduction of pharmaceutical materials is frequently performed 
by applying micronisation methods which have been well discussed in 
(Section 1.8.1.2). Grinding (milling) technique has been employed over 
the years to improve the physicochemical properties of drugs (Al–Hamidi 
et al., 2013; 2010). Dichi et al. (2018) applied dry grinding technique to 
reinvestigate paracetamol–caffeine, aspirin–caffeine, and paracetamol–
aspirin phase equilibria diagrams. On the other hand, Jain et al. (2014) 
formulated a eutectic mixture of aspirin−paracetamol with enhanced 
physico–mechanical properties in comparison to paracetamol and aspirin 
physical mixture which was well discussed in (Section.1.3.4). 
Aspirin (acetylsalicylic acid, C6H5C3O4H4) (ASP) is a drug widely used as 
antipyretic (pain reliever), anti–inflammatory (reduces swelling) and  
analgesic (fever reducer) mainly because of its high effectiveness, low 
cost and low toxicity (Brayfield, 2014; Linares et al., 2004) and it is 
administered extensively via the oral route (BNF, 2016). On the other 
hand, Caffeine (C8H10N402; 1, 3, 7−trimethylpurine-2, 6−dione,) (CAF) is 
inexpensive, readily available and broadly used psychoactive drug in the 
world (Sahoo et al., 2015) and is widely used cold remedies for its 
stimulant action and consumed in coffee, tea and a variety of soft drinks 
(Dichi et al., 2014). Many pharmaceutical molecules including, CAF shows 
polymorphism which is a common phenomenon in pharmaceutical fields 
and possesses two known polymorphic structures the form I which is 
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stable at ambient pressure from the transition temperature (145 °C) to its 
melting point of 236°C and the Form II is stable polymorph at room 
temperature until 145 °C (Pinto et al., 2006; Dichi et al., 2014). However, 
it has poor flowability due to its needle–like shaped crystals leading to 
aggregates (Garekani et al., 2015; Jbilou et al., 2015). UK Medicines and 
Healthcare Regulatory Authority (MHRA) in 1991 first permitted the 
combination of PA and CAF for medical use (MHRA, 1991). Besides, the 
increase in the content of CAF in the mixture immensely enhances the 
solubility of paracetamol (Tkachenko et al., 2003). 
The combination of PA, ASP and CAF is being used in the United Kingdom 
as Anadin extra, which contributes to the efficacy of oral analgesics with 
better performance than their individually active pharmaceutical 
ingredients. Therefore, in this study, two plastically deforming drugs (ASP 
and CAF) will be combined to enhance the tabletability performance of PA 
with no binder added and, it is more likely for hydrogen bonding 
interaction, to occur between these three drugs.  
There is no published work which has attempted to increase the tableting 
performance of paracetamol with caffeine and aspirin by employing 
various processing methods. In order to avoid pseudo–polymorphs 
formation (Hydrates or solvates) of ASP and CAF, no water or organic 





Table 16. Some Chemical properties of aspirin and caffeine. 
 
 
Product Physical properties References 
Aspirin (ASP) Melting point: 135 ºC  
Solubility (37 ºC) (10 mg/ml) 
Chomcharn, and 
Xanthos, (2013) 
Enthalpy of fusion: Δfush = 93.19 
J g−1 
(Jain et al., 2014) 
Solubility pH (1.2) (25 ºC): 0.061 mg/ml  
PKa (25 ºC): 3.5  
 
 
(Rasool et al., 2010) 
Caffeine 
(CAF) 
 Melting point: 235.6 ºC 
Enthalpy of fusion: Δfush = 104.9 J g
−1 
 
(Klimova and Leitner, 
2012) 
  
the solubility of (37.47± 1.01 mg/ml) 
in water at 37 ºC 
 (Sriamornsak and 
Kennedy,2007) 





7.1. Engineering of PA–ASP–CAF formulations  
 7.1.1. Physical mixing 
 PA, ASP and CAF (25:25:13 w: w) powders were mixed using low shear 
mixing technique as described in (Section 2.2.1.1). 
7.1.2. Dry high shear mixing  
PA, ASP and CAF (25:25:13 w: w) powders were blended for 1 min and 2 
min by applying high shear mixing technique as described in (Section 
2.2.1.2). 
7.1.3. Milling   
 PA, ASP and CAF (25:25:13 w: w) powders were milled for 5 min (ML5) 
and 10 min (ML10) using milling method as described in (Section 
2.2.1.7). 
7.1.4. Tablet preparation 
Each tablet has a weight of 565 ± 0.5 mg for the various formulations 
and 500 ± 0.5 mg for PA, ASP and CAF were compressed using the 
method described in (Section 2.14). 
7.2. Results and discussions 
7.2.1. Particle size distribution 
All spans calculated from the ML and DHS data were higher than 2, 
indicating that the breadth of the distributions was relatively broad (Fan 
et al. (2005). Both commercial ASP and commercial CAF demonstrated 
smaller PSDs compared to PA. The physical mixing of PA–ASP–CAF 
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displayed reduced VMDs compared to PA. Meanwhile, the dry high shear 
(1 min & 2 min) and milling (5 min & 10 min) displayed significantly 
reduced PSDs compare to PA (Table 17). The PSDs (d10% values) of PA–
ASP–CAF mixture demonstrated subsequent order PM> DHS1=DHS2 > 
ML5 = ML10 (Table 17). It is remarkable that mixtures prepared using 
DHS and ML processes displayed a remarkable decrease in their VMDs as 
their span values increases which deduced their smaller PSDs. The 
reduced size in PSDs in the DHS (PA–ASP–CAF) (1 min & 2 min) could be 
due to higher energy applied to the mixtures. Meanwhile for the mixtures 
using milling (5 min & 10 min), the increase in the particle size due to the 
collisions between the metallic balls and the particles, as evident the 
increased in d10% values (Table 17). The latter results will have an impact 











Table 17. Particle size distribution (i.e. particle size at 10%(d10%),50%( 
d50%, median diameter and 90%(d90%) volume distribution and span) 
(mean ± SD, n=3) of commercial paracetamol (PA), commercial aspirin 
(ASP), commercial Caffeine (CAF) and PA–ASP–CAF mixtures co–
processed using physical mixing (PM), dry high shear for 1min (DHS1), 
dry high shear for 2 min (DHS2), milling for 5 min (ML5) and milling for 





Product d10% (µm) d50% (µm) d90%(µm) VMD (µm) Span 
PA 254 ± 22 506 ± 30 911 ± 39.3 548 ± 30.2 1.3 ± 0 
ASP 250.3 ± 7.2 423.3 ± 13 
676 ± 22.5 
444 ±11.5 1 ± 0 
CAF 8.5 ± 0.1 52.3 ± 0.5 
163.3 ± 1.1 
72.3 ± 1 3 ± 0 
PM(PA–ASP–CAF) 71 ± 1.2 388 ± 10.1 
709 ± 34 
401.3 ± 15 2 ± 0 
DHS1(PA–ASP–CAF) 4.1 ± 0.2 26 ± 2.4 
155 ± 3.5 
55.3 ± 1 6 ± 0 
DHS2(PA–ASP–CAF) 4.2 ± 0.1 28.3 ± 1 193.3 ± 6.4 62 ± 12 7 ± 0.2 
ML5(PA–ASP–CAF) 3 ± 0 24.1 ± 1 
110 ± 5 
43.4 ± 2 4.4 ± 0.2 
ML10(PA–ASP–
CAF) 
3 ± 0 29 ± 1.2 
133.3 ± 28.3 
49.3 ± 7 4.5 ±1 
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7.2.1. Scanning electron microscopy  
Many pharmaceutical parameters such as flow properties and compaction 
characteristic of drug powder can be impacted by the morphology of the 
API, which makes it a vital parameter in the pharmaceutical process 
(Dhumal et al., 2010). (Figure 29) displays the SEM micrographs of PA, 
ASP, CAF and PA–ASP–CAF mixtures. PA morphology was explained in 
(Section 3.3.5), and ASP displayed an oblong shape meanwhile, CAF 
crystals exhibited a columnar shape (Figure 29), the physical mixture 
(PM) displayed a mix of crystal habits of the marketed products. Whereas, 
the SEM of all the engineered mixtures (DHS1, DHS2, ML5, ML10) showed 





Figure 29. Scanning electron microscopy (SEM) and particles size 
distributions micrographs of commercial paracetamol (PA), commercial 
aspirin (ASP), commercial Caffeine (CAF) and PA–ASP–CAF mixtures co–
processed using physical mixing (PM), dry high shear for 1min (DHS1), 
dry high shear for 2 min (DHS2), milling for 5 min (ML5) and milling for 
10 min (ML10). 
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7.2.2. Solid state properties 
7.2.2.1. Powder X–ray diffraction 
The PXRD patterns of the various samples are shown in (Figure 30). The 
PXRD patterns of the commercial PA displayed various characteristic 
angles at 2θ values, as seen in (Section 3.3.4). Whereas the diffraction 
pattern of commercial ASP displayed different characteristic peaks 
specifically at 15.6°, 23.1° and 27.0° that were noticeable and the main 
peak at 15.6° was particularly distinctive (Lin, et al., 2012). On the other 
hand, CAF (form II) showed prominent diffraction peaks at 12.06°, 24.1°, 
26.4°, and 27.1° (Park and Yeo, 2008; Illangakoon et al., 2014). The 
diffractogram of physical mixing PM (PA–ASP–CAF) displayed an overlap 
of the various characteristic peaks of Form I PA, ASP (form I) and (form II 
CAF) samples. Also, the PXRD patterns of the products obtained using dry 
high shear mixing (DHS1 (PA–ASP–CAF) and DHS2 (PA–ASP–CAF) and 
milling (ML5 (PA–ASP–CAF) and ML10 (PA–ASP–CAF) methods showed 
the same pattern that matches the sum of the marketed samples as 
observed in the physical mixing but with reduced peak intensities due to 
the differences in particle sizes. Regardless of the method employed, the 
engineered ternary mixtures showed the absence of any unstable forms 
from the marketed products (orthorhombic forms of PA, CAF form I), 





Figure 30. Powder X–ray diffraction of commercial paracetamol (PA), 
commercial aspirin (ASP), commercial Caffeine (CAF) and PA–ASP–CAF 
mixtures co–processed using physical mixing (PM), dry high shear for 
1min (DHS1), dry high shear for 2 min (DHS2), milling for 5 min (ML5) 
and milling for 10 min (ML10). 
 
7.2.2.2. Fourier transform infrared spectroscopy  
FT–IR studies were conducted to explore the nature and extent of 
interactions between drugs in the solid state. The mixing or blending of 
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two or more drugs causes changes in the oscillating dipole of the 
molecules; this will manifest itself as changes in the frequency and 
bandwidth of interacting groups in the FT–IR spectra (Figure 31). If 
interaction existed between the various drugs, the functional groups in 
the FT–IR spectra will show band shifts and widening as compared to the 
spectra of the pure drugs before mixing (Figure 31). The FT–IR 
characteristic bands of the monoclinic form of PA (Table 5) were present 
in the spectra of commercial PA and all PA‒ASP‒CAF mixtures (Figure 
31). The diagnostic bands of the PA orthorhombic form as discussed in 
(Section 3.3.4) were not present in the spectra of commercial PA and all 
PA‒ASP‒CAF mixtures indicating the presence of the PA monoclinic form 
in all the mixtures under study. 
Analysis of the molecular structures of, PA as displayed in (Figure 1; 
Table 5), ASP and CAF as shown in (Table 18). Because of the presence of 
–NH and –OH in paracetamol’s structure it suggests that H–bonding may 
exist between the N–H or O‒H moieties (H donors) of PA with the 
carbonyl group (C=O, H acceptor) of ASP and two carbonyl groups (C=O, 
H acceptor) and one basic imidazole nitrogen group (proton acceptors) of 
CAF. Such intermolecular interactions should be revealed by shifts in the 
N–H, O‒H, and C=O stretches. Additionally, the formation of hydrogen 
bonds or dipolar occurs between PA with other compounds having 
identical group(s) and the carbonyl groups have been reported (Grant et 
al., 1980). The FT–IR spectra of PA, ASP, CAF and PA–ASP–CAF mixtures 
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are shown in (Figure 31). The physical mixture prepared using physical 
mixing showed insignificant changes in absorption intensities in 
comparison to the marketed paracetamol, suggesting a reduced 
interparticulate interaction between PA, ASP and CAF (Figure 31). 
The mixtures prepared using dry high shear mixing (DHS1 and DHS2) 
showed minor reductions in absorption intensities (i.e., increased band 
broadening) between 3100 cm−1 and 3200 cm−1 compared with the peaks 
observed from marketed PA (Figure 31). The band broadening became 
more pronounced for the mixtures prepared using milling technique for 
five minutes and ten minutes at (ML5 and ML10) (Figure 31). This 
indicated a strong intermolecular hydrogen bonding between the PA, ASP 
and CAF mixtures compared to the mixture obtained using physical 
mixing. The mixtures prepared using milling technique (ML5 and ML10) 
showed decreases in the absorption intensities between 1605 and 1660 
cm−1 (amide I, carbonyl stretch), between 1600 and 1620 cm−1 (skeletal 
aryl C–C stretch) and between 1500 and 1200 cm−1 (aryl C=H, C=H 
symmetric bending, C–0 stretch). The presence of weak hydrophobic 
interactions is observed in these mixtures due to the reductions in the 
absorption intensities between PA, ASP and CAF. However, with the 
physical mixing, there were no hydrophobic interactions between the 
drugs (Figure 31). A drastic reduction in absorption intensity was 
noticeable for PA–ASP–CAF mixtures prepared using milling technique in 
the region between 1605 cm–1 to 1656 cm–1 (C=0, keto–amide groups) of 
CAF. This indicated the intermolecular hydrogen bond interaction between 
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amide group of PA and carbonyl of CAF molecule via either one of the two 
keto–amide groups of CAF (N−H⋯O). Additionally, there was no shift or 
any reduction in intensities at 1755 cm–1 and 1692 cm–1, which indicated 
that the two keto–amide groups of CAF overshadowed the one carbonyl 
group of ASP, implying insignificant interaction between the carbonyl of 
ASP and PA. This highlighted that the carbonyl groups of CAF were more 
prominent and formed strong hydrogen bonds with PA (Figure 31). 
In conclusion, paracetamol and caffeine formed strong hydrogen bonding 
compared to PA and ASP. This implies that, the effect of introducing a 
competing two strong carbonyl groups (H bond acceptors) (CAF) in the 
presence of PA, the basic nitrogen preferentially forms O−H· · ·N 
hydrogen bonds; the N–H donor adhering to the rule that all good donors 













Table 18. Chemical structure and FT–IR characteristic absorption bands 
of, aspirin (ASP) (Ajun et al., 2009), caffeine (CAF) (Illangakoon et al., 




Compound Chemical structure 




1650 cm–1(C=O stretch) of the 
amide group; 1435 cm–1 and 1504 
cm–1 (C=C stretch) 
 
ASP     
 
C=C (carbons of the Benzene ring) 
1605 cm–1 ; 1755 cm–1 (=C–0 an 
ester), 1692 cm–1 (–C=0), 





Figure 31. Fourier transform infrared spectroscopy (FT–IR) of 
commercial paracetamol (PA), commercial aspirin (ASP), commercial 
Caffeine (CAF) and PA–ASP–CAF mixtures co–processed using physical 
mixing (PM), dry high shear for 1min (DHS1), dry high shear for 2 min 





7.2.2.3. Thermogravimetric analysis  
Figure 32 shows the TGA curves of the tested commercial drugs and their 
various co−processed mixtures. In the TGA curves, the decomposition of 
drugs depicted well–defined thermal events. The samples showed no 
weight loss below their melting points, which implies no surface water 
formation. The TGA curves showed that PA, ASP and CAF remained stable 
until 222.1 ºC, 183 ºC and 213.4 ºC. CAF and PA drugs weight loss is due 
to degradation at a higher temperature. Also, a mass loss event recorded 
a maximum of 363 ºC for CAF. ASP depicted two events at 187 ºC and 
390.6 ºC. Above 150 ºC, two weight loss steps are shown as follows: (1) 
release of salicylic acid and acetic acid with the formation of an 
intermediary compound (ASP dimmers) and (2) thermal degradation of 
the intermediary compound (Edna et al., 2004). The data recorded by 
TGA confirm those shown in (Figure 32). It is noticeable that PM (PA–
ASP–CAF) demonstrated no considerable weight loss below 387.3 ºC and 
begins to degrade due to its exposure to higher temperatures. ML10(PA–
ASP–CAF) showed a further weight loss towards lower temperature, which 
could either be due to, the exposure of ASP sample to the harsh 




Figure 32. Thermogravimetric analysis (TGA) profiles of commercial 
paracetamol (PA), commercial aspirin (ASP), commercial Caffeine (CAF) 
and PA–ASP–CAF mixtures co–processed using physical mixing (PM), dry 
high shear for 1min (DHS1), dry high shear for 2 min (DHS2), milling for 







7.3. Tableting properties  
ASP is plastically deforming (Pedersen and Kristensen, 1994), CAF form II 
(plastically deforming and soft upon grinding (Ghosh et al., 2013).  
PA is brittle and known to undergo brittle fracture as it exhibits poor 
tableting characteristics because the particles of this drug are very stiff 
and therefore, inter–particulate bonding is very weak (Joiris et al., 1998). 
PA in this study displayed poor compactibility, as discussed in (Section 
3.3.5). The presence of ASP and CAF increased the tensile strength of PA–
ASP–CAF mixtures, regardless of the method of application (Figure 33). 
The TS of the PA–ASP–CAF mixtures compressed at 222 MPa was 0.76 ± 
0.0 MPa, 1.9 ± 0.0 MPa, 2.4 ± 0.1 MPa, 2.4 ± 0.2 MPa and 3.4 ± 0.3 MPa 
for mixtures prepared using PM, DHS1, DHS2, ML5 and ML10 techniques 
(Figure 33). PA–ASP–CAF prepared using, PM displayed statically different 
tabletability results (P<0.05) compare to PA. Whereas, the mixture 
prepared using DHS1 and DHS2 methods exhibited a remarkable 
increased in tabletability compare to the mixtures prepared using PM 
(Figure 33) for example, as the compression pressure increases from 37 
MPa to 222 MPa, the TS tablets increased from 0.3 MPa to 0.8 MPa, 0.7 
MPa to 1.9 MPa and from 0.4 MPa to 2.4 MPa for the mixtures prepared 
using PM, DHS1 and DHS2 methods respectively (Figure 33) indicating 
that the DHS2 technique resulted in an increase in the tensile of tablets in 
comparison to PM and DHS1 over the compression range of 37 MPa to 
222 MPa. The mixtures prepared using ML exhibited a further increase of 
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tabletability compare to the mixtures prepared using DHS technique when 
the compression pressure increased from 37 MPa to 222 MPa, the TS of 
tablets prepared using ML5 increased from 1.2 ± 0.1 MPa to 2.4  ± 0.1 
MPa meanwhile, the mixture prepared by doubling the ML time improved 
from 1.3 ± 0.2 MPa to 3.4 ± 0.3 MPa (Figure 33) and gave the best 
tabletability result at compression pressure of 222 MPa in contrast to the 
other techniques applied. So, the increased tensile strength of the tablets 
using ML method compared to the other methods could be due to the 
higher content of fine particles as seen in (Table 18) which could also 
contribute to the increased surface area and increase inter−particulate 
forces which further increased the degree of particle deformation and 
increase in hardness (Cantor et al.,2009). 
 The mixture obtained using PM technique, all the drugs (PA, ASP and 
CAF) retained their initial shapes. Meanwhile, DHS1, DHS2 ML5 and ML10 
demonstrated irregular shapes with ultrafine particles at their surfaces 
(Figure 29). Additionally, the pronounced hydrogen bonding interactions 
observed between PA, ASP and CAF especially, using the milling 
technique. The PA–ASP–CAF mixture prepared using ML (ML10) technique 




Figure 33. Tabletability profiles(mean ± SD, n = 5), of commercial 
paracetamol (PA), commercial aspirin (ASP), commercial Caffeine (CAF) 
and PA–ASP–CAF mixtures co–processed using physical mixing (PM), dry 
high shear for 1min (DHS1), dry high shear for 2 min (DHS2), milling for 






7.4. Conclusions  
Engineered mixtures of PA–ASP–CAF gave better tablets with enhanced 
tensile strength in comparison to the individual marketed form of PA and 
ASP and their usual physical mixture, which could be due to their 
enhanced micrometric properties, morphological features and the drastic 
reduction in absorbance intensity leading to the increased mechanical 
properties of the PA–ASP–CAF powders. Milling technique used for 10 min 
of the PA–ASP–CAF mixture gave the best tablets. Thus, PA, ASP and CAF 
can be simultaneously milled to acquire engineered PA–ASP–CAF mixtures 




























8 CHAPTER 8: PREPARATION OF PARACETAMOL–
5– NITROISOPHTHALIC ACID COCRYSTALS 
















A cocrystal is a multiple component crystal in which all components are 
solid under ambient conditions when in their pure form. These 
components co–exist as a stoichiometric ratio of a target molecule or ion 
and a neutral molecular cocrystal former(s)(Shan and Zaworotko, 2008).  
It has been shown that, paracetamol can form cocrystals with pyridines, 
carboxylic acid (Sander et al.,2010) and, bipyridines as shown by, Oswald 
et al.,2002 who demonstrated various multi–components crystal forms of 
PA with 1,4–dioxane, 4,4–bipyridine, N–methylmorpholine, N,N–
dimethylpiperazine, morpholine and piperazine. Additionally, a new 
ternary cocrystal containing paracetamol, piperazine and ethanol was 
obtained at elevated pressure via formation of the intermolecular 
interaction of ArO–H of paracetamol and amine (N−H) piperazine (Oswald 
and Pulham, 2008). 
 From some systematic studies on cocrystals, it was recognised that, in 
general, all good hydrogen bond donors and acceptors would be used in 
hydrogen bonding formation; which is of great importance to the design 
of the cocrystals. As it was noted that, the best hydrogen bond acceptor 
in a given crystal structure, is inclined to interact with the best hydrogen 
bond donor (Trask et al., 2006). PA and its cocrystal forms have shown 
that hydrogen–bonded PA… PA chains are robust motifs that commonly 
occur either through phenol (O−H …O=C) interactions or through the 
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coformer moieties which accept hydrogen bonds from the phenolic H, 
through N−H…0=C interactions (Oswald et al., 2002). 
5− Nitroisophthalic acid (5NIP) (Figure 34) possesses functional groups 
which can generate hydrogen–bond motifs (supramolecular synthons) 
with PA. The coformer (5NIP) contains two carboxylic acid groups that can 
act as hydrogen–bond donors and acceptor, respectively. It is expected 
that PA and 5NIP can interact via formation of heterosynthons between 
amide⋯carboxylic acid functional groups. 
 
Figure 34. Chemical structure of 5–Nitroisophthalic acid (5NIP). 
 
Additionally, 5NIP has been employed as a coformer in the 
cocrystallisation with active ingredients including; paracetamol, 
levetiracetam, etiracetam, carbamazepine and dapsone (Hiendrawan et 
al.,2016; George et al., 2014; Fleischman et al., 2003; Smith and 
Wermuth, 2013). 
   Over the past years, several authors have studied the enhancement of 
the physicomechanical properties of different APIs. However, no marketed 
drug products utilise cocrystals despite, the positive application of 
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cocrystallisation to influence the physical properties of a drug, which could 
be due to the thermodynamic stability of cocrystals (Schartman, 2009). 
    In this investigation, the formation of pure cocrystals of PA and the 
coformer (5NIP) were attempted through different techniques including; 
slow cooling crystallisation, water evaporation, dry milling, high shear, 
freeze−drying and wet–milling. The wet−milling process performed at 
different milling times (1s, 1min, 10 min, 15 min, 20 min and 30 min) and 
using various solvents (hexane, acetone, methanol, water, butanol and 
ethanol). The processing techniques including, milling time and solvents 
were used to produce pure cocrystals were achieved only with slow 
cooling with methanol, slow cooling with water and wet–milling 
(methanol, butanol and ethanol) for 30 min. 
No published work is available in the presence of different techniques to 
improve the physicomechanical properties of PA via PA–5NIP cocrystal 
formation. 
8.1. Engineering of PA–5NIP formulations 
8.1.1. Effect of various preparation methods. 
(i) Low shear mixing 
An equimolar mixture of paracetamol and 5−Nitroisophthalic acid 
(PA−5NIP) powders was prepared using low shear mixing technique as 




An equimolar mixture of paracetamol and 5−Nitroisophthalic acid 
(PA−5NIP) powders) were milled for 30 min after adding 5 mL of different 
solvents including; ethanol, butanol and methanol and applying the 
milling method as described in (Section 2.2.1.7). All the mixtures were 
kept in the fume cupboard for 24h for complete evaporation of the 
solvents and were stored in a sealed glass vial for at least seven days at 
the laboratory conditions (22 ºC, RH = 50%). The engineered powders 
were sieved as described in (Section 2.3). 
 (iii) Cooling crystallisation  
(6% w/v) solutions of an equimolar mixture of paracetamol and 5–
Nitroisophthalic acid (PA−5NIP) were prepared by dissolving PA–5NIP in 
200 mL of deionised water under stirring (200 rpm) at 70 ºC and 
methanol (without heat). The resultant clear solution was left uncovered 
in laboratory conditions for five days using batch cooling crystallisation 
method as described in (Section 2.2.1.4). The cocrystals obtained were 
sieved using the technique described in (Section 2.3). 
8.2. Results and Discussions 
8.2.1. Scanning electron microscopy and particle size 
distribution 
(Figure 35) displays micrographs of PA, 5NIP, PM (PA–5NIP) and PA–5NIP 
cocrystals powders. The PM (PA–5NIP) and 5NIP crystals exhibited 
angular habits. The SEM micrographs under high magnification revealed 
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that the cocrystals prepared using various techniques including, SCW 
(PA–5NIP) showed irregular shape whereas, and SCM (PA–5NIP) 
displayed agglomerates consisting of needle–shaped individual cocrystals 
entangled. MLM (PA–5NIP), MLB (PA–5NIP) and MLE (PA–5NIP) powders 
displayed an irregular shaped structure.  
  The mixture of PA and 5NIP prepared using low shear mixing method PM 
(PA–5NIP) displayed a decrease in mean diameter (VMD) compared to the 
marketed PA (Table 19) this could be due to the molar ratio differences 
between PA and 5NIP; as 5NIP particles whose VMD values are higher 
compared to PA (Table 19) as affirmed by SEM micrographs (Figure 35). 
On the other hand, the cocrystals of PA–5NIP obtained using both cooling 
crystallisation, and milling techniques demonstrated a drastic reduction in 
VMDs values compare to the commercial PA and PM (PA–5NIP) (Table 
19), and their PSDs showed statistically different results (P<0.05). This is 
affirmed by the SEM observations, which showed a difference in the 
structure of mixtures prepared using milling and slow cooling 
crystallisation methods (Figure 35). As it should be noted that the largest 
mean size diameter of the cocrystals recorded was around 232 ± 18.2 µm 
in comparison to the PA and 5NIP starting materials which were around 
548 ± 30.2 µm and 826.3 ± 3.3 µm. 
The slight reduction in the bulk for the mixture prepared using PM method 
compared to PA is due to the presence of 5NIP powders whose bulk and 
tap density values are smaller than those of PA (Table 19). Whereas, all 
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the cocrystals prepared using both slow cooling crystallisation and milling 
techniques showed higher CI values which is consistent with the patterns 
in bulk and tap density changes compared to PA (Table 19) and, as 




Table 19. Particle size distribution (i.e. particle size at 10%(d10%), 50%(d50%, median diameter and 90%(d90%) mean 
diameter (VMD) (mean ± SD, n=3), bulk density (Db), tap density (Dt), cohesivity (1/b) and Carr’s index (CI) (mean ± SD, 
n=3) of PA, 5NIP, physical mixing(PM) and PA−5NIP cocrystals prepared using slow cooling crystallisation and wet−milling.
Product 
 






) 1/b CI (%) 
PA 254 ± 22 506 ± 30 911 ± 39.3 548 ± 30.2 0.8 ± 0 0.8 ± 0 4 ± 0 3.2 ± 0.3 
5NIP 14 ± 0.2 280 ± 18.3 2217 ± 6 826.3 ± 3.2 0.5 ± 0 0.73 ± 0 6 ± 0 32.7 ± 1.5 
PM(PA-5NIP) 62.3 ± 10 439 ± 23 866 ± 40.3 461.3 ± 26 0.62 ± 0 0.84 ± 0 3 ± 0 26.7 ± 0.6 
SCW(PA-5NIP) 5.2 ± 0 42.1 ± 0 226 ± 2 84.1 ± 0.3 0.4 ± 0 0.4 ± 0 7 ±1.1 37.0 ± 0.0 
SCM(PA-5NIP) 5.2 ± 0 155 ± 9 396 ± 7 1756 ± 3.5 0.5 ± 0 0.7 ± 0 4 ± 0 32.0 ± 0.0 
MLM(PA–5NIP) 20.2 ± 1.1 192 ± 16.1 441 ± 21 
213 ± 13 
0.6 ± 0 
 
0.8 ± 0 
 
8 ± 0 28.0 ±0.0 
MLB(PA-5NIP) 6.4 ± 0 86 ± 6 386.3 ± 34.1 
147.3 ± 12 
0.5 ± 0 0.8 ± 0 27 ± 0 37.0 ± 0.0 




Figure 35. Scanning electron microscopy micrographs of PA, 5NIP, 
physical mixing (PM) and PA−5NIP cocrystals prepared using slow cooling 




8.3. Solid state properties 
8.3.1 Powder X–ray diffraction 
In the solid state, the formation of a new crystalline phase can be 
categorised by applying PXRD and DSC to monitor the phase purity of the 
cocrystals formed using various preparation methods. The binary mixture 
of the components under consideration with the molar ratio (1:1) was 
coprocessed using PM, SCW, SCM, MLM, MLB and MLE. 
 The PXRD analysis was carried out for Commercial PA, commercial 5NIP, 
PM (PA–5NIP) and all the cocrystals of PA–5NIP coprocessed using SCW, 
SCM, MLM, MLB and MLE techniques as shown in (Figure 36). The 
commercial PA’s PXRD pattern, as displayed in (Figure 26) possessed 
characteristic peaks which are well discussed in (Section 3.3.3). Whereas, 
the commercial 5NIP displayed characteristic peaks at 2θ values of, 
18.01°, 20.37°, 21.32°, 23.83° and 28.60°. The diffractogram of the 
physical mixture presented an overlap of the characteristic peaks of each 
component; whereas, the cocrystals prepared showed a singular pattern 
that matches neither, each species nor the sum as observed in the 
physical mixing (Figure 36). The diffractogram of SCW (PA−5NIP) and 
SCM (PA−5NIP) cocrystals showed identical characteristic peaks at 2θ 
values of 5.38°, 11.20°, 18.79°, 21.31°, 25.68° and 27.45°). Whereas, 
the cocrystals of PA–5NIP obtained using wet–milling technique in the 
presence of methanol (MLM(PA–5NIP)); butanol(MLB(PA–5NIP)) and 
ethanol(MLE(PA–5NIP)) displayed characteristic peaks at 2θ values at 
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(5.40°, 11.31°, 18.92°, 21.42°, 25.79°, 27.44°); (5.47°, 10.91°, 18.94°, 
21.48°, 25.63°, 27.44°) and (5.52°, 11.36°, 18.82°, 21.49°, 25.92°) and 
27.57°). All the cocrystals obtained using the various techniques in this 
research are corroborating with the formation of a new crystallographic 
structure, suggesting that these samples are pure cocrystals. The 
diffraction patterns obtained from all the cocrystals were closer to the 
result obtained from the pure cocrystal of PA–5NIP diffraction pattern 







Figure 36. Powder X–ray diffraction of PA, 5NIP, physical mixing (PM) 
and PA−5NIP cocrystals prepared using slow cooling crystallisation and 
wet−milling and reduction in % of relative crystallinity in comparison to 




8.3.1.2. Fourier transform infrared spectroscopy 
Formation of cocrystal or a eutectic is dependent on the dominance of 
heteromeric and homomeric molecular interactions in a given combination 
of materials. Various factors like nature of intermolecular interactions and 
supramolecular synthons, functional group disposition and 
complementarity, interaction strength, and packing efficiency play a vital 
role in the formation of eutectic or cocrystal (Cherukuvada, 2016). 
Furthermore, the presence of functional groups including, amides and 
carboxylic acids provide an ability to engage in a supramolecular event 
with cocrystal formers, which possesses complementary hydrogen bond 
donor and acceptor sites, thus forming pharmaceutical cocrystals (Padrela 
et al., 2009). The FT−IR spectra of PA, 5NIP and PA−5NIP cocrystals are 
shown in (Figure 37). From the chemical structures of PA and 5NIP, the 
coformer (5NIP) possesses two carboxylic groups in its structure, which 
are functional groups particularly amenable to the formation of 
supramolecular hetero–synthons with complimenting a functional group 
including, the amide group found in the structure of PA, providing 
evidence of the new hydrogen bond (NH…..…O and HO…C=O). Also, 
bonds between the acid and each paracetamol represent the fulfilment of 
the ‘best-donor–best–acceptor’ rule, whereby the acid and the basic 
nitrogen play these respective roles (Trask et al.,2006).  
PA shows characteristic absorption peaks at 1630 cm−1 and 3304 cm−1, 
which are assigned to C=O and N–H stretching of the secondary amide 
(Figure 37). Whereas, the spectrum of 5NIP has peaks corresponding to 
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carboxylic C=O and O–H stretching at 1697 cm−1 and 2939 cm−1, 
respectively (Figure 37) suggesting the structural units of the hydrogen–
bonded carboxylic acid dimers form in the 5NIP crystalline lattice. The 
spectrum of the PA–5NIP cocrystal has three new distinctive peaks at 
1611.77 cm−1, 1695.42 cm−1 and 1697.46 cm−1 that did not exist before 
and which are assigned to C=O stretching of the amide group in PA and 
the two carboxylic acid groups in 5NIP, respectively (Figure 37). The shift 
in the C=O stretching frequency from 1646.41cm−1 and 1626 cm−1 in the 
component phases to 1611.77 cm−1 and 1696.42 cm−1 in the cocrystal 
implies that the C=O groups participate in weaker hydrogen bonds 
accompanying cocrystal formation. A hypsochromic shift in the O–H and 
N–H stretching frequency verifies the formation of weaker hydrogen 
bonds is accompanying cocrystallisation in absorption bands at 3348.00 
cm−1 and 3464.29 cm−1. We also pointed out the carbonyl stretch C=O of 
PA−5NIP cocrystal showed stretching band at 1697.46 cm−1, indicated 
that the carboxylic acid group is in the neutral state thus, confirms that 
proton transfer did not occur between PA and 5NIP and the resulting 




Figure 37. Fourier transform infrared of PA, 5NIP, physical mixing (PM) 




8.3.1.3. Thermal analysis 
DSC experiments were carried out to investigate the thermal behaviour of 
PA, 5NIP, and 5NIP physical mixture (1:1 molar ratio) and PA–5NIP 
cocrystals (Figure 38). It shows that PA and 5NIP exhibited an 
endothermic melting peaks at (169.3 ± 0.3) °C and (261.5± 0.7) °C as 
shown in (Table 20; Figure 38) indicating their melting points and the PA–
5NIP cocrystals exhibited single endothermic melting point (Figure 38). 
The melting temperatures of all the cocrystals were between 
corresponding pure starting solids (Figure 38). Whereas, that DSC 
analysis of the physical mixture of PA and 5NIP (1:1 molar ratio); PM 
(PA–5NIP) showed three endothermic peaks (Figure 38); First 
endothermic peak at (171.1 ± 0.7) °C is ascribed as cocrystal eutectic 
melting with an excess of high–melting component. The second peak at 
(211.9 ± 0.3) °C could be the melting point of the cocrystal, followed by 
the endothermic peak (264.7± 0.1) °C corresponding to the 
decomposition of cocrystal as confirmed by thermal gravimetric analysis 
(TGA) results whereby PA, 5NIP and PA–5NIP cocrystals were thermally 
stable until 254 ºC, which agrees for degradation temperatures reported 
previously for PA (Section 3.3.4) (Figure 38). In conclusion, the phase 
purity of cocrystals was established based on the absence of characteristic 
peaks of 5NIP and PA in the PXRD pattern and clean baseline and unique 





Table 20. Thermal properties of PA, 5NIP and the five cocrystals of (PA–
5NIP (n=3). 
 
TGA was conducted to analyse the changes in cocrystals weight in 
comparison to the change of temperature (Figure 39). TGA curve showed 
no weight loss on PA–5NIP cocrystals until their various melting points 
which indicates the absence of solvate or hydrate rather than PA–5NIP 
cocrystals. TGA of PA–5NIP cocrystal also showed a mass loss after its 
melting point, which could be attributed to the degradation of the 
cocrystal (Figure 39).  







PA 169.3 ± 0.3 170.8 ± 0.3 164.5 ± 0.6 
5NIP 261.5 ± 0.7 263.1 ± 0.7 160.0 ± 0.2 
SCW(PA–5NIP) 206.1± 0.1 208.5 ± 0.1 153.9 ± 0.1 
SCM(PA–5NIP) 206.5± 0.8 209.1 ± 0.8 150.7 ± 0.6 
MLM(PA–5NIP) 204.9± 0.7 207.0 ± 0.7 149.7 ± 0.4 
MLB(PA–5NIP) 204.7± 0.4 206.7 ± 0.4 152.9 ± 0.6 
MLE(PA–5NIP) 204.6± 1.2 206.8 ± 1.2 154.8 ± 1.3 
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Figure 38. Differential Scanning calorimetry of PA, 5NIP, physical mixing 









Figure 39. Thermogravimetric analysis of PA, 5NIP, physical mixing (PM) 



























Table 21. Percentage of crystallinity and Water content (n=3) recorded 
of PA, 5NIP, physical mixing (PM) and PA−5NIP cocrystals prepared using 
slow cooling crystallisation and wet−milling. 
 
 
8.3.1.4. Relative humidity (Rh) and stability comparison 
Due to the practical effects of hydrate formation upon processing, 
formulation, packaging and storage, the stability of solid drug material 
relative to atmospheric moisture is vital to the pharmaceutical industry. 
Thus, the stability profiles of 5NIP and all the cocrystals (PA–5NIP) were 
performed to assess whether these cocrystals offered enhanced physical 
stability profiles after being stored at 75% RH for six months and, further 
compared to the PXRD patterns of the samples before exposure. The 
results of PXRD analysis displayed that PXRD patterns of 5NIP and all the 




PA 100% 0.2 ± 0 
5NIP 99% 0.5 ± 0 
PM (PA–5NIP) 96% 0.4 ± 0 
SCW (PA–5NIP) 36.2% 0.4 ± 0 
SCM (PA–5NIP) 34.9% 0.2 ± 0 
MLM (PA–5NIP) 32.6% 0.6 ± 0 
MLB (PA–5NIP) 30.2% 1 ± 0 
MLE (PA–5NIP) 28.7% 0.7 ± 0 
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PA–5NIP cocrystals stay the same (SM 3). All the PA–5NIP cocrystals 
investigated under the accelerated humidity condition were all physically 
stable, which indicates the non–hygroscopicity of the synthesised molecular 
cocrystals. 
8.3.1.5. Tableting properties 
The cocrystal powders were compressed into tablets to examine their 
mechanical behaviour in dependence of the solid–state form of the PA. 
Compactability was investigated by plotting the tensile strength of the 
tablets as a function of compaction pressure (Figure 40). This observation 
can be explained by either 5NIP or the cocrystal formation, changing the 
tableting behaviour of the PA. In other to eliminate the influence of 5NIP, 
a physical mixture of PA and 5NIP was tableted at different compaction 
pressures. The compactability of this physical mixture was lower 
compared to that of the cocrystal powders across the compaction range of 
37 to 222 Mpa. Even though the crushing strength of 5NIP compacts was 
increased from 37 Mpa to 111 Mpa but suddenly decreased with further 
compression pressure. Also, severe lamination was observed at 148 Mpa, 
an indication of poor compactibility. 
The results displayed in (Figure 40) showed an increased tabletability of 
paracetamol which resulted due to the formation of 1:1 cocrystal of PA 
and 5NIP. Hiendrawan et al. (2016) reported the formation of PA 
cocrystal using 5NIP as a coformer by applying rapid solvent evaporation 
technique which displayed an enhancement in the tabletability property. 
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During the tabletability test using 29.4 KN compaction pressure, tablets of 
PA–5NIP showed tensile strength value of 2.78 MPa. This study revealed 
that tabletability properties of the reported PA–5NIP cocrystal were 
superior to the past study using wet milling. MLE(PA–5NIP) demonstrated 
the highest tensile strength, compared to the others (SCW, SCM, MLM 
and MLB) could be due to the drastic reduction in crystallinity which is 
known to impact the tabletablity performance of powders by increasing 
their tensile strength (Kaialy et al., 2016)(Table 21) or it was also 
suggested that MLE (PA–5NIP) might have different molecular packing 
compared to the other cocrystals due to its slightly reduced melting point 
(Walsh et al., 2002)(Figure 38) or maybe MLE (PA–5NIP) has higher slip 
planes in its crystal structure compared to other cocrystals as, slip planes 
in the crystal lattice allow easier slip, enable greater plasticity (greater 
bonding area) therefore, form stronger tablets (Karki et al., 2009). 
Overall, this may indicate that PA–5NIP cocrystallised from ethanol 
underwent more plastic and less elastic deformation during compression 






Figure 40. Tableting profile of PA, 5NIP, physical mixing (PM) and 




PA–5NIP cocrystal was successfully prepared using various methods and 
different solvents, namely, slow solvent cooling, slow water cooling, and 
wet milling with (methanol, butanol and ethanol). 
 The resultant cocrystals were characterised by PXRD, DSC, TGA and 
FT−IR. In comparison to the starting materials, the preparation methods 
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and the solvents had a significant effect on the physicochemical and 
mechanical properties of the cocrystals obtained. The cocrystal prepared 
using wet−milling in the presence of ethanol showed the best tableting 
properties due to the reduced relative degree of crystallinity. Also, PA–
5NIP cocrystals were stable at 40 ºC /75% RH throughout six months 
confirmed by stability studies. The results of this investigation 
demonstrate that cocrystallisation with 5NIP shows an invaluable way to 























9 CHAPTER 9: FREEZE DRYING OF 
PARACETAMOL–CHONDROITIN MIXTURES 
















Many studies have demonstrated the pharmacological benefits Of CHONS 
which includes, Anti–inflammatory effect (Vergés et al., 2005; Abe et al., 
2016; Linares et al., 2015), Anti–oxidant (Xiong et al., 2007), Malaria 
(Fried et al., 2000), Allergic response (Sakai et al., 2002) and 
chondroprotective effects (Das and Hammad, 2000; Orth et al., 2002). 
Chondroitin sulfates (CHONSs) (Figure 41) are abundantly and broadly 
distributed in nasal septa (Nakano et al., 2000) and they are also found in 
humans’ cartilage, bone, cornea, skin and the arterial wall. The molecular 
weight of CHONS comprises of ~15 to 150 basic units of D–galactosamine 
and D–glucuronic acid, which ranges from 5000 to 50 000 d (Avachat and 
Kotwal, 2007). CHONSs are heteropolysaccharides with different sulfated 
residues of N–acetyl–D–galactosamine that are connected by β (1–>3) 
bonds, and these CHONSs are purified from several tissues made–up of 
other sequences of uronic acids (D–glucuronic or L–iduronic) (Mucci et al., 
2000; Imanari et al., 1996; Cassaro and Dietrich, 1977). The 
disaccharides inside the polysaccharide chains have different number and 
position of sulfate groups. For example, Chondroitin sulfate ( 
chondroitin−6 sulfate) is principally constituted of a disaccharide unit 
[(1−>4) −O− (D−glucopyranosyluronic acid) – (1–>3) –O– (2–N-
acetamido–2–deoxy–D–galactopyranosyl–6–sulfate and the regular 
disaccharide sequence of chondroitin sulfate A is chondroitin−4−sulfate 
which is composed of [(1–>4) –O– (D–glucopyranosyluronic acid) – (1–
>3) –O– (2–N–acetamido–2–deoxy–D–galactopyranosyl–4–sulfate)]. 
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CHONS is administered at a dosage of 1200 mg divided into three doses 
per day and has now become a part of the therapeutic armoury of the 
French rheumatologist. At the range of dosages commonly consumed, the 
evidence shows that chondroitin sulfate produces no identifiable pattern 
of adverse effect; thus, it is not lethal (Hathcock and Shao, 2007).  
 
Figure 41. Chemical structure of chondroitin sulfate C and its salt form 
 
 It has been suggested that if PA is inadequately effective, the physician 
should contemplate halting and swapping treatment or adding on other 
therapies (Bruyère et al., 2016). Therefore, since no published work has 
ever been conducted using paracetamol and chondroitin sulfates. For the 
very first time, the combination of PA and CHONS will be investigated in 
order to enhance the mechanical properties of paracetamol. 
9.1. Engineering of PA–CHONS formulations 
 9.1.1. Low shear mixing  
Commercial PA and commercial CHONS (10:4 w/w) powders and freeze–
dried PA and freeze–dried CHON (10:4 w/w) were mixed separately using 
low shear mixing method as described in (Section 2.2.1.1).  
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9.1.2. Freeze drying  
10% w/v solution was prepared by dissolving 10 g (w/w) of CHON in 
deionised water for a final volume of 100 mL. The flasks containing CHON 
solution were frozen using liquid nitrogen, while the flasks were stirred to 
allow maximum surface area for ten minutes and were freeze dried using 
the technique described in (Section 2.2.1.6). The FD CHONS powders 
were sieved using the technique described in (Section 2.3).  
3.5% w/v solution was prepared by dissolving 14 g of PA–CHON in 
deionised water for a final volume of 400 mL. The flasks containing PA–
CHON solution was frozen using liquid nitrogen, while the flasks were 
stirred to allow maximum surface area for ten minutes and were freeze 
dried using the technique described in (Section 2.2.1.6). The FD (PA–
CHONS) powders were sieved using the technique described in (Section 
2.3).  
9.1.3. Tablet preparation 
Each tablet weighs 700 mg ± 0.5 mg for the various formulations, and 
500 mg ± 0.5 mg for PA and CHONS were all compressed using the 
method described in (Section 2.14).   
9.2. Results and Discussions 
9.2.1. Morphology and particle size distribution 
Commercial PA, freeze–dried paracetamol (FDPA), commercial chondroitin 
(CHONS), freeze–dried chondroitin sulfate sodium salt (FDCHONS), 
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Physical mixing of PA and CHONS (PM (PA–CHONS)), physical mixing of 
FDPA and FD CHONS (PM (FDPA–FDCHONS)) and freeze−dried PA–
CHONS FD (PA–CHONS) showed different sizes and morphologies as 
characterized by SEM (Figure 42). The morphology of the PA was well 
described in (Section 3.3.5) whereas, the commercial CHONS is visualised 
as smooth–surfaced spherical particles. The PM (PA–CHONS) displays a 
mixture of two different habits, an angular and smooth–surfaced spherical 
shaped, which affirms the presence of both PA and CHONS particles 
(Figure 42). The FDPA obtained in the absence of the polysaccharide 
demonstrates that the PA crystals changed from angular shape to 
elongated/flattened shape (Figure 42), and the crystal size of commercial 
PA decreases from a mean diameter (VMD) of 548 ± 30.2 µm to a VMD of 
21 ± 2.1 µm for FDPA (Table 22). The physical mixture of both 
commercial products PA: CHONS displays a mean diameter of 194 ± 5.1 
µm and FDPA: FDCHONS physical mixture showed an irregular shape 
(Figure 42) with a VMD of 756 ± 15 µm (Table 22) 
SEM micrographs of FD (PA−CHONS) displayed continuous and porous 
structures, with the pores being the result of ice crystal formation during 
the freeze drying process (Tan et al., 2009). Additionally, those pores in 
the formation are also due to the presence of CHONS (Figure 42). 
 The bulk density of FD PA crystals was > to that of PA (0.03 ± 0 g/cm3 
versus 0.8 ± 0 g/cm3) (Table 23). FDPA in the absence of CHONS showed 
a considerably lower tap density than PA (0.07 ± 0 g/cm3 versus 0.8 ± 0 
g/cm3) (Table 23), this could be attributed to the pronounced internal 
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friction (i.e., additional void space) between FD crystals due to their 
irregular shape (Figure 42).  
(Table 23) Show that all FDPA powders showed increased (1/b values), 
compared to the PA, indicating their slightly increased cohesivity. It is 
generally known that particles of the same material with smaller size tend 
to have higher cohesivity compared to larger particle size, consequently 
more cohesive (Agbor Rose and Kaialy, 2019; Kaialy et al., 2012a). This 
validates the latter statement for the case of FDPA crystals which showed 
a slight increase in cohesivity compared to commercial PA. Also, both PM 
(FDPA–FDCHONS) and FD (PA–CHONS) demonstrated dissimilar particle 
sizes (Span values, P<0.05) compared to that of PM(PA–CHONS) (Figure 
42, Table 22) which could also be linked to their irregular and flaky crystal 





Figure 42. Scanning electron microscopy micrographs of commercial 
paracetamol (PA), commercial chondroitin sulfate sodium salt (CHONS), 
freeze dried paracetamol (FDPA), freeze dried chondroitin sulfate sodium 
salt (FDCHONS), and PA−CHONS mixtures (5:2, w:w) co–processed by 




Table 22. Particle size distribution (i.e. particle size at 10% (d10%), 50% ( 
d50%, median diameter and 90% (d90%) volume distribution and span) 
(mean ± SD, n = 3) for commercial paracetamol (PA), commercial 
chondroitin sulfate sodium salt (CHONS), freeze dried paracetamol 
(FDPA), freeze dried chondroitin sulfate sodium salt (FDCHONS), and 
PA−CHONS mixtures (5:2, w:w) coprocessed by physical mixing (PM) and 








Product  d10% (µm)  d50% (µm)  d90% (µm)  VMD (µm)  Span 
PA  254 ± 22 506 ± 30  911 ± 39.3  548 ± 30.2  1.3 ± 0 
CHONS 32 ± 0.2 80.4 ± 0.5 137 ± 1 82.3 ± 1 1.4 ± 0 
FDPA 2.3 ± 0.1 16 ± 8.4 43 ± 2 21 ± 2.1 3 ± 1.1 
FDCHONS 
 
89.3 ± 4.3 222 ± 9 394.3 ± 14 233 ± 7 1.4 ± 0 
PM(PA–CHONS) 80 ± 9 170 ± 6.2 348 ± 4.3 194 ± 5.1 2 ± 0 
PM(FDPA–
FDCHONS) 
8.3 ± 1 597 ± 15 1777 ± 15.3 756 ± 15 3 ± 0 
FD(PA–CHONS) 11.4 ± 0.1 31 ± 2.0 120 ± 8.1 56 ± 4 3.5 ± 0.2 
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Table 23. Bulk density (Db), tap density (Dt) and cohesivity (1/b) (mean 
± SD, n = 3) for commercial paracetamol (PA), commercial chondroitin 
sulfate sodium salt (CHONS), freeze–dried paracetamol (FDPA) and 
PA−CHONS mixtures (5:2, w:w) co–processed by physical mixing (PM) 
and freeze drying (FD). 
 
9.2.2. Powder X–ray diffraction 
The CHONS used in this work due to the inhomogeneity of its composition 
and the fact that they are studied in their salt forms makes them 
relatively amorphous in the solid state which falls in accordance with 
(Denuziere et al., 1996). (Figure 43) depicts a hollow shape which 
indicates the amorphous nature of CHONS whereas, PA, which is 
crystalline displays various characteristic peaks at 2θ values which were 
well discussed in (Section 3.3.4). As shown in (Figure 43), the X–ray 
pattern of FD (PA–CHONS) shows a reduced peak height from 11–30° 
Product  Db (g/cm
3
)  Dt (g/cm
3)  1/b  
PA  0.8 ± 0 0.8 ± 0 4 ± 0 
CHONS 0.7 ± 0 0.9 ± 0 4 ± 1 
FDPA 0.03 ± 0 0.1 ± 0 4.5 ± 0 
PM(PA–CHONS) 0.6 ± 0.5 0.6 ± 0.5 3 ± 1.1 
PM(FDPA–FDCHONS) 0.2 ± 0 0.3 ± 0 4.4 ± 0 
FD(PA–CHONS) 0.01 ± 0 0.02 ± 0 6 ± 1 
224 
 
that implies reduced crystallinity of the drug. The intensity in FD (PA–
CHONS) has been found to reduce to a greater extent in comparison to 
the other mixtures, which may be attributed to the presence of CHONS in 
its lyophilised form. Additionally, the decrease in crystallinity (Figure 43) 
occurs, perhaps due to strong chemical bond formation between PA and 
CHONS. 
 
Figure 43. Powder X–ray diffraction (PXRD) patterns of commercial 
paracetamol (PA), commercial chondroitin sulfate sodium salt (CHONS), 
freeze dried paracetamol (FDPA), freeze dried chondroitin sulfate sodium 
salt (FDCHONS), and PA−CHONS mixtures (5:2, w: w) co–processed by 
physical mixing (PM) and freeze drying (FD). 
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9.2.3. Fourier transform infrared 
The FT−IR spectrum of commercial PA depicts characteristic peaks which 
were well discussed in (Section 3.3.4). The FT−IR spectrum of 
commercial CHONS (Figure 44) shows a broad band between 3100–3600 
cm–1 assigned to –OH and to N–H vibrational stretching in which, the –OH 
stretching overlaps the N–H. The presence of the amide groups (I and II) 
are depicted by characteristic peaks at 1606 cm−1, COO− anti−symmetry 
stretching (1558 cm−1), COO− symmetry stretching (1413 cm−1). Bands 
at 1410 cm−1 and 1375 cm−1 are indicating towards overlapping of C–O 
stretching and –OH variable−angle vibrations and confirms the presence 
of carboxyl group. Amide III region (~ from 1200–1300 cm–1) is related 
to the C–N and C–C stretching, N–H bonds, and CH2 wagging from the 
glycine backbone and proline side chain (Corradetti et al., 2016). The 
peaks at 1222 cm−1 and 1046 cm−1 signified S—O and —C—O—S 
stretching vibrations, respectively for both commercial and freeze dried 
CHONS. These results were closer to that obtained by (Crispim et al., 
2012; Khan et al., 2013). The peak at approximately 850 cm−1 was used 
to identify chondroitin-4-sulfate, and a peak at 820 cm−1 was used to 
indicate chondroitin-6-sulfate (Wang et al.,2019). The spectra of the 
commercial CHONS and freeze dried CHONS from bovine exhibited peaks 
at 820.17 cm−1, suggesting that the marketed product and the freeze 
dried CHONS obtained mainly consisted of chondroitin-6-sulfate 
(Garnjanagoonchorn et al., 2007). 
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No significant change in band intensity was observed in the FDPA 
spectrum. However, the insertion of CHONS caused a significant change 
within the various formulations (Figure 44). The reduction in absorbance 
intensity of the band assigned to –OH, could be due to an increase of 
spread of CHONS in the freeze dried formulation. Also, slight shifts in 
absorbance intensities were observed for the freeze dried formulation 
(FD(PA–CHONS) at the carbonyl region (C=O) from 1650 cm–1 to 1654 
cm–1 which indicated the intermolecular or intramolecular H−bonding 
among N−H groups in PA which were disrupted by S═0− groups in 
CHONS. Furthermore, the co–freeze dried mixture demonstrate a shift in 
band at 1226 cm−1 due to stretching vibrations of S=O− bond from 
sulfate groups of CHONS (1222 cm−1) and N–H group of PA (1224 cm−1), 
followed by another shift from 1434 to 1440 cm−1 could be due to the 
presence of protonated NH3
+, this strongly affirms the new H−bonding 
was formed between N−H group in PA as hydrogen donor, and the by S═0 
group in CHONS, as hydrogen acceptors via (N–H…..O–S) interaction. 
(Denuziere, et al.1996; Tan et al. 2018) successfully prepared a complex 
of chitosan and GAGs (Chondroitin sulfate) in their salt form and 
suggested that the complex corresponded to the interaction between 
NH3




Figure 44. Fourier transform infrared (FT-IR) absorption spectra of 
commercial paracetamol (PA), commercial chondroitin sulfate sodium salt 
(CHONS), freeze–dried paracetamol (FDPA), freeze–dried chondroitin 
sulfate sodium salt (FDCHONS), and PA−CHONS mixtures (5:2, w: w) co–
processed by physical mixing (PM) and freeze drying (FD). 
 
9.2.4. Thermogravimetric analysis  
TGA thermogram of PA was shown and discussed in (Section 3.3.4). The 
thermogram of FDPA was thermally stable till 168 ºC but, a slight shift 
was observed to a lower temperature in comparison to PA due to the 
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presence of fine particles (reduced d10% values) as demonstrated by SEM 
(Figure 42, Table 23). CHONS demonstrated a weight loss stage one of 
2wt % loss at 76 ºC due to the evaporation of surface water 
(dehydration) caused by the presence of functional groups (COO– and –
OS030–) in CHONS which are known to be highly hydrophilic and could 
tightly interact with water molecules via dipole−dipole or ion−dipole and 
CHONS incorporated impact the water content in various samples 
(Bonkovoski et al., 2014). As heating ramps to  233 ºC, approximately 10 
wt % mass loss of the original product at this stage were encountered. All 
the fraction and bound water were desorbed from the molecules. A drastic 
pattern of mass loss was shown when CHONS was further heated from 
242 ºC to 410 ºC range, which may be due to the random breakage of 





) (Qiao et al.,2005). To tell whether the thermal 
stability was enhanced after the CHONS was introduced in the different 
formulations of PM (PA–CHONS), PM (FDPA–FDCHONS) and FD 
(PA−CHONS). The PM (PA–CHONS) sample was comparatively thermally 
stable but less stable than PA, which could be linked to the presence of 
CHONS molecules, as seen by the slight shift (Figure 45). 
 The weight loss of the FD(PA−CHONS) mixture showed two degradation 
stages; (i) ~ 4 wt% (FD(PA-CHONS)) and 5 wt % PM (FDPA −FDCHONS) 
loss 76 ºC (dehydration), ~ wt 8% (at 200 ºC) and (ii) the events related 
to the degradation happened at 242 ºC to 410 ºC range. The first 
degradation temperature of FD (PA−CHONS) was lower than the 
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commercial CHONS because during the FD process, a small amount of 
water molecules could be present at the surface and the presence of 
CHONS could contribute to the slight increase in the amount of water. 
However, the weight loss amounts were not too significant in the FD 
(PA−CHONS) mixture (Figure 45). It was obvious that, PM(FDPA–
FDCHONS) was slightly thermally stable than the FD(PA–CHONS) which 
could be linked to the higher structural organisation (crystallinity) (da 
Silva et al., 2017) which is confirmed by the PXRD results (Figure 44) and 
its very porous nature (Figure 42). Conclusively, the effect of PA on 
















Figure 45. Thermogravimetric analysis curves of commercial paracetamol 
(PA), commercial chondroitin sulfate sodium salt (CHONS), freeze–dried 
paracetamol (FDPA), freeze–dried chondroitin sulfate sodium salt 
(FDCHONS), and PA−CHONS mixtures (5:2, w: w) co–processed by 
physical mixing (PM) and freeze drying (FD). 
9.2.5. Tableting properties 
Both commercial PA and commercial CHONS showed poor mechanical 
properties, with the highest TS of only 0.18 ± 0.02 MPa and 0.16 ± 0.03 
MPa at a compression pressure of 148 MPa (Figure 16 & 46). The 
lyophilised PA in the absence of CHONS demonstrated a slight 
improvement of mechanical properties, with the highest TS of 0.56 ± 0.02 
MPa at a compression pressure of 74 MPa. The presence of CHONS used 
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as biopolymer did not improve the mechanical properties of PA in physical 
mixing as no TS at all compression pressures were achieved (Figure 46). 
On the other hand, the tabletability profiles of the physical mix of FDPA 
and FDCHONS (PM(FDPA–FDCHONS)) demonstrated an enhancement in 
tabletability compared to the physical mixing of both marketed forms, i.e., 
with the compression pressure increasing from 37 to 222 MPa, the TS for 
PM(PA–CHONS) was zero whereas, that of (PM(FDPA–FDCHONS)) 
increased from 1.28 to 3.8 MPa, for the mixture obtained using the same 
method (Figure 46) which implies that, the physical mixing of both 
lyophilised PA and lyophilised CHONS increased the TS of tablets 
compared to the physical mixing of the two commercial products over the 
compression pressure range of 37 to 222 MPa. The mixture prepared 
using co–freeze dried of both PA and CHONS (FD (PA–CHONS)) showed 
an outstanding enhancement in tabletability in comparison to PM (FDPA–
FDCHONS)). For example, when the compression pressure increased from 
37 to 222 MPa, the TS of tablets prepared using PM (FDPA–FDCHONS) 
increased from 1.3 ± 0.1 MPa to 3.8 ± 0.0 MPa, whilst that prepared 
using FD (PA–CHONS) increased from 2.7 ± 0.2 MPa to 3.9 ± 0.0 MPa 
(Figure 46). It is quite evident that the co–freeze dried (PA–CHONS) 
mixture showed the best compression properties among the mixtures 
under this study recording TS of 3.9 ± 0.0 MPa at a compression pressure 
of 222 MPa. The increased tensile strength of the tablets of the mixture 
obtained using freeze drying method in comparison to the PM of the two 
commercial products (PA and CHONS) was due to the presence of the 
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strong intermolecular bond formation through hydrogen bonding 
especially in the FD(PA−CHONS) mixture (Figure 46). Also, in disparity to 
the mixture prepared using physical mixing (PM (PA−CHONS) in which the 
shapes of both PA and CHONS retained their morphology whereas, no 
distinct individual PA or CHONS particles were envisaged in FD 
(PA−CHONS) (Figure 46), this implies the inhomogeneity in PM 
(PA−CHONS) for CHONS to bind tightly to onto PA surfaces. The 
lyophilised method in the presence of CHONS drastically reduces the 
crystallinity of the mixture (Figure 42). Consequently, it can be confirmed 
that reduced crystallinity is one of the contributors to the superior 
tableting performance of monoclinic paracetamols freeze dried with 
CHONS in comparison to PM (PA–CHONS).  
The tableting behaviour of PA processed using FD method in the absence 
of CHONS was comparatively poor as PA (Figure 46). The enhancement of 
the mechanical properties as shown in the results proved the strong 
intermolecular hydrogen bonding interaction induced via freeze drying 
method in the presence of CHONS thus, the effect of the size of particles 





Figure 46. Tensile strength (mean ± SD, n=5) versus compression 
pressure for commercial paracetamol (PA), commercial chondroitin sulfate 
sodium salt (CHONS), freeze–dried paracetamol (FDPA), freeze–dried 
chondroitin sulfate sodium salt (FDCHONS), and PA−CHONS mixtures 
(5:2, w: w) co–processed by physical mixing (PM) and freeze drying (FD). 
     Weak tablets are often prone to breakage during production, 
transportation and end use which can result in waste that no longer 
meets required product specifications. Furthermore, surface damage by 
chipping is aesthetically undesirable and can affect content uniformity 
(Hare et al., 2018). The percent friability of the subsequent tablets 
234 
 
obtained from commercial PA, FDPA, and commercial CHONS was above 
1%. Whereas, PM (FDPA−FDPA) and FD (PA−CHONS) mixtures recorded 
(0.73% and 0.17%) and were shown by using a compression pressure of 
148 MPa and all tablets obtained from the latter mixtures showed friability 
values less than 1%. For an existing uncoated and compressed tablet 
product in general, ≤1% weight loss is acceptable. Although, it is 
suggested for new formulations not yet having adequate packaging data, 
a more conservative weight loss of ≤0.8% is preferable (USP, 2014; 
Pharm Eur, 2013; JP, 2011). 
9.3. In−vitro studies 
The comparison of dissolution profile using f2 has also been adopted by 
food and drug administration (FDA) in the assessment of similarity 
between two dissolution profiles (Boateng et al., 2009; Yuksel et al., 
2000; Hiendrawan et al., 2014). It was observed that dissolution profile of 
FDPA, PM (FDPA–FDCHONS)) and FD (PA–CHONS) and were all similar to 
PA as indicated by f1 and f2 value (6.30 & 67.17(FDPA); (8.37 & 
63.32)(PM(FDPA–FDCHONS)) and (13.38 & 54.67)FD(PA–CHONS) which 
subsequently supports the claim as the dissolution parameters for the 
water soluble (DE%; MDR(min) and  MDR(min) for PA(68.4 ± 8; 0.8 ± 
0.1; 54.2 ± 11) values in comparison  to FDPA(72.5 ± 3; 0.8 ± 0.0 and 
46.1 ± 6), PM(FDPA–FDCHONS)(63.2 ± 4; 0.6 ± 0 and 59.1 ± 6.2) and 




 Solubility may be defined as the amount of a substance that dissolves in 
each volume of solvent at a specified temperature (Bergström et al., 
2004). The solubility of PA, FDPA and PA–CHONS samples were measured 
in deionised water by slurring excessed solids in water at 37 ºC for 24 h. 
The solubility value of, PA–CHONS samples were 15.54 mg/mL for (PM 
(FDPA–FDCHONS)) and 15.54 mg/mL for FD (PA–CHONS which were very 
slightly lower than the solubility of, PA (17.54 mg/mL) and FDPA (16.94 
mg/mL). Nonetheless, all the samples were classified as sparingly soluble. 
The very slight reduced solubility values of PA–CHONS samples did not 
cause any problem in the dissolution of PA. 
In general, the value of the commercial PA is in good agreement with 
(Sumathi and Ray, 2002). The aqueous solubility measured deviate in 
average 10% concerning the data presented by (Mota et al., 2009) and 
5.8% with (Etman and Naggar, 1990). These deviations of this magnitude 
are typically found when comparing solubility data from different authors. 
The effective arrangement of crystal packing in the samples through the 
strong intermolecular interactions such a hydrogen bonding holding the 
compacts together or the relatively higher cohesive forces with the 
processed powders could potentially reduce the effective surface area for 
solubility. Alternatively, the presence of hydrophilic additive could 
decrease the resistance to the effective diffusion of the solubilised PA in 
the case of the FD (PA–CHONS) mixture. The present study showed that 
the presence of the additive did not retard the dissolution rate of PA, 
however slightly reduced the solubility. 
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Nonetheless, it immensely improved the mechanical properties of PA 
tablets, especially, with FD (PA–CHONS) powders. Some other techniques 
were conducted; however failed to enhance the physicomechanical 
properties of PA (e.g., (dry and wet) high shear mixing, batch cooling, 
water evaporation and milling). 
 
 
Figure 47. Release profiles for commercial paracetamol (PA), freeze dried 
paracetamol (FDPA) and PA−CHONS mixtures (5:2, w: w) co–processed 

































9.5. Conclusions  
A novel mixture of PA–CHONS was obtained and possessed improved 
micromeritic and mechanical properties via freeze drying technique in the 
presence of the highly hydrophilic polysaccharide (biopolymer). No 
polymorphic transformation was induced by the freeze drying process. 
However, reduced crystallinity which was influenced by the presence of 
the biopolymer used during freeze drying was observed. The change in 
crystal habit and reduction in crystallinity, in turn, influenced the 
compaction behaviour of paracetamol crystals. The co–freeze dried PA–
CHONS produced stronger tablets than the commercial paracetamol.  
Physicomechanical properties of PA can be immensely improved via the 
selection of a suitable additive during FD. The physical mixtures of FDPA 
and FDCHONS or co–freeze dried PA and CHONS samples were more 
valuable and showed the best tabletability when compared to other 
paracetamols at compression pressures from 37 to 222 MPa. However, 
there was no difference in dissolution performance between the 












































Commercial curcumin (CUR) is a hydrophobic compound having the 
chemical name of (1,7–bis(4–hydroxy–3–methoxyphenyl)–1,6–
heptadiene–3,5–dione)(Figure 48) with a molecular weight of 368g/mol 
and a melting point of 183 ºC. CUR is composed of three main 
components together denoted to as curcuminoid which are 
bisdemethoxycurcumin (3%), demethoxycurcumin (17%) and curcumin 
(77%) (Anand et al., 2007). CUR is a golden–yellow solid, natural 
compound primarily used for food colouring and, often used as a dye 
owing to its vibrant colour. Furthermore, it is derived from the rhizome of 
curcuma longa with a wide variety of medicinal benefits (Salem et al., 
2014) including, anti–inflammatory (Sharma et al., 2005), antioxidant 
(Joe and Lokesh, 1994), anti–cancer (Ireson et al., 2001), wound healing 
and rheumatoid arthritis (Dcodhar et al., 2013).  
CUR is safe even at high doses of 12 g/day in humans (Lao et al., 2006). 
However, it is hindered by its enormously reduced aqueous solubility of 
aqueous buffer pH=5.0 (Tønnesen et al., 2002), also, relatively insoluble 
in water (Sharma et al., 2005). CUR has poor absorption from the 
gastrointestinal tract, thermal treatment, light, metallic ions, enzymes, 
oxygen and ascorbic acid (Paramera et al., 2011; Gowthamarajan et al., 
2012). Also, when taken orally, only traces appear in the blood. 
Meanwhile most of the dose is excreted through the faeces (38–75%). 
Chemically CUR decomposes rapidly in neutral and alkaline medium, 
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above 90% of CUR, decomposition occurs within 30 min in pH 7.4 buffer 
medium (Wang et al., 1997). 
 CUR has a potential as a pharmaceutical excipient (Tønnesen et al., 
2002; Salem et al., 2014), and an interesting model compound as it 
possesses three polymorphic forms, form I (monoclinic) and orthorhombic 
form II and III, commercially available CUR crystals are the monoclinic 
forms and the space group is P2/n and exists primarily in its enolic form 
in solution. CUR molecule also exists as tautomers of β–diketonic form 
(di–keto) and enolic form (enol) (Sanphui et al., 2014; Thorat et al., 
2015) (Figure 48). 
 
Figure 48. Chemical structure of curcumin (Keto and enol form). 
 CUR has been selected for blending and milling with PA. The main focus 
of the present study is to develop paracetamol–curcumin (PA–CUR) 
tablets with improved tableting properties. Until now, no study is available 
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on PA–CUR tableting properties. For the first time, the tableting properties 
of PA will be improved in the presence of CUR via milling technique. 
10.2. Engineering of PA–CUR formulations 
10.2.1. Low shear mixing 
 PA and CUR (10:4 w: w) powders were mixed using low shear mixing 
technique as described in (Section 2.2.1.1). 
10.2.2. Dry Milling   
PA and CUR (10:4 w: w) powders were milled for 5min (ML5), 6min 
(ML6), 7min (ML7) and 10min (ML10) using the milling technique 
described in (Section 2.2.1.7). 
10.2.3. Tablet preparation 
Each tablet weighs 700 mg ± 0.5 mg for the various formulations, and 
500 mg ± 0.5 mg for PA and 500 mg ± 0.5 mg CUR were all compressed 
using the method described (Section 2.14).   
10.3. Results and Discussions 
10.3.1. Morphology and particle size distribution 
Scanning electron microscopy was used to envisage the morphology of 
commercial PA, commercial CUR and the various mixtures of PA–CUR 
using techniques such as, physical mixing PM (PA–CUR) and milling ML 
(PA−CUR) using various time intervals; 5 min, 6 min, 7 min and 10 min 
(ML5, ML6, ML7 and ML10) (Figure 49). The morphology of PA was well 
discussed in (Section 3.3.4) whereas; CUR revealed a clear crystalline 
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nature and showed the presence of large prismatic–cube/tabular 
crystalline particles with rough surface edges (Figure 49). In the case of 
the PM (PA–CUR) mixture which demonstrated two distinct shapes 
consisting of both PA and CUR habits. Meanwhile, PA–CUR mixture milled 
at various time intervals (ML5, ML6, ML7 and ML10) morphologies were 
neither a flake−like structure nor polyhedral crystals but exhibited a 
combination of large and small aggregates/clumps of PA–CUR assemblies 
(Figure 49). The apparent morphological change from tabular structures 
to smaller aggregates must be due to well–mixed PA and CUR in PA–CUR 
mixtures (ML5, ML6, ML7 and ML10). Also, most of the large aggregates 
disappeared with an increase in milling time of PA and CUR, i.e., ML5 (PA–
CUR) to ML10 (PA–CUR). The ML10 (PA–CUR) mixture demonstrated tiny 
clusters/aggregates compared to other blends (ML5, ML6 and ML7) 
(Figure 49). This alteration of crystal structure further suggests the 
formation of well spread CUR on PA particles. 
 PA–CUR mixture prepared using physical mixing technique showed 
increased span values compared with marketed PA (Table 25). This was 
caused by the span value of the CUR particles, which was higher than that 
of commercial PA (Table 25), as confirmed by SEM micrographs. A trend 
of higher span values could be observed with the increased in milling time 
(i.e., ML5 < ML6 <ML7< ML10) (Table 25). For example, the span values 
of PA–CUR mixtures using various timing (ML5, ML6, ML7 and ML10) were 
3 ± 0.1 μm, 4.2 ± 0.1 μm, 9.5 ± 0.4 μm, and 11 ± 0 μm, respectively 
(Table 25). Additionally, the mixtures above showed smaller mean 
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diameters (VMDs ranging from 858 ± 25.3 μm to 86 ± 6 μm) compared 
with the mixture prepared using physical mixing (PM) technique with a 
VMD of 1237 ± 51 μm (Table 25). The lower VMDs for the mixtures 
prepared using milling compared to PM was due to the reduced d10% 
values (ML10<ML7<ML6<ML5<PM) as shown in (Table 25). 
 
 
Figure 49. Scanning electron microscopy micrographs of commercial 
paracetamol (PA), commercial curcumin (CUR), and PA–CUR mixtures 
(5:2, w/w) prepared using physical mixing (PM (PA–CUR)), and milling at 
various timing (ML5, ML6, ML7 and ML10). 
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10.3.2. Powder density and cohesivity 
 All PA–CUR mixtures showed lower bulk and tap densities, higher 
cohesivity (1/b), and higher CI values than PA (Table 24). However, the 
bulk density, tap density and cohesivity of the mixtures prepared using 
milling method were not statistically different (p > 0.05) (Table 24). The 
mixtures prepared using milling for 10 min (ML10) showed further 
reductions in bulk density as well as increases in cohesivity compared to 
the PA powder (Table 24). The reductions in the bulk and tap densities for 
the mixtures prepared using physical mixing method compared with 
commercial PA were due to the presence of smaller particle sizes of CUR 
powder, whose bulk and tap density values are less than those of 
commercial PA (Table 24). The reductions in bulk and tap densities for the 
powders prepared using milling technique compared with a mixture 
prepared using physical mixing method were caused by their considerably 
smaller particle sizes (VMD, d10%) as shown in (Table 25). As revealed 
by the higher cohesivity values which are associated with considerable 
increases in the strength of the interparticle forces (Table 25). The 
mixtures prepared using milling technique exhibited reduced flowabilities 
compared to the physical mixing method as indicated by their 
considerably higher CI values from 28 ± 0% to 34 ± 0% as shown in 
(Table 24) this is linked to their increased span values and higher fines 
particles (d10%). This provides further evidence for their stronger 













Table  24.  Bulk density (Db), tap density (Dt), cohesivity (1/b), and Carr index (CI) for commercial paracetamol 
(PA), commercial curcumin (CUR), and PA–CUR mixtures (5:2, w/w) prepared using physical mixing (PM), and 





) 1/b CI (%) 
PA 0.8 ± 0 0.8 ± 0 4 ± 0 3.2 ± 0.3 
CUR 0.4 ± 0 0.6 ± 0 28.3 ± 0 34 ± 0 
PM(PA–CUR) 0.63 ± 0 0.9 ± 0 11 ± 0 28 ± 0 
ML5(PA–CUR) 0.42 ± 2.3 0.63 ± 0 59 ± 2.3 34 ± 0 
ML6(PA–CUR) 0.34 ± 0 0.54 ± 0 59 ± 2.3 34 ± 0 
ML7(PA–CUR) 0.4 ± 0 0.6 ± 0 60 ± 0 34 ± 0 




Table 25. Particle size distribution for commercial paracetamol (PA), commercial curcumin (CUR), and PA–CUR 
mixtures (5:2, w/w) prepared using physical mixing (PM), and milling at various timing (ML5, ML6, ML7 and 
ML10). Data given for particle size at 10% (d10%), 50% (d50%, median diameter), and 90% (d90%) of the volume 
distribution, the volume mean diameter (VMD), and the span of the volume distribution (see Eq. (1)). Data 
expressed as mean ± SD,n=3.
Product d10% (µm) d50% (µm) d90% (µm) VMD (µm) Span 
PA 254 ± 22 506 ± 30 911 ± 39.3 548 ± 30.2 1.3 ± 0 
CUR 
4 ± 0 18 ± 1 85.2 ± 5 44 ± 4 5 ± 0 
PM(PA–CUR) 
53.3 ± 24 1200 ± 46 2350 ± 20 1237 ± 51.3 2 ± 0 
ML5(PA–CUR) 
5 ± 1 789 ± 40.2 2133.3 ± 32.1 858 ± 25.3 3 ± 0 
ML6(PA–CUR) 
3.4 ± 0.2 490 ± 17 2073.3 ± 32.1 796 ± 17.3 4.2 ± 0 
ML7(PA–CUR) 
3 ± 0.3 25.3 ± 5 243 ± 37.2 76.3 ± 13 10 ± 0 
ML10(PA–CUR) 
3 ± 0.0 25.3 ± 1 276 ± 18 86 ± 6 10 ± 0.0 
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10.4. Solid–state properties 
10.4.1. Powder X–ray diffraction 
After numerous attempts to prepare cocrystals of PA–CUR using grinding 
and solution–based techniques, a pure cocrystal was not obtained. 
Instead, the physical mixing of PA: CUR (10:4, w/w in total 14g) was 
milled. The X−ray diffraction patterns of PA, CUR, PM (PA–CUR) and ML5 
(PA–CUR), ML6 (PA–CUR), ML7 (PA–CUR) and ML10 (PA–CUR) are shown 
in (Figure 50). The commercial PA exhibited diffraction angles as well 
discussed in (Section 3.3.4). On the other hand, the marketed available 
CUR used for this investigation was the known Form I (monoclinic form) 
(Sanphui et al., 2011). Its sharp characteristic peak indicates the 
crystalline structure of CUR as shown by distinct peak at 2θ  values of, 
8.85°, 17.46°, 23.32°, 24.49°, 25.56° and a series of small peaks at 
12.19°, 14.48°, 18.13°, 19.41°, 21.13°, 23.32°, 24.49°, 26.07°, 26.73°, 
27.34° and 28.91° similar to the results obtained by (Pushpalatha et al., 
2018). The diffractogram of physical mixture PM (PA−CUR) and all the 
milled mixtures (ML5, ML6, ML7, ML10 (PA–CUR)) presented only an 
overlap of the characteristic peaks of each component that matches the 
sum of both species (Figure 50). The PXRD patterns of all the PA–CUR 
mixtures ruled out the transformation of the monoclinic form to the 
orthorhombic form, in both PA and CUR which indicated that the initial 
crystalline state of commercial PA and CUR are maintained for all PA‒CUR 
mixtures regardless of the mixing technique. The height of the peaks of 
curcumin reduces as the milling time increases, which could be due to the 
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entrapment of CUR particles on PA particles, thereby reducing their 
occurrence (Figure 50). 
 
Figure 50. Powder X–ray diffraction of commercial paracetamol (PA), 
commercial curcumin (CUR), and PA–CUR mixtures (5:2, w/w) prepared 
using physical mixing (PM (PA–CUR)), and milling method at various 
timing (ML5, ML6, ML7 and ML10) 
10.4.2. Fourier transform infrared spectrum 
FT−IR spectroscopy was used to ascertain the hydrogen bonding 
interactions between PA and CUR molecules, which was also relevant to 
supplement microstructural change of PA and PA–CUR mixtures. FT–IR 
spectra of PA, CUR, PM (PA–CUR), ML5 (PA−CUR), ML6 (PA−CUR), ML7 
(PA−CUR) and ML10 (PA−CUR) are displayed in (Figure 51). A broad 
absorption band at the range of 3400 and 3450 cm–1 was due to 
overlapping of a hydroxyl group and amino group stretching vibrations 
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(Liu et al., 2016) was observed in all five spectra. The peaks at 2963, 
1430 and 1376 cm–1 can be assigned to the C–H stretching modes and 
deformation of methyl groups. Likewise, the broad absorbance band at 
1601.59 cm–1 assigned to C=C stretching of aromatic rings. The C–O 
stretching absorption bands appear at, 1428.17 cm-1, (enol C–O) and 
1273.11 cm–1 (phenol C–O) (Liu et al., 2016). Also, in the FT−IR 
spectrum, a sharp absorption peak at 967.07 cm–1 can be observed which 
corresponds to the in–plane bending mode of the C–H aromatic and the 
peak at 820 cm−1 relates to the stretching vibrations of C–O groups 
present in commercial CUR (Mai et al., 2012). Peaks at 1626.07 and 
1601.59 cm–1 represents the C–O (amide I band) stretching of CUR 
(Govindaraj et al., 2014) and N–H (amide II band) of PA carbon chains as 
discussed in (Section 3.3.4) respectively. The FT−IR characteristic bands 
of the monoclinic form of PA as discussed in (Section 3.3.4) retained the 
diagnostic bands indicative of form I in all the mixtures of PA−CUR. 
The carbonyl group (C=0, H) of CUR being a stronger electron acceptor 
than the hydroxyl group of the CUR might be favoured in H–bonding with 
PA (N−H, H) a strong hydrogen bond donor. Small changes in the drug 
N−H stretching and the O−H regions can be used to provide information 
about PA−CUR intermolecular hydrogen−bonding interactions. The shift 
and reduction in absorbance intensity have been found across the spectra 
of PA mixed with CUR compared to PA. The mixtures prepared using 
physical mixing showed a slight decrease in absorption intensities in 
comparison to PA (Figure 51), which implies a reduced inter−particle 
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interaction between PA and CUR. On the other hand, the band broadening 
became more noticeable for the mixtures prepared using milling at 
different timing (i.e. ML5, ML6 and ML7)(Figure 51) hence; it implies a 
higher level of intermolecular hydrogen bonding between PA and CUR in 
the mixtures prepared using milling. Also, the mixture milled for 10 min 
(ML10) exhibited decreased furthermore probably because of the strong 
hydrogen bonding interaction formed between two ketone groups of CUR 
and amide of PA molecule i.e the hydrogen bond interaction brings about 
the reduction of absorption intensity of N−H and the slight shift to higher 
wavenumber from 3321.37 cm−1 to 3327.64 cm−1. The peak at 1281.27 
cm–1 was assigned to the C−O stretching vibration of the benzene ring 
(Feng, Liu, Zhao, & Hu, 2012), which was regarded as a characteristic 
peak found in CUR and PA–CUR mixtures. The changes of the C−O bond 
and N−H bond are observed by FT−IR spectrum as seen in (Figure 51).  
 The mixture of PA−CUR milled for 10 min showed a drastic reduction in 
absorbance intensity at various typical peaks in PA and CUR, which 
demonstrated that PA and CUR had been homogeneously blended. A more 
substantial shift indicates stronger/more extensive hydrogen bonding) 
(Wegiel et al., 2014). Therefore, the FT–IR spectra showed that hydrogen 
bonding interactions are more likely to occur in the mixtures using milling 
compared to the physical mixing where the interaction is minimal. Higher 
milling time during grinding results in higher levels of PA–CUR interaction; 
this is probably because the increase in shear forces during milling causes 
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entrapment of CUR particles into the host PA particle surfaces. So, it can 






















Figure  51. Fourier transform infrared spectroscopy (FT–IR) spectra of 
commercial paracetamol (PA), commercial curcumin (CUR), and PA–CUR 
mixtures (5:2, w/w) prepared using physical mixing (PM (PA–CUR)), and 

























































































































10.4.3. Thermogravimetric analysis 
Thermogravimetric Curve for commercial materials and PA–CUR mixtures 
were carried out to assess their thermal behaviour as shown in (Figure 
52), where the mass versus temperature curve was portrayed showing 
the degradation of PA, CUR and PA–CUR mixtures with increasing 
temperature. The TGA curves of PA and PA–CUR mixtures showed weight 
loss in the temperature range close to the range as discussed in (Section 
3.3.4) which denotes the melting point of monoclinic PA, then subsequent 
weight loss due to degradation. CUR molecule remained thermally stable 
up to 150.2ºC and then began to lose weight continuously reaching the 
first maximum rate of weight loss at 168.7 ºC, as depicted in the TGA 
curve (Figure 52). The loss of volatile impurities during the melting of 
CUR is linked to the step above followed with the loss of two water 
molecules due to dehydroxylation of O–H groups (Zebib et al., 2010; 
Souguir et al., 2013). No weight loss occurred below 100 ºC (Figure 52), 
indicating the absence of a significant amount of free water in all 
mixtures. A slight shift towards lower melting onsets was observed for the 
mixtures prepared using milling technique when compared with the 
mixture prepared using physical mixing method (Figure 52). This 
difference may be attributable to their starkly different physical properties 
such as their considerably lower VMDs (Table 27; Figure 52).  
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Figure 52. Thermogravimetric analysis curves of commercial paracetamol 
(PA), commercial curcumin (CUR), and PA–CUR mixtures (5:2, w/w) 
prepared using physical mixing (PM (PA–CUR)), and milling method at 
various timing (ML5, ML6, ML7 and ML10). 
10.4.4. Tableting properties 
The tabletability of PA was poor at various compression pressures, as 
discussed in (Section 3.3.5). In contrast, CUR exhibited far much better 
tabletability as the TS of CUR tablets increased with increasing pressure 
and reached ~ 2.2 ± 0.1 MPa at the compaction pressure of 222 MPa with 
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low variability in the tablet tensile strength. The presence of the drug to 
CUR (5:2 ratio w/w) improved the mechanical properties of PA in all PA–
CUR mixtures (Figure 53). 
The TS of PA–CUR mixture compressed at 222 MPa was 0.9 ± 0.1 MPa, 
3.0 ± 0.0 MPa, 2.9 ± 0.1 MPa and 3.2 ± 0.0 MPa for the mixtures 
prepared using PM, ML5, ML6/ML7, and ML10 methods (Figure 53). 
 The tableting performance of PA was slightly improved by physically 
mixing with CUR and was intermediate between those of PA and CUR 
(Figure 53) for example, with the compression pressure increasing from 
37 to 222 MPa, the TS of tablets increased from 0.2 to 0.9 MPa. 
 Compressed tablets with TS of at least 2 MPa was obtained at 185 MPa 
from the milling mixtures of PA–CUR (ML5, ML6 and ML7) (Figure 53), for 
example, the TS of 0.6 to 3.0 MPa was obtained at a compression 
pressure of 37 to 222 MPa (Figure 53). On the other hand, tabletability of 
PA was substantially improved after milling with CUR for 10 min. For 
example, when the compression pressure increased from 37 to 222 MPa, 
the TS of tablets increased from 0.6 ± 0.0 MPa to 3.2 ± 0.0 MPa (Figure 
53). It is apparent that the PA–CUR mixture prepared using ML10 showed 
the best compression properties among the mixtures obtained during this 
study showed, TS of 3.3 ± 0.0 MPa at a compression pressure of 185 
MPa. Compared with the mixtures prepared using PM technique, the 
mixtures acquired with ML10 produced the best tablets under the 
compression pressure range of 37 to 222 MPa. 
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The increased tensile strengths of the tablets containing mixtures 
prepared with ML10 technique shows of stronger interparticle bonding for 
between PA and CUR. Such superior tabletability is attributed to the 
higher level of PA‒CUR interaction via hydrogen bonding, especially with 
the milling sample (Figure 52). Also, in disparity to the mixtures prepared 
using PM technique in which the morphologies of both PA 
(subangular/polyhedral) and CUR (tabular) particles could be observed 
(Figure 49), no distinct individual CUR particles were seen in mixtures 
prepared using milling method (Figure 49). 
 The mechanistic understanding of the superior tableting performance of 
ML10 (PA−CUR) would require elucidation of its crystal structure if it is 
possible that the component molecules in ML10 (PA−CUR) mixture form 
either a flat hydrogen column since the molecular arrangement is known 
to improve crystal plasticity and tabletabilty (Karki et al., 2009). 
According to (Sun, 2011) when plasticity is enhanced, crystals can form a 
larger bonding area under pressure and therefore a strong tablet. 
 Overall, irrespective of the milling timing, the enhanced tableting 
performance in this investigation demonstrated the applicability of milling 




Figure 53. Tensile strength (mean ± SD, n = 5) versus compression 
pressure for commercial paracetamol (PA), commercial curcumin (CUR), 
and PA–CUR mixtures (5:2, w/w) prepared using physical mixing (PM) 
and milling at various timing (ML5, ML6, ML7 and ML10). 
10.5. Dissolution Studies 
The dissolution profile of commercial PA and the mixtures of PA−CUR 
products are shown in (Figure 54). After 3 min, the milled PA−CUR had 
the highest percentage of PA released (Figure 54) and a complete drug 
dissolution was achieved within the first 21 min, which was further 
reflected by the highest dissolution efficiency (DE180 min of 90.8 ± 1.3%) 
and the shortest mean dissolution time (MDT of 2.9 ± 0.5 min) in the 
presence of 5% sodium starch glycolate (Primojel) among the mixtures 
studied. On the other hand, commercial PA demonstrated the slowest 
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dissolution compared to the engineered PA and CUR products which was 
also reflected by the lowest dissolution efficiency (DE180 min of 
68.4 ± 7.5%) and the highest mean dissolution time (MDT of 54.2 ± 11.4 
% min) among paracetamols mixtures studied (Figure 54). 
Results of this investigation indicate that 5% w/w of primogel in the 
mixture as dissolution medium is suitable for routine in vitro dissolution 
testing of PA formulations. PA–CUR obtained using physical mixing also 
showed an enhancement of PA dissolution, as it released PA within 30 
min, whereas the dissolution of the commercial PA took about 3h. Also, it 
was observed that the mean dissolution rate of PA from the physical 
mixture was ~2.2 times higher than that of commercial PA; this may be 
due to a better dispersion of PA particles in the form of the physical 
mixture with CUR. The release rate of PA was 80% with ML10 (PA–CUR) 
compared to PM (PA–CUR) within 15 min under the same test conditions. 
Also, these results indicate that milling is an effective approach for 
improving the dissolution rate of PA. The greater dissolution of PA from 
ML10 (PA−CUR) can be attributed to the change in crystallinity pattern 
(reduced peak heights), morphology (i.e., crystal habit), shape and size 
of ML10 (PA−CUR) that led in enhancing in the dissolution medium 
(Panzade et al., 2017); for example, the physical mixing method tends to 
produce larger primary particles with a broader size distribution and a 




On the other hand, the sharp increased and highest rate (90%) in the 
dissolution rate were due to the enlarged surface area of the micronised 
drug particles, as particle size reduction leads to an enlarged effective 
surface area in the diffusion layer, which would increase the drug 
dissolution rate (Noyes and Whitney, 1897).   
Nevertheless, the dissolution of these mixtures ML10(PA–CUR) and 
PM(PA−CUR) due to the release of more than 80% PA in dissolution 
medium within 30 min, as required according to the requirement (USP, 
2008). 
 The present investigation showed that the milling technique not only 
improved the mechanical properties of paracetamol tablets but also the 
processed PA in some cases had better dissolution performance than the 






Figure 54. Release profiles for commercial paracetamol (PA), PA–CUR 
mixtures (5:2, w/w) prepared using physical mixing (PM) and milling for 
10 min ML10  
10.7. Conclusions 
Processing of PA−CUR mixtures on the micrometric and mechanical 
properties should be well considered. In disparity to physical mixing and 
milling techniques promoted hydrogen bonding between PA and CUR with 
subsequent improvements in the mechanical properties of the resultant 
mixtures in the presence of 5:2 (w/w) CUR. Henceforth, such improved 
material properties with milling may be exploitable in the formulation 












































CHAPTER 11: SUMMARY AND FUTURE WORKS 












Solid oral drug administration entails steps such as, the formation of a 
stable drug compact which can withstand mechanical shock upon 
transportation, drug release and transport to the site of action. 
Oral drug administration is the most versatile and popular route among 
other routes due to the ease of ingestion, patient compliance and pain 
avoidance. Also, the solid oral dosage forms such as tablets are cheap to 
manufacture and do not require a sterile environment. 
Many new chemical entities developed possess a poor mechanical 
characteristic, which is one of the major hurdles that formulation 
scientists and pharmaceutical companies face every day. 
In this research study, the tableting deficiency of paracetamol was 
overcome by applying various engineering methods via processing drug–
excipient and drug/drug formulations. Consequently, employing suitable 
processing techniques in the presence of plastically deforming excipient or 
drugs particles is vital for enhancing solid dosage performance. Therefore, 
numerous methods including, blending, milling, solvent evaporation, 
batch cooling crystallisation, freeze drying and cocrystallisation were used 
in the presence of the known plastically deforming binder 
polyvinylpyrrolidone and other common drugs including; Ibuprofen, 
caffeine, aspirin, curcumin, chondroitin sulphate and the coformer 5–
nitroisophthalic acid, in order to enhance the mechanical performance of 
paracetamol from the binary and ternary mixtures.  
 Important parameters affecting the outcomes of the particles’ properties 
were identified. It was shown that the micrometric properties for 
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paracetamol: polyvinylpyrrolidone mixtures blended were dependent on 
the energy of mixing employed as, the energy of mixing increased so is 
the tensile strength of paracetamol: polyvinylpyrrolidone mixtures. Also, 
the milling time in the cases of paracetamol: Curcumin and 
paracetamol/aspirin/caffeine as the timing increase, so was the 
tabletability. The temperature of freezing on paracetamol–
polyvinylpyrrolidone mixtures by applying freeze drying technique 
appeared to be a critical factor in the control of the mechanical behaviour, 
for example, enhanced mechanical performance was obtained for the 
formulations containing paracetamol−polyvinylpyrrolidone mixture frozen 
at considerable low temperature with liquid nitrogen (−196 ºC), as the 
tensile strength of the tablets increased with decreased in temperatures 
(−196 ºC > −80 ºC >−20 ºC). Among all the processing techniques 
investigate, freeze drying with liquid nitrogen was shown to be the 
ultimate method in preparing engineered particles with an immense 
increase in tabletability. The effect of other drugs properties, when 
combined with paracetamol on their performance, was evaluated. 
Processing of two or more drugs was proven to be a promising approach 
to enhance the mechanical properties of paracetamol, as paracetamol and 
ibuprofen tablets showed better tensile than their marketed component, 
the same applies to paracetamol/aspirin/caffeine. Cocrystals of 
paracetamol and the coformer 5–nitroisophthalic acid demonstrated far 
much better mechanical properties than their commercial components 
through processing in the presence of polar solvents specifically. The use 
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of co–engineering techniques on the poorly compactable drug offers great 
prospect at improving mechanical performance via the manipulation of 
their physicochemical properties. Also, mechanical properties 
enhancement can be linked to changes in key physicochemical properties 
of the excipient/other drugs, which can be heightened via the processing 
technique applied. 
Future work 
In the present study, in order to appraise the impact of the various 
engineered methods in the presence of the excipient/drugs on the 
physicochemical and mechanical performance, paracetamol was included 
in all processed formulations as the model drug. Nonetheless, substantial 
data are essential where the performance of various formulations is 
compared in the case of different hydrophobic and highly hydrophilic 
drugs. It was noteworthy that numerous factors impacted the 
performance of the co–processing formulations. Analyses such as surface 
properties could be performed to identify the most vital parameters 
holding the engineered particle in a stable compact in the acquired 
formulations. Some formulations demonstrated slightly reduced flow; 
thus, the employability of lubricants and anti adherents should be added 
into the formulations in other to obtain a great product. 
Further investigations in the future such as the use of other engineering 
techniques including, antisolvent crystallisation, spray drying or hot melt 
extrusion should be applied in the mixtures of paracetamol–chondroitin to 
enhance the mechanical properties of PA will be much needed. 
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In vivo tests should be performed in order to evaluate their 
pharmacokinetic performance/ characteristics, especially on paracetamol–
chondroitin and paracetamol−curcumin formulations on osteoarthritis and 
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Supplementary materials (SM) 
SM. 1. Water absorbed over the period of three months of commercial 
ibuprofen (IBU), and the mixtures (PA: IBU, 5:2 w/w) prepared Physical 
mixing (PM), compact milling (CPM); batch cooling crystallisation (BCC) ; 
Freeze drying (FD) and Milling (ML). 
Products Initial weight(g) at 
0 day 





































SM. 2. Powder X–ray diffraction of PA, 5NIP, physical mixing and PA−5NIP 
cocrystals prepared using slow cooling crystallisation and wet−milling and 





SM. 3. PXRD comparison plots showing, the stability of the cocrystals 
before and after six months (6M), exposed at high humidity temperature 
(40ºC, RH 75%). 
